54089-8  Newborn screening panel American Health Information Community (AHIC)Newborn screening panel American Health Information Community (AHIC)Newborn screening panel: -: Pt: ^Patient: -: AHIC  

PANEL HIERARCHY  (view this panel in the LForms viewer)

  LOINC#   LOINC Name R/O/C  Cardinality  Ex. UCUM Units 
  54089-8   Newborn screening panel American Health Information Community (AHIC)Newborn screening panel American Health Information Community (AHIC)Newborn screening panel: -: Pt: ^Patient: -: AHIC    
       57128-1   Newborn Screening Report summary panelNewborn Screening Report summary panelNewborn Screening Report summary panel: -: Pt: ^Patient: -: C 0..1   
            57721-3   Reason for lab test in Dried blood spotReason for lab test in Dried blood spotReason for lab test: Type: Pt: Bld.dot: Nom: R 1..1   
            57718-9   Sample quality of Dried blood spotSample quality of Dried blood spotSample condition: Type: Pt: Bld.dot: Nom: R 1..1   
            57130-7   Newborn screening report - overall interpretationNewborn screening report - overall interpretationNewborn screening report - overall interpretation: Imp: Pt: ^Patient: Nom: C 1..*   
            57131-5   Newborn conditions with positive markers [Identifier] in Dried blood spotNewborn conditions with positive markers [Identifier] in Dried blood spotNewborn conditions with positive markers: Prid: Pt: Bld.dot: Nom: R 1..*   
            57720-5   Newborn conditions with equivocal markers [Identifier] in Dried blood spotNewborn conditions with equivocal markers [Identifier] in Dried blood spotNewborn conditions with equivocal markers: Prid: Pt: Bld.dot: Nom: R 1..*   
            57724-7   Newborn screening short narrative summaryNewborn screening short narrative summaryNewborn screening short narrative summary: Txt: Pt: ^Patient: Nar: O 0..1   
            57129-9   Full newborn screening summary report for display or printingFull newborn screening summary report for display or printingFull newborn screening summary report for display or printing: -: Pt: ^Patient: Doc: O 0..1   
            57719-7   Conditions tested for in this newborn screening study [Identifier] in Dried blood spotConditions tested for in this newborn screening study [Identifier] in Dried blood spotConditions tested for in this newborn screening study: ID: Pt: Bld.dot: Nom: R 1..*   
            69969-4   Newborn screening report overall laboratory commentNewborn screening report overall laboratory commentNewborn screening report overall laboratory comment: Txt: Pt: ^Patient: Nar: O 0..*   
       57717-1   Newborn screen card data panelNewborn screen card data panelNewborn screen card data panel: -: Pt: Bld.dot: -: C    
            57716-3   State printed on filter paper card [Identifier] in NBS cardState printed on filter paper card [Identifier] in NBS cardState printed on filter paper card: ID: Pt: NBS card: Nom: R    
            79566-6   Collection method - Dried blood spotCollection method - Dried blood spotCollection method: Type: Pt: Bld.dot: Nom: O    
            8339-4   Birthweight R  
            58229-6   Body weight Measured --when specimen takenBody weight Measured --when specimen takenBody weight^when specimen taken: Mass: Pt: ^Patient: Qn: Measured O  
            57715-5   Time of birth R   {clock_time} 
            73806-2   Newborn age in hoursNewborn age in hoursNewborn age in hours: Time: Pt: ^Patient: Qn: O  
            57722-1   Birth plurality of PregnancyBirth plurality of PregnancyBirth plurality: Num: Pt: Pregnancy: Ord: R    
            57714-8   Obstetric estimation of gestational ageObstetric estimation of gestational ageObstetric estimation of gestational age: Time: Pt: ^Patient: Qn: R   wk 
            57713-0   Infant factors that affect newborn screening interpretationInfant factors that affect newborn screening interpretationInfant factors that affect newborn screening interpretation: Find: Pt: ^Patient: Nom: R 1..*   
            67703-9   Other infant factors that affect newborn screening interpretation NarrativeOther infant factors that affect newborn screening interpretation NarrativeOther infant factors that affect newborn screening interpretation: Find: Pt: ^Patient: Nar: C 0..*   
            67706-2   Maternal factors that affect newborn screening interpretationMaternal factors that affect newborn screening interpretationMaternal factors that affect newborn screening interpretation: Find: Pt: ^Mother: Nom: O 0..*   
            67707-0   Other maternal factors that affect newborn screening interpretation NarrativeOther maternal factors that affect newborn screening interpretation NarrativeOther maternal factors that affect newborn screening interpretation: Find: Pt: ^Mother: Nar: C 0..*   
            77739-1   Mother's Hepatitis B virus surface Ag statusMother's Hepatitis B virus surface Ag statusHepatitis B virus surface Ag: PrThr: Pt: ^Mother: Ord: C    
            57712-2   Mother's educationMother's educationMother's education: Hx: Pt: ^Mother: Ord: O 0..1   
            67704-7   Feeding typesFeeding typesFeeding types: Find: Pt: ^Patient: Nom: R 1..*   
            67705-4   Other feeding types NarrativeOther feeding types NarrativeOther feeding types: Find: Pt: ^Patient: Nar: C 0..*   
            79569-0   Blood product given [Type]Blood product given [Type]Blood product given: Type: Pt: ^Patient: Nom: C    
            62317-3   Date of last blood product transfusionDate of last blood product transfusionDate of last blood product transfusion: TmStp: Pt: ^Patient: Qn: O 0..1   
            58232-0   Hearing loss risk indicators [Identifier]Hearing loss risk indicators [Identifier]Hearing loss risk indicators: Prid: Pt: ^Patient: Nom: C 1..*   
            54106-0   Newborn hearing screen methodNewborn hearing screen methodNewborn hearing screen method: Type: Pt: Ear: Nom: C    
            54108-6   Newborn hearing screen of Ear - leftNewborn hearing screen of Ear - leftNewborn hearing screen: Arb: Pt: Ear.left: Ord: C    
            54109-4   Newborn hearing screen of Ear - rightNewborn hearing screen of Ear - rightNewborn hearing screen: Arb: Pt: Ear.right: Ord: C    
            73700-7   CCHD newborn screening interpretationCCHD newborn screening interpretationCCHD newborn screening interpretation: Imp: Pt: ^Patient: Nom: C    
            73698-3   Reason CCHD oxygen saturation screening not performedReason CCHD oxygen saturation screening not performedReason CCHD oxygen saturation screening not performed: Find: Pt: ^Patient: Nom: C    
            57723-9   Unique bar code number of Current sampleUnique bar code number of Current sampleUnique bar code number: ID: Pt: Current sample: Nom: R    
            57711-4   Unique bar code number of Initial sampleUnique bar code number of Initial sampleUnique bar code number: ID: Pt: Initial sample: Nom: C    
            62323-1   Post-discharge provider ID [Identifier]Post-discharge provider ID [Identifier]Post-discharge provider ID: ID: Pt: Provider: Nom: C 0..1   
            62324-9   Post-discharge provider name in ProviderPost-discharge provider name in ProviderPost-discharge provider name: Pn: Pt: Provider: Nom: C 0..1   
            62325-6   Post-discharge provider practice IDPost-discharge provider practice IDPost-discharge provider practice ID: ID: Pt: Provider: Nom: C 0..1   
            62326-4   Post-discharge provider practice namePost-discharge provider practice namePost-discharge provider practice name: ID: Pt: Provider: Nom: C 0..1   
            62327-2   Post-discharge provider practice addressPost-discharge provider practice addressPost-discharge provider practice address: Addr: Pt: Provider: Nom: C 0..1   
            62328-0   Post-discharge provider practice telephone numberPost-discharge provider practice telephone numberPost-discharge provider practice telephone number: Tele: Pt: Provider: Nom: C 0..1   
            62329-8   Birth hospital facility ID [Identifier] in FacilityBirth hospital facility ID [Identifier] in FacilityBirth hospital facility ID: ID: Pt: Facility: Nom: C 0..1   
            62330-6   Birth hospital facility nameBirth hospital facility nameBirth hospital facility name: ID: Pt: Facility: Nom: C 0..1   
            62331-4   Birth hospital facility addressBirth hospital facility addressBirth hospital facility address: Addr: Pt: Facility: Nom: C 0..1   
            62332-2   Birth hospital facility phone number in FacilityBirth hospital facility phone number in FacilityBirth hospital facility phone number: Tele: Pt: Facility: Nom: C 0..1   
       57794-0   Newborn screening test results panel - Dried blood spot C    
            53261-4   Amino acid newborn screen panelAmino acid newborn screen panelAmino acid newborn screen panel: SCnc: Pt: Bld.dot: -: C    
                 46733-2   Amino acidemias newborn screen interpretationAmino acidemias newborn screen interpretationAmino acidemias: Imp: Pt: Bld.dot: Nom: C    
                 57710-6   Amino acidemias newborn screening comment-discussionAmino acidemias newborn screening comment-discussionAmino acidemias newborn screening comment-discussion: Txt: Pt: Bld.dot: Nar: C    
                 57793-2   Amino acidemia disorder suspected [Identifier] in Dried blood spotAmino acidemia disorder suspected [Identifier] in Dried blood spotAmino acidemia disorder suspected: Prid: Pt: Bld.dot: Nom: C    
                 46746-4   Phenylketonuria and variants/​Biopterin defects newborn screen interpretationPhenylketonuria and variants/​Biopterin defects newborn screen interpretationPhenylketonuria and variants &or biopterin defects: Imp: Pt: Bld.dot: Nom: C    
                 58231-2   Phenylketonuria and variants/​Biopterin defects newborn screening comment-discussionPhenylketonuria and variants/​Biopterin defects newborn screening comment-discussionPhenylketonuria and variants &or biopterin defects newborn screening comment-discussion: Txt: Pt: Bld.dot: Nar: C    
                 46743-1   Maple syrup urine disease newborn screen interpretationMaple syrup urine disease newborn screen interpretationMaple syrup urine disease: Imp: Pt: Bld.dot: Nom: C    
                 58230-4   Maple syrup urine disease newborn screening comment-discussionMaple syrup urine disease newborn screening comment-discussionMaple syrup urine disease newborn screening comment-discussion: Txt: Pt: Bld.dot: Nar: C    
                 47539-2   3-Methylhistidine [Moles/​volume] in Dried blood spot3-Methylhistidine [Moles/​volume] in Dried blood spot3-Methylhistidine: SCnc: Pt: Bld.dot: Qn: C   umol/L 
                 53232-5   5-Oxoproline+​Pipecolate [Moles/​volume] in Dried blood spot5-Oxoproline+​Pipecolate [Moles/​volume] in Dried blood spot5-Oxoproline+​Pipecolate: SCnc: Pt: Bld.dot: Qn: C   umol/L 
                 53394-3   5-Oxoproline+​Pipecolate/​Phenylalanine [Molar ratio] in Dried blood spot5-Oxoproline+​Pipecolate/​Phenylalanine [Molar ratio] in Dried blood spot5-Oxoproline+​Pipecolate/​Phenylalanine: SRto: Pt: Bld.dot: Qn: C   {Ratio} 
                 53150-9   Alanine+​Beta Alanine+​Sarcosine [Moles/​volume] in Dried blood spotAlanine+​Beta Alanine+​Sarcosine [Moles/​volume] in Dried blood spotAlanine+​Beta Alanine+​Sarcosine: SCnc: Pt: Bld.dot: Qn: C   umol/L 
                 53393-5   Alloisoleucine+​Isoleucine+​Leucine+​Hydroxyproline+​Valine/​Phenylalanine+​Tyrosine [Molar ratio] in Dried blood spotAlloisoleucine+​Isoleucine+​Leucine+​Hydroxyproline+​Valine/​Phenylalanine+​Tyrosine [Molar ratio] in Dried blood spotAlloisoleucine+​Isoleucine+​Leucine+​Hydroxyproline+​Valine/​Phenylalanine+​Tyrosine: SRto: Pt: Bld.dot: Qn: C   {Ratio} 
                 53152-5   Alloisoleucine+​Isoleucine+​Leucine+​Hydroxyproline [Moles/​volume] in Dried blood spotAlloisoleucine+​Isoleucine+​Leucine+​Hydroxyproline [Moles/​volume] in Dried blood spotAlloisoleucine+​Isoleucine+​Leucine+​Hydroxyproline: SCnc: Pt: Bld.dot: Qn: C   umol/L 
                 53153-3   Alloisoleucine+​Isoleucine+​Leucine+​Hydroxyproline/​Phenylalanine [Molar ratio] in Dried blood spotAlloisoleucine+​Isoleucine+​Leucine+​Hydroxyproline/​Phenylalanine [Molar ratio] in Dried blood spotAlloisoleucine+​Isoleucine+​Leucine+​Hydroxyproline/​Phenylalanine: SRto: Pt: Bld.dot: Qn: C   {Ratio} 
                 53154-1   Alloisoleucine+​Isoleucine+​Leucine+​Hydroxyproline/​Alanine [Molar ratio] in Dried blood spotAlloisoleucine+​Isoleucine+​Leucine+​Hydroxyproline/​Alanine [Molar ratio] in Dried blood spotAlloisoleucine+​Isoleucine+​Leucine+​Hydroxyproline/​Alanine: SRto: Pt: Bld.dot: Qn: C   {Ratio} 
                 47562-4   Arginine [Moles/​volume] in Dried blood spotArginine [Moles/​volume] in Dried blood spotArginine: SCnc: Pt: Bld.dot: Qn: C   umol/L 
                 75214-7   Arginine/​Ornithine [Molar ratio] in Dried blood spotArginine/​Ornithine [Molar ratio] in Dried blood spotArginine/​Ornithine: SRto: Pt: Bld.dot: Qn: C   {ratio} 
                 53398-4   Arginine/​Phenylalanine [Molar ratio] in Dried blood spotArginine/​Phenylalanine [Molar ratio] in Dried blood spotArginine/​Phenylalanine: SRto: Pt: Bld.dot: Qn: C   {Ratio} 
                 53062-6   Argininosuccinate [Moles/​volume] in Dried blood spotArgininosuccinate [Moles/​volume] in Dried blood spotArgininosuccinate: SCnc: Pt: Bld.dot: Qn: C   umol/L 
                 53200-2   Argininosuccinate/​Arginine [Molar ratio] in Dried blood spotArgininosuccinate/​Arginine [Molar ratio] in Dried blood spotArgininosuccinate/​Arginine: SRto: Pt: Bld.dot: Qn: C   {Ratio} 
                 53155-8   Asparagine+​Ornithine [Moles/​volume] in Dried blood spotAsparagine+​Ornithine [Moles/​volume] in Dried blood spotAsparagine+​Ornithine: SCnc: Pt: Bld.dot: Qn: C   umol/L 
                 53395-0   Asparagine+​Ornithine/​Serine [Molar ratio] in Dried blood spotAsparagine+​Ornithine/​Serine [Molar ratio] in Dried blood spotAsparagine+​Ornithine/​Serine: SRto: Pt: Bld.dot: Qn: C   {Ratio} 
                 53396-8   Asparagine+​Ornithine/​Phenylalanine [Molar ratio] in Dried blood spotAsparagine+​Ornithine/​Phenylalanine [Molar ratio] in Dried blood spotAsparagine+​Ornithine/​Phenylalanine: SRto: Pt: Bld.dot: Qn: C   {Ratio} 
                 47573-1   Aspartate [Moles/​volume] in Dried blood spotAspartate [Moles/​volume] in Dried blood spotAspartate: SCnc: Pt: Bld.dot: Qn: C   umol/L 
                 42892-0   Citrulline [Moles/​volume] in Dried blood spotCitrulline [Moles/​volume] in Dried blood spotCitrulline: SCnc: Pt: Bld.dot: Qn: C   umol/L 
                 54092-2   Citrulline/​Arginine [Molar ratio] in Dried blood spotCitrulline/​Arginine [Molar ratio] in Dried blood spotCitrulline/​Arginine: SRto: Pt: Bld.dot: Qn: C   {Ratio} 
                 53157-4   Citrulline/​Phenylalanine [Molar ratio] in Dried blood spotCitrulline/​Phenylalanine [Molar ratio] in Dried blood spotCitrulline/​Phenylalanine: SRto: Pt: Bld.dot: Qn: C   {Ratio} 
                 53399-2   Citrulline/​Tyrosine [Molar ratio] in Dried blood spotCitrulline/​Tyrosine [Molar ratio] in Dried blood spotCitrulline/​Tyrosine: SRto: Pt: Bld.dot: Qn: C   {Ratio} 
                 47623-4   Glutamate [Moles/​volume] in Dried blood spotGlutamate [Moles/​volume] in Dried blood spotGlutamate: SCnc: Pt: Bld.dot: Qn: C   umol/L 
                 47633-3   Glycine [Moles/​volume] in Dried blood spotGlycine [Moles/​volume] in Dried blood spotGlycine: SCnc: Pt: Bld.dot: Qn: C   umol/L 
                 47643-2   Histidine [Moles/​volume] in Dried blood spotHistidine [Moles/​volume] in Dried blood spotHistidine: SCnc: Pt: Bld.dot: Qn: C   umol/L 
                 53158-2   Homocitrulline [Moles/​volume] in Dried blood spotHomocitrulline [Moles/​volume] in Dried blood spotHomocitrulline: SCnc: Pt: Bld.dot: Qn: C   umol/L 
                 47689-5   Lysine [Moles/​volume] in Dried blood spotLysine [Moles/​volume] in Dried blood spotLysine: SCnc: Pt: Bld.dot: Qn: C   umol/L 
                 47700-0   Methionine [Moles/​volume] in Dried blood spotMethionine [Moles/​volume] in Dried blood spotMethionine: SCnc: Pt: Bld.dot: Qn: C   umol/L 
                 53397-6   Methionine/​Alloisoleucine+​Isoleucine+​Leucine+​Hydroxyproline [Molar ratio] in Dried blood spotMethionine/​Alloisoleucine+​Isoleucine+​Leucine+​Hydroxyproline [Molar ratio] in Dried blood spotMethionine/​Alloisoleucine+​Isoleucine+​Leucine+​Hydroxyproline: SRto: Pt: Bld.dot: Qn: C   {Ratio} 
                 53156-6   Methionine/​Phenylalanine [Molar ratio] in Dried blood spotMethionine/​Phenylalanine [Molar ratio] in Dried blood spotMethionine/​Phenylalanine: SRto: Pt: Bld.dot: Qn: C   {Ratio} 
                 75215-4   Ornithine/​Citrulline [Molar ratio] in Dried blood spotOrnithine/​Citrulline [Molar ratio] in Dried blood spotOrnithine/​Citrulline: SRto: Pt: Bld.dot: Qn: C   {ratio} 
                 29573-3   Phenylalanine [Moles/​volume] in Dried blood spotPhenylalanine [Moles/​volume] in Dried blood spotPhenylalanine: SCnc: Pt: Bld.dot: Qn: C   umol/L 
                 35572-7   Phenylalanine/​Tyrosine [Molar ratio] in Dried blood spotPhenylalanine/​Tyrosine [Molar ratio] in Dried blood spotPhenylalanine/​Tyrosine: SRto: Pt: Bld.dot: Qn: C   {Ratio} 
                 47732-3   Proline [Moles/​volume] in Dried blood spotProline [Moles/​volume] in Dried blood spotProline: SCnc: Pt: Bld.dot: Qn: C   umol/L 
                 53392-7   Proline/​Phenylalanine [Molar ratio] in Dried blood spotProline/​Phenylalanine [Molar ratio] in Dried blood spotProline/​Phenylalanine: SRto: Pt: Bld.dot: Qn: C   {Ratio} 
                 47742-2   Serine [Moles/​volume] in Dried blood spotSerine [Moles/​volume] in Dried blood spotSerine: SCnc: Pt: Bld.dot: Qn: C   umol/L 
                 53231-7   Succinylacetone [Moles/​volume] in Dried blood spotSuccinylacetone [Moles/​volume] in Dried blood spotSuccinylacetone: SCnc: Pt: Bld.dot: Qn: C   umol/L 
                 47784-4   Threonine [Moles/​volume] in Dried blood spotThreonine [Moles/​volume] in Dried blood spotThreonine: SCnc: Pt: Bld.dot: Qn: C   umol/L 
                 53159-0   Tryptophan [Moles/​volume] in Dried blood spotTryptophan [Moles/​volume] in Dried blood spotTryptophan: SCnc: Pt: Bld.dot: Qn: C   umol/L 
                 35571-9   Tyrosine [Moles/​volume] in Dried blood spotTyrosine [Moles/​volume] in Dried blood spotTyrosine: SCnc: Pt: Bld.dot: Qn: C   umol/L 
                 47799-2   Valine [Moles/​volume] in Dried blood spotValine [Moles/​volume] in Dried blood spotValine: SCnc: Pt: Bld.dot: Qn: C   umol/L 
                 53151-7   Valine/​Phenylalanine [Molar ratio] in Dried blood spotValine/​Phenylalanine [Molar ratio] in Dried blood spotValine/​Phenylalanine: SRto: Pt: Bld.dot: Qn: C   {Ratio} 
            58092-8   Acylcarnitine newborn screen panelAcylcarnitine newborn screen panelAcylcarnitine newborn screen panel: -: Pt: Bld.dot: -: C    
                 58088-6   Acylcarnitine newborn screen interpretationAcylcarnitine newborn screen interpretationAcylcarnitine: Imp: Pt: Bld.dot: Nar: C    
                 58093-6   Acylcarnitine newborn screening comment-discussionAcylcarnitine newborn screening comment-discussionAcylcarnitine newborn screening comment-discussion: Txt: Pt: Bld.dot: Nar: C    
                 57084-6   Fatty acid oxidation newborn screen panelFatty acid oxidation newborn screen panelFatty acid oxidation newborn screen panel: -: Pt: Bld.dot: -: C    
                      46736-5   Fatty acid oxidation defects newborn screen interpretationFatty acid oxidation defects newborn screen interpretationFatty acid oxidation defects: Imp: Pt: Bld.dot: Nom: C    
                      57792-4   Fatty acid oxidation conditions suspected [Identifier] in Dried blood spotFatty acid oxidation conditions suspected [Identifier] in Dried blood spotFatty acid oxidation conditions suspected: Prid: Pt: Bld.dot: Nom: C    
                      57709-8   Fatty acid oxidation defects newborn screening comment-discussionFatty acid oxidation defects newborn screening comment-discussionFatty acid oxidation defects newborn screening comment-discussion: Txt: Pt: Bld.dot: Nar: C    
                      38481-8   Carnitine free (C0) [Moles/​volume] in Dried blood spotCarnitine free (C0) [Moles/​volume] in Dried blood spotCarnitine.free (C0): SCnc: Pt: Bld.dot: Qn: C   umol/L 
                      53233-3   Carnitine free (C0)/​Palmitoylcarnitine (C16) [Molar ratio] in Dried blood spotCarnitine free (C0)/​Palmitoylcarnitine (C16) [Molar ratio] in Dried blood spotCarnitine.free (C0)/​Palmitoylcarnitine (C16): SRto: Pt: Bld.dot: Qn: C   {Ratio} 
                      53234-1   Carnitine free (C0)/​Stearoylcarnitine (C18) [Molar ratio] in Dried blood spotCarnitine free (C0)/​Stearoylcarnitine (C18) [Molar ratio] in Dried blood spotCarnitine.free (C0)/​Stearoylcarnitine (C18): SRto: Pt: Bld.dot: Qn: C   {Ratio} 
                      53235-8   Carnitine free (C0)/​Palmitoylcarnitine (C16)+​Stearoylcarnitine (C18) [Molar ratio] in Dried blood spotCarnitine free (C0)/​Palmitoylcarnitine (C16)+​Stearoylcarnitine (C18) [Molar ratio] in Dried blood spotCarnitine.free (C0)/​Palmitoylcarnitine (C16)+​Stearoylcarnitine (C18): SRto: Pt: Bld.dot: Qn: C   {Ratio} 
                      53236-6   Carnitine.free (C0)+​Acetylcarnitine (C2)+​Propionylcarnitine (C3)+​Palmitoylcarnitine (C16)+​Oleoylcarnitine (C18:1)+​Stearoylcarnitine (C18)/​Citrulline [Molar ratio] in Dried blood spotCarnitine.free (C0)+​Acetylcarnitine (C2)+​Propionylcarnitine (C3)+​Palmitoylcarnitine (C16)+​Oleoylcarnitine (C18:1)+​Stearoylcarnitine (C18)/​Citrulline [Molar ratio] in Dried blood spotCarnitine.free (C0)+​Acetylcarnitine (C2)+​Propionylcarnitine (C3)+​Palmitoylcarnitine (C16)+​Oleoylcarnitine (C18:1)+​Stearoylcarnitine (C18)/​Citrulline: SRto: Pt: Bld.dot: Qn: C   {Ratio} 
                      75211-3   Propionylcarnitine (C3)+​Palmitoylcarnitine (C16) [Moles/​volume] in Dried blood spotPropionylcarnitine (C3)+​Palmitoylcarnitine (C16) [Moles/​volume] in Dried blood spotPropionylcarnitine (C3)+​Palmitoylcarnitine (C16): SCnc: Pt: Bld.dot: Qn: C   umol/L 
                      75212-1   Malonylcarnitine (C3-DC)/​Decanoylcarnitine (C10) [Molar ratio] in Dried blood spotMalonylcarnitine (C3-DC)/​Decanoylcarnitine (C10) [Molar ratio] in Dried blood spotMalonylcarnitine (C3-DC)/​Decanoylcarnitine (C10): SRto: Pt: Bld.dot: Qn: C   {ratio} 
                      54462-7   Malonylcarnitine (C3-DC) [Moles/​volume] in Dried blood spotMalonylcarnitine (C3-DC) [Moles/​volume] in Dried blood spotMalonylcarnitine (C3-DC): SCnc: Pt: Bld.dot: Qn: C   umol/L 
                      75213-9   Malonylcarnitine (C3-DC)+​3-Hydroxybutyrylcarnitine (C4-OH)/​Decanoylcarnitine (C10) [Molar ratio] in Dried blood spotMalonylcarnitine (C3-DC)+​3-Hydroxybutyrylcarnitine (C4-OH)/​Decanoylcarnitine (C10) [Molar ratio] in Dried blood spotMalonylcarnitine (C3-DC)+​3-Hydroxybutyrylcarnitine (C4-OH)/​Decanoylcarnitine (C10): SRto: Pt: Bld.dot: Qn: C   {ratio} 
                      50157-7   Acetylcarnitine (C2) [Moles/​volume] in Dried blood spotAcetylcarnitine (C2) [Moles/​volume] in Dried blood spotAcetylcarnitine (C2): SCnc: Pt: Bld.dot: Qn: C   umol/L 
                      53166-5   Butyrylcarnitine+​Isobutyrylcarnitine (C4) [Moles/​volume] in Dried blood spotButyrylcarnitine+​Isobutyrylcarnitine (C4) [Moles/​volume] in Dried blood spotButyrylcarnitine+​Isobutyrylcarnitine (C4): SCnc: Pt: Bld.dot: Qn: C   umol/L 
                      53167-3   Butyrylcarnitine+​Isobutyrylcarnitine (C4)/​Acetylcarnitine (C2) [Molar ratio] in Dried blood spotButyrylcarnitine+​Isobutyrylcarnitine (C4)/​Acetylcarnitine (C2) [Molar ratio] in Dried blood spotButyrylcarnitine+​Isobutyrylcarnitine (C4)/​Acetylcarnitine (C2): SRto: Pt: Bld.dot: Qn: C   {Ratio} 
                      53168-1   Butyrylcarnitine+​Isobutyrylcarnitine (C4)/​Propionylcarnitine (C3) [Molar ratio] in Dried blood spotButyrylcarnitine+​Isobutyrylcarnitine (C4)/​Propionylcarnitine (C3) [Molar ratio] in Dried blood spotButyrylcarnitine+​Isobutyrylcarnitine (C4)/​Propionylcarnitine (C3): SRto: Pt: Bld.dot: Qn: C   {Ratio} 
                      53169-9   Butyrylcarnitine+​Isobutyrylcarnitine (C4)/​Octanoylcarnitine (C8) [Molar ratio] in Dried blood spotButyrylcarnitine+​Isobutyrylcarnitine (C4)/​Octanoylcarnitine (C8) [Molar ratio] in Dried blood spotButyrylcarnitine+​Isobutyrylcarnitine (C4)/​Octanoylcarnitine (C8): SRto: Pt: Bld.dot: Qn: C   {Ratio} 
                      50102-3   3-Hydroxybutyrylcarnitine (C4-OH) [Moles/​volume] in Dried blood spot3-Hydroxybutyrylcarnitine (C4-OH) [Moles/​volume] in Dried blood spot3-Hydroxybutyrylcarnitine (C4-OH): SCnc: Pt: Bld.dot: Qn: C   umol/L 
                      45211-0   Hexanoylcarnitine (C6) [Moles/​volume] in Dried blood spotHexanoylcarnitine (C6) [Moles/​volume] in Dried blood spotHexanoylcarnitine (C6): SCnc: Pt: Bld.dot: Qn: C   umol/L 
                      53173-1   3-Hydroxyhexanoylcarnitine (C6-OH) [Moles/​volume] in Dried blood spot3-Hydroxyhexanoylcarnitine (C6-OH) [Moles/​volume] in Dried blood spot3-Hydroxyhexanoylcarnitine (C6-OH): SCnc: Pt: Bld.dot: Qn: C   umol/L 
                      45207-8   Glutarylcarnitine (C5-DC) [Moles/​volume] in Dried blood spotGlutarylcarnitine (C5-DC) [Moles/​volume] in Dried blood spotGlutarylcarnitine (C5-DC): SCnc: Pt: Bld.dot: Qn: C   umol/L 
                      53174-9   Octenoylcarnitine (C8:1) [Moles/​volume] in Dried blood spotOctenoylcarnitine (C8:1) [Moles/​volume] in Dried blood spotOctenoylcarnitine (C8:1): SCnc: Pt: Bld.dot: Qn: C   umol/L 
                      53175-6   Octanoylcarnitine (C8) [Moles/​volume] in Dried blood spotOctanoylcarnitine (C8) [Moles/​volume] in Dried blood spotOctanoylcarnitine (C8): SCnc: Pt: Bld.dot: Qn: C   umol/L 
                      53176-4   Octanoylcarnitine (C8)/​Acetylcarnitine (C2) [Molar ratio] in Dried blood spotOctanoylcarnitine (C8)/​Acetylcarnitine (C2) [Molar ratio] in Dried blood spotOctanoylcarnitine (C8)/​Acetylcarnitine (C2): SRto: Pt: Bld.dot: Qn: C   {Ratio} 
                      53177-2   Octanoylcarnitine (C8)/​Decanoylcarnitine (C10) [Molar ratio] in Dried blood spotOctanoylcarnitine (C8)/​Decanoylcarnitine (C10) [Molar ratio] in Dried blood spotOctanoylcarnitine (C8)/​Decanoylcarnitine (C10): SRto: Pt: Bld.dot: Qn: C   {Ratio} 
                      53178-0   3-Hydroxyoctanoylcarnitine (C8-OH)+​Malonylcarnitine (C3-DC) [Moles/​volume] in Dried blood spot3-Hydroxyoctanoylcarnitine (C8-OH)+​Malonylcarnitine (C3-DC) [Moles/​volume] in Dried blood spot3-Hydroxyoctanoylcarnitine (C8-OH)+​Malonylcarnitine (C3-DC): SCnc: Pt: Bld.dot: Qn: C   umol/L 
                      53402-4   3-Hydroxyoctanoylcarnitine (C8-OH)+​Malonylcarnitine (C3-DC)/​Butyrylcarnitine+​Isobutyrylcarnitine (C4) [Molar ratio] in Dried blood spot3-Hydroxyoctanoylcarnitine (C8-OH)+​Malonylcarnitine (C3-DC)/​Butyrylcarnitine+​Isobutyrylcarnitine (C4) [Molar ratio] in Dried blood spot3-Hydroxyoctanoylcarnitine (C8-OH)+​Malonylcarnitine (C3-DC)/​Butyrylcarnitine+​Isobutyrylcarnitine (C4): SRto: Pt: Bld.dot: Qn: C   {Ratio} 
                      53179-8   3-Hydroxyoctanoylcarnitine (C8-OH)+​Malonylcarnitine (C3-DC)/​Decanoylcarnitine (C10) [Molar ratio] in Dried blood spot3-Hydroxyoctanoylcarnitine (C8-OH)+​Malonylcarnitine (C3-DC)/​Decanoylcarnitine (C10) [Molar ratio] in Dried blood spot3-Hydroxyoctanoylcarnitine (C8-OH)+​Malonylcarnitine (C3-DC)/​Decanoylcarnitine (C10): SRto: Pt: Bld.dot: Qn: C   {Ratio} 
                      53180-6   Decadienoylcarnitine (C10:2) [Moles/​volume] in Dried blood spotDecadienoylcarnitine (C10:2) [Moles/​volume] in Dried blood spotDecadienoylcarnitine (C10:2): SCnc: Pt: Bld.dot: Qn: C   umol/L 
                      45198-9   Decenoylcarnitine (C10:1) [Moles/​volume] in Dried blood spotDecenoylcarnitine (C10:1) [Moles/​volume] in Dried blood spotDecenoylcarnitine (C10:1): SCnc: Pt: Bld.dot: Qn: C   umol/L 
                      45197-1   Decanoylcarnitine (C10) [Moles/​volume] in Dried blood spotDecanoylcarnitine (C10) [Moles/​volume] in Dried blood spotDecanoylcarnitine (C10): SCnc: Pt: Bld.dot: Qn: C   umol/L 
                      53182-2   3-Hydroxydecenoylcarnitine (C10:1-OH) [Moles/​volume] in Dried blood spot3-Hydroxydecenoylcarnitine (C10:1-OH) [Moles/​volume] in Dried blood spot3-Hydroxydecenoylcarnitine (C10:1-OH): SCnc: Pt: Bld.dot: Qn: C   umol/L 
                      53183-0   Glutarylcarnitine (C5-DC)+​3-Hydroxydecanoylcarnitine (C10-OH) [Moles/​volume] in Dried blood spotGlutarylcarnitine (C5-DC)+​3-Hydroxydecanoylcarnitine (C10-OH) [Moles/​volume] in Dried blood spotGlutarylcarnitine (C5-DC)+​3-Hydroxydecanoylcarnitine (C10-OH): SCnc: Pt: Bld.dot: Qn: C   umol/L 
                      53403-2   Glutarylcarnitine (C5-DC)+​3-Hydroxydecanoylcarnitine (C10-OH)/​Butyrylcarnitine+​Isobutyrylcarnitine (C4) [Molar ratio] in Dried blood spotGlutarylcarnitine (C5-DC)+​3-Hydroxydecanoylcarnitine (C10-OH)/​Butyrylcarnitine+​Isobutyrylcarnitine (C4) [Molar ratio] in Dried blood spotGlutarylcarnitine (C5-DC)+​3-Hydroxydecanoylcarnitine (C10-OH)/​Butyrylcarnitine+​Isobutyrylcarnitine (C4): SRto: Pt: Bld.dot: Qn: C   {Ratio} 
                      53184-8   Glutarylcarnitine (C5-DC)+​3-Hydroxydecanoylcarnitine (C10-OH)/​3-Hydroxyisovalerylcarnitine (C5-OH) [Molar ratio] in Dried blood spotGlutarylcarnitine (C5-DC)+​3-Hydroxydecanoylcarnitine (C10-OH)/​3-Hydroxyisovalerylcarnitine (C5-OH) [Molar ratio] in Dried blood spotGlutarylcarnitine (C5-DC)+​3-Hydroxydecanoylcarnitine (C10-OH)/​3-Hydroxyisovalerylcarnitine (C5-OH): SRto: Pt: Bld.dot: Qn: C   {Ratio} 
                      53185-5   Glutarylcarnitine (C5-DC)+​3-Hydroxydecanoylcarnitine (C10-OH)/​Octanoylcarnitine (C8) [Molar ratio] in Dried blood spotGlutarylcarnitine (C5-DC)+​3-Hydroxydecanoylcarnitine (C10-OH)/​Octanoylcarnitine (C8) [Molar ratio] in Dried blood spotGlutarylcarnitine (C5-DC)+​3-Hydroxydecanoylcarnitine (C10-OH)/​Octanoylcarnitine (C8): SRto: Pt: Bld.dot: Qn: C   {Ratio} 
                      53186-3   Glutarylcarnitine (C5-DC)+​3-Hydroxydecanoylcarnitine (C10-OH)/​Palmitoylcarnitine (C16) [Molar ratio] in Dried blood spotGlutarylcarnitine (C5-DC)+​3-Hydroxydecanoylcarnitine (C10-OH)/​Palmitoylcarnitine (C16) [Molar ratio] in Dried blood spotGlutarylcarnitine (C5-DC)+​3-Hydroxydecanoylcarnitine (C10-OH)/​Palmitoylcarnitine (C16): SRto: Pt: Bld.dot: Qn: C   {Ratio} 
                      45200-3   Dodecenoylcarnitine (C12:1) [Moles/​volume] in Dried blood spotDodecenoylcarnitine (C12:1) [Moles/​volume] in Dried blood spotDodecenoylcarnitine (C12:1): SCnc: Pt: Bld.dot: Qn: C   umol/L 
                      45199-7   Dodecanoylcarnitine (C12) [Moles/​volume] in Dried blood spotDodecanoylcarnitine (C12) [Moles/​volume] in Dried blood spotDodecanoylcarnitine (C12): SCnc: Pt: Bld.dot: Qn: C   umol/L 
                      53188-9   3-Hydroxydodecenoylcarnitine (C12:1-OH) [Moles/​volume] in Dried blood spot3-Hydroxydodecenoylcarnitine (C12:1-OH) [Moles/​volume] in Dried blood spot3-Hydroxydodecenoylcarnitine (C12:1-OH): SCnc: Pt: Bld.dot: Qn: C   umol/L 
                      53189-7   3-Hydroxydodecanoylcarnitine (C12-OH) [Moles/​volume] in Dried blood spot3-Hydroxydodecanoylcarnitine (C12-OH) [Moles/​volume] in Dried blood spot3-Hydroxydodecanoylcarnitine (C12-OH): SCnc: Pt: Bld.dot: Qn: C   umol/L 
                      53190-5   Tetradecadienoylcarnitine (C14:2) [Moles/​volume] in Dried blood spotTetradecadienoylcarnitine (C14:2) [Moles/​volume] in Dried blood spotTetradecadienoylcarnitine (C14:2): SCnc: Pt: Bld.dot: Qn: C   umol/L 
                      53191-3   Tetradecenoylcarnitine (C14:1) [Moles/​volume] in Dried blood spotTetradecenoylcarnitine (C14:1) [Moles/​volume] in Dried blood spotTetradecenoylcarnitine (C14:1): SCnc: Pt: Bld.dot: Qn: C   umol/L 
                      53192-1   Tetradecanoylcarnitine (C14) [Moles/​volume] in Dried blood spotTetradecanoylcarnitine (C14) [Moles/​volume] in Dried blood spotTetradecanoylcarnitine (C14): SCnc: Pt: Bld.dot: Qn: C   umol/L 
                      53193-9   Tetradecenoylcarnitine (C14:1)/​Acetylcarnitine (C2) [Molar ratio] in Dried blood spotTetradecenoylcarnitine (C14:1)/​Acetylcarnitine (C2) [Molar ratio] in Dried blood spotTetradecenoylcarnitine (C14:1)/​Acetylcarnitine (C2): SRto: Pt: Bld.dot: Qn: C   {Ratio} 
                      53194-7   Tetradecenoylcarnitine (C14:1)/​Dodecenoylcarnitine (C12:1) [Molar ratio] in Dried blood spotTetradecenoylcarnitine (C14:1)/​Dodecenoylcarnitine (C12:1) [Molar ratio] in Dried blood spotTetradecenoylcarnitine (C14:1)/​Dodecenoylcarnitine (C12:1): SRto: Pt: Bld.dot: Qn: C   {Ratio} 
                      53195-4   Tetradecenoylcarnitine (C14:1)/​Palmitoylcarnitine (C16) [Molar ratio] in Dried blood spotTetradecenoylcarnitine (C14:1)/​Palmitoylcarnitine (C16) [Molar ratio] in Dried blood spotTetradecenoylcarnitine (C14:1)/​Palmitoylcarnitine (C16): SRto: Pt: Bld.dot: Qn: C   {Ratio} 
                      70159-9   Tetradecenoylcarnitine (C14:1)/​Tetradecanoylcarnitine (C14) [Molar ratio] in Dried blood spotTetradecenoylcarnitine (C14:1)/​Tetradecanoylcarnitine (C14) [Molar ratio] in Dried blood spotTetradecenoylcarnitine (C14:1)/​Tetradecanoylcarnitine (C14): SRto: Pt: Bld.dot: Qn: C   {ratio} 
                      53196-2   3-Hydroxytetradecadienoylcarnitine (C14:2-OH) [Moles/​volume] in Dried blood spot3-Hydroxytetradecadienoylcarnitine (C14:2-OH) [Moles/​volume] in Dried blood spot3-Hydroxytetradecadienoylcarnitine (C14:2-OH): SCnc: Pt: Bld.dot: Qn: C   umol/L 
                      53197-0   3-Hydroxytetradecenoylcarnitine (C14:1-OH) [Moles/​volume] in Dried blood spot3-Hydroxytetradecenoylcarnitine (C14:1-OH) [Moles/​volume] in Dried blood spot3-Hydroxytetradecenoylcarnitine (C14:1-OH): SCnc: Pt: Bld.dot: Qn: C   umol/L 
                      50281-5   3-Hydroxytetradecanoylcarnitine (C14-OH) [Moles/​volume] in Dried blood spot3-Hydroxytetradecanoylcarnitine (C14-OH) [Moles/​volume] in Dried blood spot3-Hydroxytetradecanoylcarnitine (C14-OH): SCnc: Pt: Bld.dot: Qn: C   umol/L 
                      53198-8   Palmitoleylcarnitine (C16:1) [Moles/​volume] in Dried blood spotPalmitoleylcarnitine (C16:1) [Moles/​volume] in Dried blood spotPalmitoleylcarnitine (C16:1): SCnc: Pt: Bld.dot: Qn: C   umol/L 
                      53199-6   Palmitoylcarnitine (C16) [Moles/​volume] in Dried blood spotPalmitoylcarnitine (C16) [Moles/​volume] in Dried blood spotPalmitoylcarnitine (C16): SCnc: Pt: Bld.dot: Qn: C   umol/L 
                      50121-3   3-Hydroxypalmitoleylcarnitine (C16:1-OH) [Moles/​volume] in Dried blood spot3-Hydroxypalmitoleylcarnitine (C16:1-OH) [Moles/​volume] in Dried blood spot3-Hydroxypalmitoleylcarnitine (C16:1-OH): SCnc: Pt: Bld.dot: Qn: C   umol/L 
                      50125-4   3-Hydroxypalmitoylcarnitine (C16-OH) [Moles/​volume] in Dried blood spot3-Hydroxypalmitoylcarnitine (C16-OH) [Moles/​volume] in Dried blood spot3-Hydroxypalmitoylcarnitine (C16-OH): SCnc: Pt: Bld.dot: Qn: C   umol/L 
                      53201-0   3-Hydroxypalmitoylcarnitine (C16-OH)/​Palmitoylcarnitine (C16) [Molar ratio] in Dried blood spot3-Hydroxypalmitoylcarnitine (C16-OH)/​Palmitoylcarnitine (C16) [Molar ratio] in Dried blood spot3-Hydroxypalmitoylcarnitine (C16-OH)/​Palmitoylcarnitine (C16): SRto: Pt: Bld.dot: Qn: C   {Ratio} 
                      45217-7   Linoleoylcarnitine (C18:2) [Moles/​volume] in Dried blood spotLinoleoylcarnitine (C18:2) [Moles/​volume] in Dried blood spotLinoleoylcarnitine (C18:2): SCnc: Pt: Bld.dot: Qn: C   umol/L 
                      53202-8   Oleoylcarnitine (C18:1) [Moles/​volume] in Dried blood spotOleoylcarnitine (C18:1) [Moles/​volume] in Dried blood spotOleoylcarnitine (C18:1): SCnc: Pt: Bld.dot: Qn: C   umol/L 
                      53241-6   Stearoylcarnitine (C18) [Moles/​volume] in Dried blood spotStearoylcarnitine (C18) [Moles/​volume] in Dried blood spotStearoylcarnitine (C18): SCnc: Pt: Bld.dot: Qn: C   umol/L 
                      53400-8   Stearoylcarnitine (C18)/​Propionylcarnitine (C3) [Molar ratio] in Dried blood spotStearoylcarnitine (C18)/​Propionylcarnitine (C3) [Molar ratio] in Dried blood spotStearoylcarnitine (C18)/​Propionylcarnitine (C3): SRto: Pt: Bld.dot: Qn: C   {Ratio} 
                      50109-8   3-Hydroxylinoleoylcarnitine (C18:2-OH) [Moles/​volume] in Dried blood spot3-Hydroxylinoleoylcarnitine (C18:2-OH) [Moles/​volume] in Dried blood spot3-Hydroxylinoleoylcarnitine (C18:2-OH): SCnc: Pt: Bld.dot: Qn: C   umol/L 
                      50113-0   3-Hydroxyoleoylcarnitine (C18:1-OH) [Moles/​volume] in Dried blood spot3-Hydroxyoleoylcarnitine (C18:1-OH) [Moles/​volume] in Dried blood spot3-Hydroxyoleoylcarnitine (C18:1-OH): SCnc: Pt: Bld.dot: Qn: C   umol/L 
                      50132-0   3-Hydroxystearoylcarnitine (C18-OH) [Moles/​volume] in Dried blood spot3-Hydroxystearoylcarnitine (C18-OH) [Moles/​volume] in Dried blood spot3-Hydroxystearoylcarnitine (C18-OH): SCnc: Pt: Bld.dot: Qn: C   umol/L 
                      53836-3   ABCD1 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method NarrativeABCD1 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method NarrativeABCD1 gene targeted mutation analysis: Prid: Pt: Bld/​Tiss: Nar: Molgen    
                 57085-3   Organic acid newborn screen panelOrganic acid newborn screen panelOrganic acid newborn screen panel: -: Pt: Bld.dot: -: C    
                      46744-9   Organic acidemias newborn screen interpretationOrganic acidemias newborn screen interpretationOrganic acidemias: Imp: Pt: Bld.dot: Nom: C    
                      57791-6   Organic acidemia conditions suspected [Identifier] in Dried blood spotOrganic acidemia conditions suspected [Identifier] in Dried blood spotOrganic acidemia conditions suspected: Prid: Pt: Bld.dot: Nom: C    
                      57708-0   Organic acidemias defects newborn screening comment-discussionOrganic acidemias defects newborn screening comment-discussionOrganic acidemias defects newborn screening comment-discussion: Txt: Pt: Bld.dot: Nar: C    
                      50157-7   Acetylcarnitine (C2) [Moles/​volume] in Dried blood spotAcetylcarnitine (C2) [Moles/​volume] in Dried blood spotAcetylcarnitine (C2): SCnc: Pt: Bld.dot: Qn: C   umol/L 
                      53237-4   Acrylylcarnitine (C3:1) [Moles/​volume] in Dried blood spotAcrylylcarnitine (C3:1) [Moles/​volume] in Dried blood spotAcrylylcarnitine (C3:1): SCnc: Pt: Bld.dot: Qn: C   umol/L 
                      53160-8   Propionylcarnitine (C3) [Moles/​volume] in Dried blood spotPropionylcarnitine (C3) [Moles/​volume] in Dried blood spotPropionylcarnitine (C3): SCnc: Pt: Bld.dot: Qn: C   umol/L 
                      53161-6   Propionylcarnitine (C3)/​Methionine [Molar ratio] in Dried blood spotPropionylcarnitine (C3)/​Methionine [Molar ratio] in Dried blood spotPropionylcarnitine (C3)/​Methionine: SRto: Pt: Bld.dot: Qn: C   {Ratio} 
                      53162-4   Propionylcarnitine (C3)/​Carnitine.free (C0) [Molar ratio] in Dried blood spotPropionylcarnitine (C3)/​Carnitine.free (C0) [Molar ratio] in Dried blood spotPropionylcarnitine (C3)/​Carnitine.free (C0): SRto: Pt: Bld.dot: Qn: C   {Ratio} 
                      53163-2   Propionylcarnitine (C3)/​Acetylcarnitine (C2) [Molar ratio] in Dried blood spotPropionylcarnitine (C3)/​Acetylcarnitine (C2) [Molar ratio] in Dried blood spotPropionylcarnitine (C3)/​Acetylcarnitine (C2): SRto: Pt: Bld.dot: Qn: C   {Ratio} 
                      54462-7   Malonylcarnitine (C3-DC) [Moles/​volume] in Dried blood spotMalonylcarnitine (C3-DC) [Moles/​volume] in Dried blood spotMalonylcarnitine (C3-DC): SCnc: Pt: Bld.dot: Qn: C   umol/L 
                      67708-8   Malonylcarnitine (C3-DC)+​3-Hydroxybutyrylcarnitine (C4-OH) [Moles/​volume] in Dried blood spotMalonylcarnitine (C3-DC)+​3-Hydroxybutyrylcarnitine (C4-OH) [Moles/​volume] in Dried blood spotMalonylcarnitine (C3-DC)+​3-Hydroxybutyrylcarnitine (C4-OH): SCnc: Pt: Bld.dot: Qn: C   umol/L 
                      75213-9   Malonylcarnitine (C3-DC)+​3-Hydroxybutyrylcarnitine (C4-OH)/​Decanoylcarnitine (C10) [Molar ratio] in Dried blood spotMalonylcarnitine (C3-DC)+​3-Hydroxybutyrylcarnitine (C4-OH)/​Decanoylcarnitine (C10) [Molar ratio] in Dried blood spotMalonylcarnitine (C3-DC)+​3-Hydroxybutyrylcarnitine (C4-OH)/​Decanoylcarnitine (C10): SRto: Pt: Bld.dot: Qn: C   {ratio} 
                      53164-0   Propionylcarnitine (C3)/​Palmitoylcarnitine (C16) [Molar ratio] in Dried blood spotPropionylcarnitine (C3)/​Palmitoylcarnitine (C16) [Molar ratio] in Dried blood spotPropionylcarnitine (C3)/​Palmitoylcarnitine (C16): SRto: Pt: Bld.dot: Qn: C   {Ratio} 
                      53166-5   Butyrylcarnitine+​Isobutyrylcarnitine (C4) [Moles/​volume] in Dried blood spotButyrylcarnitine+​Isobutyrylcarnitine (C4) [Moles/​volume] in Dried blood spotButyrylcarnitine+​Isobutyrylcarnitine (C4): SCnc: Pt: Bld.dot: Qn: C   umol/L 
                      53167-3   Butyrylcarnitine+​Isobutyrylcarnitine (C4)/​Acetylcarnitine (C2) [Molar ratio] in Dried blood spotButyrylcarnitine+​Isobutyrylcarnitine (C4)/​Acetylcarnitine (C2) [Molar ratio] in Dried blood spotButyrylcarnitine+​Isobutyrylcarnitine (C4)/​Acetylcarnitine (C2): SRto: Pt: Bld.dot: Qn: C   {Ratio} 
                      53168-1   Butyrylcarnitine+​Isobutyrylcarnitine (C4)/​Propionylcarnitine (C3) [Molar ratio] in Dried blood spotButyrylcarnitine+​Isobutyrylcarnitine (C4)/​Propionylcarnitine (C3) [Molar ratio] in Dried blood spotButyrylcarnitine+​Isobutyrylcarnitine (C4)/​Propionylcarnitine (C3): SRto: Pt: Bld.dot: Qn: C   {Ratio} 
                      53169-9   Butyrylcarnitine+​Isobutyrylcarnitine (C4)/​Octanoylcarnitine (C8) [Molar ratio] in Dried blood spotButyrylcarnitine+​Isobutyrylcarnitine (C4)/​Octanoylcarnitine (C8) [Molar ratio] in Dried blood spotButyrylcarnitine+​Isobutyrylcarnitine (C4)/​Octanoylcarnitine (C8): SRto: Pt: Bld.dot: Qn: C   {Ratio} 
                      53170-7   Tiglylcarnitine (C5:1) [Moles/​volume] in Dried blood spotTiglylcarnitine (C5:1) [Moles/​volume] in Dried blood spotTiglylcarnitine (C5:1): SCnc: Pt: Bld.dot: Qn: C   umol/L 
                      45207-8   Glutarylcarnitine (C5-DC) [Moles/​volume] in Dried blood spotGlutarylcarnitine (C5-DC) [Moles/​volume] in Dried blood spotGlutarylcarnitine (C5-DC): SCnc: Pt: Bld.dot: Qn: C   umol/L 
                      75216-2   Glutarylcarnitine (C5-DC)/​Malonylcarnitine (C3-DC) [Molar ratio] in Dried blood spotGlutarylcarnitine (C5-DC)/​Malonylcarnitine (C3-DC) [Molar ratio] in Dried blood spotGlutarylcarnitine (C5-DC)/​Malonylcarnitine (C3-DC): SRto: Pt: Bld.dot: Qn:   {ratio} 
                      67701-3   Glutarylcarnitine (C5-DC)+​3-Hydroxyhexanoylcarnitine (C6-OH)/​Palmitoylcarnitine (C16) [Molar ratio] in Dried blood spotGlutarylcarnitine (C5-DC)+​3-Hydroxyhexanoylcarnitine (C6-OH)/​Palmitoylcarnitine (C16) [Molar ratio] in Dried blood spotGlutarylcarnitine (C5-DC)+​3-Hydroxyhexanoylcarnitine (C6-OH)/​Palmitoylcarnitine (C16): SRto: Pt: Bld.dot: Qn: C   {Ratio} 
                      67710-4   Glutarylcarnitine (C5-DC)+​3-Hydroxyhexanoylcarnitine (C6-OH) [Moles/​volume] in Dried blood spotGlutarylcarnitine (C5-DC)+​3-Hydroxyhexanoylcarnitine (C6-OH) [Moles/​volume] in Dried blood spotGlutarylcarnitine (C5-DC)+​3-Hydroxyhexanoylcarnitine (C6-OH): SCnc: Pt: Bld.dot: Qn: C   umol/L 
                      67711-2   Glutarylcarnitine (C5-DC)+​3-Hydroxyhexanoylcarnitine (C6-OH)/​Octanoylcarnitine (C8) [Molar ratio] in Dried blood spotGlutarylcarnitine (C5-DC)+​3-Hydroxyhexanoylcarnitine (C6-OH)/​Octanoylcarnitine (C8) [Molar ratio] in Dried blood spotGlutarylcarnitine (C5-DC)+​3-Hydroxyhexanoylcarnitine (C6-OH)/​Octanoylcarnitine (C8): SRto: Pt: Bld.dot: Qn: C   {Ratio} 
                      45216-9   Isovalerylcarnitine+​Methylbutyrylcarnitine (C5) [Moles/​volume] in Dried blood spotIsovalerylcarnitine+​Methylbutyrylcarnitine (C5) [Moles/​volume] in Dried blood spotIsovalerylcarnitine+​Methylbutyrylcarnitine (C5): SCnc: Pt: Bld.dot: Qn: C   umol/L 
                      53238-2   Isovalerylcarnitine+​Methylbutyrylcarnitine (C5)/​Carnitine.free (C0) [Molar ratio] in Dried blood spotIsovalerylcarnitine+​Methylbutyrylcarnitine (C5)/​Carnitine.free (C0) [Molar ratio] in Dried blood spotIsovalerylcarnitine+​Methylbutyrylcarnitine (C5)/​Carnitine.free (C0): SRto: Pt: Bld.dot: Qn: C   {Ratio} 
                      53239-0   Isovalerylcarnitine+​Methylbutyrylcarnitine (C5)/​Acetylcarnitine (C2) [Molar ratio] in Dried blood spotIsovalerylcarnitine+​Methylbutyrylcarnitine (C5)/​Acetylcarnitine (C2) [Molar ratio] in Dried blood spotIsovalerylcarnitine+​Methylbutyrylcarnitine (C5)/​Acetylcarnitine (C2): SRto: Pt: Bld.dot: Qn: C   {Ratio} 
                      53240-8   Isovalerylcarnitine+​Methylbutyrylcarnitine (C5)/​Propionylcarnitine (C3) [Molar ratio] in Dried blood spotIsovalerylcarnitine+​Methylbutyrylcarnitine (C5)/​Propionylcarnitine (C3) [Molar ratio] in Dried blood spotIsovalerylcarnitine+​Methylbutyrylcarnitine (C5)/​Propionylcarnitine (C3): SRto: Pt: Bld.dot: Qn: C   {Ratio} 
                      53401-6   Isovalerylcarnitine+​Methylbutyrylcarnitine (C5)/​Octanoylcarnitine (C8) [Molar ratio] in Dried blood spotIsovalerylcarnitine+​Methylbutyrylcarnitine (C5)/​Octanoylcarnitine (C8) [Molar ratio] in Dried blood spotIsovalerylcarnitine+​Methylbutyrylcarnitine (C5)/​Octanoylcarnitine (C8): SRto: Pt: Bld.dot: Qn: C   {Ratio} 
                      50106-4   3-Hydroxyisovalerylcarnitine (C5-OH) [Moles/​volume] in Dried blood spot3-Hydroxyisovalerylcarnitine (C5-OH) [Moles/​volume] in Dried blood spot3-Hydroxyisovalerylcarnitine (C5-OH): SCnc: Pt: Bld.dot: Qn: C   umol/L 
                      53171-5   3-Hydroxyisovalerylcarnitine (C5-OH)/​Carnitine.free (C0) [Molar ratio] in Dried blood spot3-Hydroxyisovalerylcarnitine (C5-OH)/​Carnitine.free (C0) [Molar ratio] in Dried blood spot3-Hydroxyisovalerylcarnitine (C5-OH)/​Carnitine.free (C0): SRto: Pt: Bld.dot: Qn: C   {Ratio} 
                      53172-3   3-Hydroxyisovalerylcarnitine (C5-OH)/​Octanoylcarnitine (C8) [Molar ratio] in Dried blood spot3-Hydroxyisovalerylcarnitine (C5-OH)/​Octanoylcarnitine (C8) [Molar ratio] in Dried blood spot3-Hydroxyisovalerylcarnitine (C5-OH)/​Octanoylcarnitine (C8): SRto: Pt: Bld.dot: Qn: C   {Ratio} 
                      53178-0   3-Hydroxyoctanoylcarnitine (C8-OH)+​Malonylcarnitine (C3-DC) [Moles/​volume] in Dried blood spot3-Hydroxyoctanoylcarnitine (C8-OH)+​Malonylcarnitine (C3-DC) [Moles/​volume] in Dried blood spot3-Hydroxyoctanoylcarnitine (C8-OH)+​Malonylcarnitine (C3-DC): SCnc: Pt: Bld.dot: Qn: C   umol/L 
                      53402-4   3-Hydroxyoctanoylcarnitine (C8-OH)+​Malonylcarnitine (C3-DC)/​Butyrylcarnitine+​Isobutyrylcarnitine (C4) [Molar ratio] in Dried blood spot3-Hydroxyoctanoylcarnitine (C8-OH)+​Malonylcarnitine (C3-DC)/​Butyrylcarnitine+​Isobutyrylcarnitine (C4) [Molar ratio] in Dried blood spot3-Hydroxyoctanoylcarnitine (C8-OH)+​Malonylcarnitine (C3-DC)/​Butyrylcarnitine+​Isobutyrylcarnitine (C4): SRto: Pt: Bld.dot: Qn: C   {Ratio} 
                      53179-8   3-Hydroxyoctanoylcarnitine (C8-OH)+​Malonylcarnitine (C3-DC)/​Decanoylcarnitine (C10) [Molar ratio] in Dried blood spot3-Hydroxyoctanoylcarnitine (C8-OH)+​Malonylcarnitine (C3-DC)/​Decanoylcarnitine (C10) [Molar ratio] in Dried blood spot3-Hydroxyoctanoylcarnitine (C8-OH)+​Malonylcarnitine (C3-DC)/​Decanoylcarnitine (C10): SRto: Pt: Bld.dot: Qn: C   {Ratio} 
                      45222-7   Methylmalonylcarnitine (C4-DC) [Moles/​volume] in Dried blood spotMethylmalonylcarnitine (C4-DC) [Moles/​volume] in Dried blood spotMethylmalonylcarnitine (C4-DC): SCnc: Pt: Bld.dot: Qn: C   umol/L 
                      67709-6   Methylmalonylcarnitine (C4-DC)+​3-Hydroxyisovalerylcarnitine (C5-OH) [Moles/​volume] in Dried blood spotMethylmalonylcarnitine (C4-DC)+​3-Hydroxyisovalerylcarnitine (C5-OH) [Moles/​volume] in Dried blood spotMethylmalonylcarnitine (C4-DC)+​3-Hydroxyisovalerylcarnitine (C5-OH): SCnc: Pt: Bld.dot: Qn: C   umol/L 
                      53181-4   Methylmalonylcarnitine (C4-DC)/​3-Hydroxyisovalerylcarnitine (C5-OH) [Molar ratio] in Dried blood spotMethylmalonylcarnitine (C4-DC)/​3-Hydroxyisovalerylcarnitine (C5-OH) [Molar ratio] in Dried blood spotMethylmalonylcarnitine (C4-DC)/​3-Hydroxyisovalerylcarnitine (C5-OH): SRto: Pt: Bld.dot: Qn: C   {Ratio} 
                      53183-0   Glutarylcarnitine (C5-DC)+​3-Hydroxydecanoylcarnitine (C10-OH) [Moles/​volume] in Dried blood spotGlutarylcarnitine (C5-DC)+​3-Hydroxydecanoylcarnitine (C10-OH) [Moles/​volume] in Dried blood spotGlutarylcarnitine (C5-DC)+​3-Hydroxydecanoylcarnitine (C10-OH): SCnc: Pt: Bld.dot: Qn: C   umol/L 
                      53403-2   Glutarylcarnitine (C5-DC)+​3-Hydroxydecanoylcarnitine (C10-OH)/​Butyrylcarnitine+​Isobutyrylcarnitine (C4) [Molar ratio] in Dried blood spotGlutarylcarnitine (C5-DC)+​3-Hydroxydecanoylcarnitine (C10-OH)/​Butyrylcarnitine+​Isobutyrylcarnitine (C4) [Molar ratio] in Dried blood spotGlutarylcarnitine (C5-DC)+​3-Hydroxydecanoylcarnitine (C10-OH)/​Butyrylcarnitine+​Isobutyrylcarnitine (C4): SRto: Pt: Bld.dot: Qn: C   {Ratio} 
                      53184-8   Glutarylcarnitine (C5-DC)+​3-Hydroxydecanoylcarnitine (C10-OH)/​3-Hydroxyisovalerylcarnitine (C5-OH) [Molar ratio] in Dried blood spotGlutarylcarnitine (C5-DC)+​3-Hydroxydecanoylcarnitine (C10-OH)/​3-Hydroxyisovalerylcarnitine (C5-OH) [Molar ratio] in Dried blood spotGlutarylcarnitine (C5-DC)+​3-Hydroxydecanoylcarnitine (C10-OH)/​3-Hydroxyisovalerylcarnitine (C5-OH): SRto: Pt: Bld.dot: Qn: C   {Ratio} 
                      53185-5   Glutarylcarnitine (C5-DC)+​3-Hydroxydecanoylcarnitine (C10-OH)/​Octanoylcarnitine (C8) [Molar ratio] in Dried blood spotGlutarylcarnitine (C5-DC)+​3-Hydroxydecanoylcarnitine (C10-OH)/​Octanoylcarnitine (C8) [Molar ratio] in Dried blood spotGlutarylcarnitine (C5-DC)+​3-Hydroxydecanoylcarnitine (C10-OH)/​Octanoylcarnitine (C8): SRto: Pt: Bld.dot: Qn: C   {Ratio} 
                      53186-3   Glutarylcarnitine (C5-DC)+​3-Hydroxydecanoylcarnitine (C10-OH)/​Palmitoylcarnitine (C16) [Molar ratio] in Dried blood spotGlutarylcarnitine (C5-DC)+​3-Hydroxydecanoylcarnitine (C10-OH)/​Palmitoylcarnitine (C16) [Molar ratio] in Dried blood spotGlutarylcarnitine (C5-DC)+​3-Hydroxydecanoylcarnitine (C10-OH)/​Palmitoylcarnitine (C16): SRto: Pt: Bld.dot: Qn: C   {Ratio} 
                      53187-1   Methylglutarylcarnitine (C6-DC) [Moles/​volume] in Dried blood spotMethylglutarylcarnitine (C6-DC) [Moles/​volume] in Dried blood spotMethylglutarylcarnitine (C6-DC): SCnc: Pt: Bld.dot: Qn: C   umol/L 
                      53165-7   Formiminoglutamate [Moles/​volume] in Dried blood spotFormiminoglutamate [Moles/​volume] in Dried blood spotFormiminoglutamate: SCnc: Pt: Bld.dot: Qn: C   umol/L 
            54078-1   Cystic fibrosis newborn screening panelCystic fibrosis newborn screening panelCystic fibrosis newborn screening panel: -: Pt: ^Patient: -: C    
                 46769-6   Cystic fibrosis newborn screen interpretationCystic fibrosis newborn screen interpretationCystic fibrosis: Imp: Pt: Bld.dot: Nom: R 1..1   
                 57707-2   Cystic fibrosis newborn screening comment-discussionCystic fibrosis newborn screening comment-discussionCystic fibrosis newborn screening comment-discussion: Txt: Pt: Bld.dot: Nar: C    
                 54083-1   CFTR gene mutations found [Identifier] in Dried blood spot NominalCFTR gene mutations found [Identifier] in Dried blood spot NominalCFTR gene targeted mutation analysis: Prid: Pt: Bld.dot: Nom: C    
                 2077-6   Chloride [Moles/​volume] in SweatChloride [Moles/​volume] in SweatChloride: SCnc: Pt: Sweat: Qn: C   mmol/L 
                 48633-2   Trypsinogen I Free [Mass/​volume] in Dried blood spotTrypsinogen I Free [Mass/​volume] in Dried blood spotTrypsinogen I.free: MCnc: Pt: Bld.dot: Qn: C   ug/L 
            54076-5   Endocrine newborn screening panelEndocrine newborn screening panelEndocrine newborn screening panel: -: Pt: Bld.dot: -: C    
                 57086-1   Congenital adrenal hyperplasia newborn screening panelCongenital adrenal hyperplasia newborn screening panelCongenital adrenal hyperplasia newborn screening panel: -: Pt: Bld.dot: -: C    
                      46758-9   Congenital adrenal hyperplasia newborn screen interpretationCongenital adrenal hyperplasia newborn screen interpretationCongenital adrenal hyperplasia: Imp: Pt: Bld.dot: Nom: R 1..1   
                      57706-4   Congenital adrenal hyperplasia newborn screening comment-discussionCongenital adrenal hyperplasia newborn screening comment-discussionCongenital adrenal hyperplasia newborn screening comment-discussion: Txt: Pt: Bld.dot: Nar: C    
                      53347-1   11-Deoxycorticosterone [Mass/​volume] in Dried blood spot11-Deoxycorticosterone [Mass/​volume] in Dried blood spot11-Deoxycorticosterone: MCnc: Pt: Bld.dot: Qn: C   ng/dL 
                      53338-0   11-Deoxycortisol [Mass/​volume] in Dried blood spot11-Deoxycortisol [Mass/​volume] in Dried blood spot11-Deoxycortisol: MCnc: Pt: Bld.dot: Qn: C   ug/dL 
                      38473-5   17-Hydroxyprogesterone [Mass/​volume] in Dried blood spot17-Hydroxyprogesterone [Mass/​volume] in Dried blood spot17-Hydroxyprogesterone: MCnc: Pt: Bld.dot: Qn: C   ng/mL 
                      53336-4   17-Hydroxyprogesterone+​Androstenedione/​Cortisol [Mass Ratio] in Dried blood spot17-Hydroxyprogesterone+​Androstenedione/​Cortisol [Mass Ratio] in Dried blood spot17-Hydroxyprogesterone+​Androstenedione/​Cortisol: MRto: Pt: Bld.dot: Qn: C   {ratio} 
                      53341-4   21-Deoxycortisol [Mass/​volume] in Dried blood spot21-Deoxycortisol [Mass/​volume] in Dried blood spot21-Deoxycortisol: MCnc: Pt: Bld.dot: Qn: C   ug/dL 
                      53343-0   Androstenedione [Mass/​volume] in Dried blood spotAndrostenedione [Mass/​volume] in Dried blood spotAndrostenedione: MCnc: Pt: Bld.dot: Qn: C   ng/dL 
                      53345-5   Cortisol [Mass/​volume] in Dried blood spotCortisol [Mass/​volume] in Dried blood spotCortisol: MCnc: Pt: Bld.dot: Qn: C   ug/dL 
                 54090-6   Thyroid newborn screening panelThyroid newborn screening panelThyroid newborn screening panel: -: Pt: Bld.dot: -: C    
                      46762-1   Congenital hypothyroidism newborn screen interpretationCongenital hypothyroidism newborn screen interpretationCongenital hypothyroidism: Imp: Pt: Bld.dot: Nom: R    
                      57705-6   Congenital hypothyroidism newborn screening comment-discussionCongenital hypothyroidism newborn screening comment-discussionCongenital hypothyroidism newborn screening comment-discussion: Txt: Pt: Bld.dot: Nar: C    
                      31144-9   Thyroxine (T4) [Mass/​volume] in Dried blood spotThyroxine (T4) [Mass/​volume] in Dried blood spotThyroxine: MCnc: Pt: Bld.dot: Qn: C   ug/dL 
                      29575-8   Thyrotropin [Units/​volume] in Dried blood spotThyrotropin [Units/​volume] in Dried blood spotThyrotropin: ACnc: Pt: Bld.dot: Qn: C   m[IU]/L 
            54079-9   Galactosemia newborn screening panelGalactosemia newborn screening panelGalactosemia newborn screening panel: -: Pt: Bld.dot: -: C    
                 46737-3   Galactosemias newborn screen interpretationGalactosemias newborn screen interpretationGalactosemias: Imp: Pt: Bld.dot: Nom: R 1..1   
                 57704-9   Galactosemias newborn screening comment-discussionGalactosemias newborn screening comment-discussionGalactosemias newborn screening comment-discussion: Txt: Pt: Bld.dot: Nar: C    
                 54084-9   Galactose [Mass/​volume] in Dried blood spotGalactose [Mass/​volume] in Dried blood spotGalactose: MCnc: Pt: Bld.dot: Qn: C   mg/dL 
                 33288-2   Galactose 1 phosphate uridyl transferase [Presence] in Dried blood spotGalactose 1 phosphate uridyl transferase [Presence] in Dried blood spotGalactose 1 phosphate uridyl transferase: PrThr: Pt: Bld.dot: Ord: C    
                 42906-8   Galactose 1 phosphate uridyl transferase [Enzymatic activity/​volume] in Dried blood spotGalactose 1 phosphate uridyl transferase [Enzymatic activity/​volume] in Dried blood spotGalactose 1 phosphate uridyl transferase: CCnc: Pt: Bld.dot: Qn: C   nmol/h/mL 
                 40842-7   Galactose 1 phosphate [Mass/​volume] in Dried blood spotGalactose 1 phosphate [Mass/​volume] in Dried blood spotGalactose 1 phosphate: MCnc: Pt: Bld.dot: Qn: C   mg/dL 
            54081-5   Hemoglobinopathies newborn screening panelHemoglobinopathies newborn screening panelHemoglobinopathies newborn screening panel: -: Pt: Bld.dot: -: C    
                 64116-7   Hemoglobin observations newborn screening panelHemoglobin observations newborn screening panelHemoglobin observations newborn screening panel: -: Pt: Bld.dot: -:    
                      64122-5   Hemoglobins that can be presumptively identified based on available controls in Dried blood spotHemoglobins that can be presumptively identified based on available controls in Dried blood spotHemoglobins that can be presumptively identified based on available controls: Find: Pt: Bld.dot: Nom: C    
                      64117-5   Most predominant hemoglobin in Dried blood spotMost predominant hemoglobin in Dried blood spotMost predominant hemoglobin: Find: Pt: Bld.dot: Nom: C    
                      64118-3   Second most predominant hemoglobin in Dried blood spotSecond most predominant hemoglobin in Dried blood spotSecond most predominant hemoglobin: Find: Pt: Bld.dot: Nom: C    
                      64119-1   Third most predominant hemoglobin in Dried blood spotThird most predominant hemoglobin in Dried blood spotThird most predominant hemoglobin: Find: Pt: Bld.dot: Nom: C    
                      64120-9   Fourth most predominant hemoglobin in Dried blood spotFourth most predominant hemoglobin in Dried blood spotFourth most predominant hemoglobin: Find: Pt: Bld.dot: Nom: C    
                      64121-7   Fifth most predominant hemoglobin in Dried blood spotFifth most predominant hemoglobin in Dried blood spotFifth most predominant hemoglobin: Find: Pt: Bld.dot: Nom: C    
                 46740-7   Hemoglobin disorders newborn screen interpretationHemoglobin disorders newborn screen interpretationHemoglobin disorders: Imp: Pt: Bld.dot: Nom: R 1..1   
                 57703-1   Hemoglobin disorders newborn screening comment-discussionHemoglobin disorders newborn screening comment-discussionHemoglobin disorders newborn screening comment-discussion: Txt: Pt: Bld.dot: Nar: C    
                 71592-0   Hemoglobinopathies conditions suspected [Identifier] in Dried blood spotHemoglobinopathies conditions suspected [Identifier] in Dried blood spotHemoglobinopathies conditions suspected: Prid: Pt: Bld.dot: Nom: C    
                 54072-4   Hemoglobin A/​Hemoglobin.total in Dried blood spotHemoglobin A/​Hemoglobin.total in Dried blood spotHemoglobin A/​Hemoglobin.total: MFr: Pt: Bld.dot: Qn: C  
                 54069-0   Hemoglobin Barts/​Hemoglobin.total in Dried blood spotHemoglobin Barts/​Hemoglobin.total in Dried blood spotHemoglobin Barts/​Hemoglobin.total: MFr: Pt: Bld.dot: Qn: C  
                 54073-2   Hemoglobin C/​Hemoglobin.total in Dried blood spotHemoglobin C/​Hemoglobin.total in Dried blood spotHemoglobin C/​Hemoglobin.total: MFr: Pt: Bld.dot: Qn: C  
                 54070-8   Hemoglobin D/​Hemoglobin.total in Dried blood spotHemoglobin D/​Hemoglobin.total in Dried blood spotHemoglobin D/​Hemoglobin.total: MFr: Pt: Bld.dot: Qn: C  
                 54071-6   Hemoglobin E/​Hemoglobin.total in Dried blood spotHemoglobin E/​Hemoglobin.total in Dried blood spotHemoglobin E/​Hemoglobin.total: MFr: Pt: Bld.dot: Qn: C  
                 54074-0   Hemoglobin F/​Hemoglobin.total in Dried blood spotHemoglobin F/​Hemoglobin.total in Dried blood spotHemoglobin F/​Hemoglobin.total: MFr: Pt: Bld.dot: Qn: C  
                 54068-2   Hemoglobin O - Arab/​Hemoglobin.total in Dried blood spotHemoglobin O - Arab/​Hemoglobin.total in Dried blood spotHemoglobin O-Arab/​Hemoglobin.total: MFr: Pt: Bld.dot: Qn: C  
                 56476-5   Hemoglobin S/​Hemoglobin.total in Dried blood spotHemoglobin S/​Hemoglobin.total in Dried blood spotHemoglobin S/​Hemoglobin.total: MFr: Pt: Bld.dot: Qn: C  
            54082-3   Infectious diseases newborn screening panelInfectious diseases newborn screening panelInfectious diseases newborn screening panel: -: Pt: Bld.dot: -: C    
                 57702-3   Infectious diseases newborn screen interpretationInfectious diseases newborn screen interpretationInfectious diseases: Imp: Pt: Bld.dot: Nom: R 1..1   
                 57701-5   Infectious diseases newborn screening comment-discussionInfectious diseases newborn screening comment-discussionInfectious diseases newborn screening comment-discussion: Txt: Pt: Bld.dot: Nar: C    
                 54086-4   HIV 1+​2 IgG Ab [Presence] in Dried blood spotHIV 1+​2 IgG Ab [Presence] in Dried blood spotHIV 1+​2 Ab.IgG: PrThr: Pt: Bld.dot: Ord: C    
                 54087-2   Toxoplasma gondii IgG Ab [Presence] in Dried blood spotToxoplasma gondii IgG Ab [Presence] in Dried blood spotToxoplasma gondii Ab.IgG: PrThr: Pt: Bld.dot: Ord: C    
                 54088-0   Toxoplasma gondii IgM Ab [Presence] in Dried blood spotToxoplasma gondii IgM Ab [Presence] in Dried blood spotToxoplasma gondii Ab.IgM: PrThr: Pt: Bld.dot: Ord: C    
            57087-9   Biotinidase newborn screening panelBiotinidase newborn screening panelBiotinidase newborn screening panel: -: Pt: Bld.dot: -: C    
                 46761-3   Biotinidase deficiency newborn screen interpretationBiotinidase deficiency newborn screen interpretationBiotinidase deficiency: Imp: Pt: Bld.dot: Nom: R 1..1   
                 57699-1   Biotinidase deficiency newborn screening comment-discussionBiotinidase deficiency newborn screening comment-discussionBiotinidase deficiency newborn screening comment-discussion: Txt: Pt: Bld.dot: Nar: C    
                 38478-4   Biotinidase [Presence] in Dried blood spotBiotinidase [Presence] in Dried blood spotBiotinidase: PrThr: Pt: Bld.dot: Ord: C    
                 75217-0   Biotinidase [Enzymatic activity/​volume] in Dried blood spotBiotinidase [Enzymatic activity/​volume] in Dried blood spotBiotinidase: CCnc: Pt: Bld.dot: Qn: C   nmoL/mL/min 
            58091-0   Glucose-6-Phosphate dehydrogenase newborn screen panelGlucose-6-Phosphate dehydrogenase newborn screen panelGlucose-6-Phosphate dehydrogenase newborn screen panel: -: Pt: Bld.dot: -: C    
                 58089-4   Glucose-6-Phosphate dehydrogenase newborn screen interpretationGlucose-6-Phosphate dehydrogenase newborn screen interpretationGlucose-6-Phosphate dehydrogenase: Imp: Pt: Bld.dot: Nar: C    
                 58090-2   Glucose-6-Phosphate dehydrogenase newborn screening comment-discussionGlucose-6-Phosphate dehydrogenase newborn screening comment-discussionGlucose-6-Phosphate dehydrogenase newborn screening comment-discussion: Txt: Pt: Bld.dot: Nar: C    
                 33287-4   Glucose-6-Phosphate dehydrogenase [Presence] in Dried blood spotGlucose-6-Phosphate dehydrogenase [Presence] in Dried blood spotGlucose-6-Phosphate dehydrogenase: PrThr: Pt: Bld.dot: Ord: C    
            62300-9   Lysosomal storage disorders newborn screening panelLysosomal storage disorders newborn screening panelLysosomal storage disorders newborn screening panel: -: Pt: Bld.dot: -: C    
                 62301-7   Lysosomal storage disorders newborn screen interpretationLysosomal storage disorders newborn screen interpretationLysosomal storage disorders: Imp: Pt: Bld.dot: Nom: C 0..1   
                 62303-3   Lysosomal storage disorders newborn screening comment-discussionLysosomal storage disorders newborn screening comment-discussionLysosomal storage disorders newborn screening comment-discussion: Txt: Pt: Bld.dot: Nar: C 0..1   
                 62302-5   Lysosomal storage disorders suspected [Identifier] in Dried blood spotLysosomal storage disorders suspected [Identifier] in Dried blood spotLysosomal storage disorders suspected: Prid: Pt: Bld.dot: Nom: C 0..1   
                 62304-1   Fabry disease newborn screening panelFabry disease newborn screening panelFabry disease newborn screening panel: -: Pt: Bld.dot: -: C    
                      62305-8   Fabry disease newborn screen interpretationFabry disease newborn screen interpretationFabry disease: Imp: Pt: Bld.dot: Nom: R 0..1   
                      62306-6   Fabry disease newborn screening comment-discussionFabry disease newborn screening comment-discussionFabry disease newborn screening comment-discussion: Txt: Pt: Bld.dot: Nar: C 0..1   
                      55908-8   Alpha galactosidase A [Enzymatic activity/​volume] in Dried blood spotAlpha galactosidase A [Enzymatic activity/​volume] in Dried blood spotAlpha galactosidase A: CCnc: Pt: Bld.dot: Qn: C 0..1  umol/L/h 
                 62307-4   Krabbe disease newborn screening panelKrabbe disease newborn screening panelKrabbe disease newborn screening panel: -: Pt: Bld.dot: -: C    
                      62308-2   Krabbe disease newborn screen interpretationKrabbe disease newborn screen interpretationKrabbe disease: Imp: Pt: Bld.dot: Nom: R 0..1   
                      62309-0   Krabbe disease newborn screening comment-discussionKrabbe disease newborn screening comment-discussionKrabbe disease newborn screening comment-discussion: Txt: Pt: Bld.dot: Nar: C 0..1   
                      62310-8   Galactosylceramidase [Enzymatic activity/​volume] in Dried blood spotGalactosylceramidase [Enzymatic activity/​volume] in Dried blood spotGalactosylceramidase: CCnc: Pt: Bld.dot: Qn: C 0..1  umol/L/h 
                 62311-6   Gaucher disease newborn screening panelGaucher disease newborn screening panelGaucher disease newborn screening panel: -: Pt: Bld.dot: -: C    
                      62312-4   Gaucher disease newborn screen interpretationGaucher disease newborn screen interpretationGaucher disease: Imp: Pt: Bld.dot: Nom: R 0..1   
                      62313-2   Gaucher disease newborn screening comment-discussionGaucher disease newborn screening comment-discussionGaucher disease newborn screening comment-discussion: Txt: Pt: Bld.dot: Nar: C 0..1   
                      55917-9   Acid beta glucosidase [Enzymatic activity/​volume] in Dried blood spotAcid beta glucosidase [Enzymatic activity/​volume] in Dried blood spotAcid beta glucosidase: CCnc: Pt: Bld.dot: Qn: C 0..*  umol/L/h 
                 79563-3   Mucopolysaccharidosis type I newborn screening panelMucopolysaccharidosis type I newborn screening panelMucopolysaccharidosis type I newborn screening panel: -: Pt: Bld.dot: -:    
                      55909-6   Alpha-L-iduronidase [Enzymatic activity/​volume] in Dried blood spotAlpha-L-iduronidase [Enzymatic activity/​volume] in Dried blood spotAlpha-L-iduronidase: CCnc: Pt: Bld.dot: Qn:   umol/h/L 
                      79564-1   Mucopolysaccharidosis type I newborn screen interpretationMucopolysaccharidosis type I newborn screen interpretationMucopolysaccharidosis type I: Imp: Pt: Bld.dot: Nom:    
                      79565-8   Mucopolysaccharidosis type I newborn screening comment-discussionMucopolysaccharidosis type I newborn screening comment-discussionMucopolysaccharidosis type I newborn screening comment-discussion: Txt: Pt: Bld.dot: Nar:    
                 62315-7   Niemann Pick disease A/​B newborn screening panelNiemann Pick disease A/​B newborn screening panelNiemann Pick disease A+​B newborn screening panel: -: Pt: Bld.dot: -: C    
                      62318-1   Niemann Pick disease A/​B newborn screen interpretationNiemann Pick disease A/​B newborn screen interpretationNiemann Pick disease A+​B: Imp: Pt: Bld.dot: Nom: R 0..1   
                      62319-9   Niemann Pick disease A/​B newborn screening comment-discussionNiemann Pick disease A/​B newborn screening comment-discussionNiemann Pick disease A+​B newborn screening comment-discussion: Txt: Pt: Bld.dot: Nar: C 0..1   
                      62316-5   Acid sphingomyelinase [Enzymatic activity/​volume] in Dried blood spotAcid sphingomyelinase [Enzymatic activity/​volume] in Dried blood spotAcid sphingomyelinase: CCnc: Pt: Bld.dot: Qn: C 0..1  umol/L/h 
                 63414-7   Pompe disease newborn screening panelPompe disease newborn screening panelPompe disease newborn screening panel: -: Pt: Bld.dot: -: C    
                      63415-4   Pompe disease newborn screen interpretationPompe disease newborn screen interpretationPompe disease: Imp: Pt: Bld.dot: Nom: R 0..*   
                      63416-2   Pompe disease newborn screening comment-discussionPompe disease newborn screening comment-discussionPompe disease newborn screening comment-discussion: Txt: Pt: Bld.dot: Nar: C 0..*   
                      55827-0   Acid alpha glucosidase [Enzymatic activity/​volume] in Dried blood spotAcid alpha glucosidase [Enzymatic activity/​volume] in Dried blood spotAcid alpha glucosidase: CCnc: Pt: Bld.dot: Qn: C 0..*  umol/L/h 
            62333-0   Severe combined immunodeficiency (SCID) newborn screening panelSevere combined immunodeficiency (SCID) newborn screening panelSevere combined immunodeficiency (SCID) newborn screening panel: -: Pt: Bld.dot: -: C    
                 62321-5   Severe combined immunodeficiency newborn screen interpretationSevere combined immunodeficiency newborn screen interpretationSevere combined immunodeficiency: Imp: Pt: Bld.dot: Nom: R 1..1   
                 62322-3   Severe combined immunodeficiency newborn screening comment-discussionSevere combined immunodeficiency newborn screening comment-discussionSevere combined immunodeficiency newborn screening comment-discussion: Txt: Pt: Bld.dot: Nar: C 0..1   
                 62320-7   T-cell receptor excision circle [#/​volume] in Dried blood spot by Probe and target amplification methodT-cell receptor excision circle [#/​volume] in Dried blood spot by Probe and target amplification methodT-cell receptor excision circle: NCnc: Pt: Bld.dot: Qn: Probe.amp.tar C 0..1  {copies} 
            85267-3   X-linked adrenoleukodystrophy (X-ALD) newborn screening panelX-linked adrenoleukodystrophy (X-ALD) newborn screening panelX-linked adrenoleukodystrophy (X-ALD) newborn screening panel: -: Pt: Bld.dot: -: C 0..1   
                 85269-9   X-linked adrenoleukodystrophy newborn screen interpretationX-linked adrenoleukodystrophy newborn screen interpretationX-linked adrenoleukodystrophy: Imp: Pt: Bld.dot: Nom: C 0..*   
                 85268-1   X-linked adrenoleukodystrophy newborn screening comment-discussionX-linked adrenoleukodystrophy newborn screening comment-discussionX-linked adrenoleukodystrophy newborn screening comment-discussion: Txt: Pt: Bld.dot: Nar: C 0..*   
                 79321-6   Lysophosphatidylcholine(26:0) [Moles/​volume] in Dried blood spotLysophosphatidylcholine(26:0) [Moles/​volume] in Dried blood spotLysophosphatidylcholine(26:0): SCnc: Pt: Bld.dot: Qn: O 0..1  umol/L 
       73738-7   Newborn screening test results panel - Point of Care    
            54111-0   Newborn hearing screening panelNewborn hearing screening panelNewborn hearing screening panel: -: Pt: ^Patient: -:    
                 57700-7   Hearing loss newborn screening comment/​discussionHearing loss newborn screening comment/​discussionHearing loss newborn screening comment-discussion: Txt: Pt: Ear: Nar:    
                 58232-0   Hearing loss risk indicators [Identifier]Hearing loss risk indicators [Identifier]Hearing loss risk indicators: Prid: Pt: ^Patient: Nom:    
                 54106-0   Newborn hearing screen methodNewborn hearing screen methodNewborn hearing screen method: Type: Pt: Ear: Nom:    
                 73741-1   Newborn hearing screen panel - Left Ear    
                      54108-6   Newborn hearing screen of Ear - leftNewborn hearing screen of Ear - leftNewborn hearing screen: Arb: Pt: Ear.left: Ord:    
                      73740-3   Screening duration of Ear - leftScreening duration of Ear - leftScreening duration: Time: Pt: Ear.left: Qn:   min 
                      73739-5   Newborn hearing screen reason not performed of Ear - leftNewborn hearing screen reason not performed of Ear - leftNewborn hearing screen reason not performed: Find: Pt: Ear.left: Nom:    
                 73744-5   Newborn hearing screen panel - Right Ear C    
                      54109-4   Newborn hearing screen of Ear - rightNewborn hearing screen of Ear - rightNewborn hearing screen: Arb: Pt: Ear.right: Ord: R 1..1   
                      73743-7   Screening duration of Ear - rightScreening duration of Ear - rightScreening duration: Time: Pt: Ear.right: Qn: C 0..1  min 
                      73742-9   Newborn hearing screen reason not performed of Ear - rightNewborn hearing screen reason not performed of Ear - rightNewborn hearing screen reason not performed: Find: Pt: Ear.right: Nom: C 0..*   
            73805-4   CCHD newborn screening panelCCHD newborn screening panelCCHD newborn screening panel: -: Pt: ^Patient: -:    
                 73700-7   CCHD newborn screening interpretationCCHD newborn screening interpretationCCHD newborn screening interpretation: Imp: Pt: ^Patient: Nom:    
                 73696-7   Oxygen saturation.preductal-oxygen saturation.postductal [Mass fraction difference] in Bld.preductal and Bld.postductalOxygen saturation.preductal-oxygen saturation.postductal [Mass fraction difference] in Bld.preductal and Bld.postductalOxygen saturation.preductal-oxygen saturation.postductal: MFrDiff: Pt: Bld.preductal+​Bld.postductal: Qn:  
                 73806-2   Newborn age in hoursNewborn age in hoursNewborn age in hours: Time: Pt: ^Patient: Qn:  
                 73699-1   Number of prior CCHD screens [#] QualitativeNumber of prior CCHD screens [#] QualitativeNumber of prior CCHD screens: Num: Pt: ^Patient: Ord:    
                 73804-7   Oxygen saturation sensor nameOxygen saturation sensor nameOxygen saturation sensor name: ID: Pt: Oxygen saturation device: Nom:    
                 73803-9   Oxygen saturation sensor typeOxygen saturation sensor typeOxygen saturation sensor type: Type: Pt: Oxygen saturation device: Nom:    
                 73802-1   Oxygen saturation sensor wrap nameOxygen saturation sensor wrap nameOxygen saturation sensor wrap name: ID: Pt: Oxygen saturation device: Nom:    
                 73801-3   Oxygen saturation sensor wrap typeOxygen saturation sensor wrap typeOxygen saturation sensor wrap type: Type: Pt: Oxygen saturation device: Nom:    
                 73800-5   Oxygen saturation sensor wrap sizeOxygen saturation sensor wrap sizeOxygen saturation sensor wrap size: Type: Pt: Oxygen saturation device: Nom:    
                 73697-5   CCHD newborn screening protocol used [Type]CCHD newborn screening protocol used [Type]CCHD newborn screening protocol used: Type: Pt: ^Patient: Nar:    
                 73698-3   Reason CCHD oxygen saturation screening not performedReason CCHD oxygen saturation screening not performedReason CCHD oxygen saturation screening not performed: Find: Pt: ^Patient: Nom:    
                 59407-7   Oxygen saturation in Blood Preductal by Pulse oximetryOxygen saturation in Blood Preductal by Pulse oximetryOxygen saturation: MFr: Pt: Bld.preductal: Qn: Pulse oximetry  
                 73799-9   Heart rate Blood Preductal Pulse oximetryHeart rate Blood Preductal Pulse oximetryHeart rate: NRat: Pt: Bld.preductal: Qn: Pulse oximetry   /min 
                 73798-1   Perfusion index Blood Preductal Pulse oximetryPerfusion index Blood Preductal Pulse oximetryPerfusion index: Ratio: Pt: Bld.preductal: Qn: Pulse oximetry  
                 73797-3   Signal quality Blood Preductal Pulse oximetrySignal quality Blood Preductal Pulse oximetrySignal quality: Find: Pt: Bld.preductal: Ord: Pulse oximetry    
                 73796-5   Infant activity during preductal oxygen saturation measurementInfant activity during preductal oxygen saturation measurementInfant activity during preductal oxygen saturation measurement: Find: Pt: ^Patient: Nom:    
                 59418-4   Oxygen saturation in Blood Postductal by Pulse oximetryOxygen saturation in Blood Postductal by Pulse oximetryOxygen saturation: MFr: Pt: Bld.postductal: Qn: Pulse oximetry  
                 73795-7   Heart rate Blood Postductal Pulse oximetryHeart rate Blood Postductal Pulse oximetryHeart rate: NRat: Pt: Bld.postductal: Qn: Pulse oximetry   /min 
                 73794-0   Perfusion index Blood Postductal Pulse oximetryPerfusion index Blood Postductal Pulse oximetryPerfusion index: Ratio: Pt: Bld.postductal: Qn: Pulse oximetry  
                 73793-2   Signal quality Blood Postductal Pulse oximetrySignal quality Blood Postductal Pulse oximetrySignal quality: Find: Pt: Bld.postductal: Ord: Pulse oximetry    
                 73792-4   Infant activity during postductal oxygen saturation measurementInfant activity during postductal oxygen saturation measurementInfant activity during postductal oxygen saturation measurement: Find: Pt: ^Patient: Nom:    
 

NAME
  Fully-Specified Name: 
Component   Property   Time   System   Scale   Method
Newborn screening panel  Pt  ^Patient  AHIC
  Long Common Name:  Newborn screening panel American Health Information Community (AHIC)
  Shortname:  NB Screen Pnl Patient AHIC

PART DEFINITION/DESCRIPTION(S)
  Part: Newborn screening panel
  Newborn screening is the process of testing newborn babies for treatable genetic, endocrinologic, metabolic and hematologic diseases. Robert Guthrie is given much of the credit for pioneering the earliest screening for phenylketonuria in the late 1960s using blood samples on filter paper obtained by pricking a newborn baby's heel on the second day of life to get a few drops of blood. Congenital hypothyroidism was the second disease widely added in the 1970s. The development of tandem mass spectrometry screening by Edwin Naylor and others in the early 1990s led to a large expansion of potentially detectable congenital metabolic diseases that affect blood levels of organic acids. Additional tests have been added to many screening programs over the last two decades. Newborn screening has been adopted by most countries around the world, though the lists of screened diseases vary widely.
  Copyright: Text is available under the Creative Commons Attribution/Share-Alike License. See http://creativecommons.org/licenses/by-sa/3.0/ for details.
 
 

BASIC ATTRIBUTES
  Class/Type: PANEL.CHEM/Lab
  Panel Type: Panel
  Common Orders Rank: #28
  First Released in Version: 2.26
  Last Updated in Version: 2.40
  Order vs. Obs.: Order
  Status: Active

PARTS

Part Type    Part No.  Part Name   
Component   LP33025-5  Newborn screening panel 
Property   LP6769-6 
Time   LP6960-1  Pt   [Point in time (spot)] 
Super System   LP6985-8  Patient 
Scale   LP7747-1 
Method   LP76307-5  AHIC   [American Health Information Community (AHIC)] 
Fragments for synonyms   LP91459-5  newborn 
Fragments for synonyms   LP34059-3  Screening 
Fragments for synonyms   LP21059-8  Panel 

LANGUAGE VARIANTS
  Chinese (CHINA)  (From: Regenstrief-generated full translation based on part translation provided by Bethune International Peace Hospital)
 
  新生儿筛查组套:  -:  时间点:  ^患者:  -:  AHIC新生儿筛查组套:  -:  时间点:  ^患者:  -:  AHIC新生儿筛查组套:  -:  时间点:  ^患者:  -:  AHIC
  Dutch (NETHERLANDS)  (From: Regenstrief-generated full translation based on part translation provided by NVKC, Dutch Society for Clinical Chemistry and Laboratory Medicine, The Netherlands)
 
  Pasgeborene screening panel:  -:  Moment:  ^Patient:  -:  AHICPasgeborene screening panel:  -:  Moment:  ^Patient:  -:  AHICPasgeborene screening panel:  -:  Moment:  ^Patient:  -:  AHIC
  French (BELGIUM)  (From: Regenstrief-generated full translation based on part translation provided by Jean M. Prevost, MD, Biopathology)
 
  Dépistage néonatal:  -:  Temps ponctuel:  ^Patient:  -:  AHICDépistage néonatal:  -:  Temps ponctuel:  ^Patient:  -:  AHICDépistage néonatal:  -:  Temps ponctuel:  ^Patient:  -:  AHIC
  French (CANADA)  (From: Regenstrief-generated full translation based on part translation provided by Canada Health Infoway Inc.)
 
  Dépistage néonatal:  -:  Temps ponctuel:  ^Patient:  -:  AHICDépistage néonatal:  -:  Temps ponctuel:  ^Patient:  -:  AHICDépistage néonatal:  -:  Temps ponctuel:  ^Patient:  -:  AHIC
  Italian (ITALY)  (From: Regenstrief-generated full translation based on part translation provided by Consiglio Nazionale delle Ricerche)
 
  Screening neonatale, panel:  -:  Pt:  ^Paziente:  -:  AHICScreening neonatale, panel:  -:  Pt:  ^Paziente:  -:  AHICScreening neonatale, panel:  -:  Pt:  ^Paziente:  -:  AHIC
  Portuguese (BRAZIL)  (From: HL7 Brazil Institute)
 
  NB Screen Pnl Patient AHICRecém nascido triagem painel:  -:  Pt:  ^Paciente:  -:  American Health Information Community (AHIC)Recém nascido triagem painel:  -:  Pt:  ^Paciente:  -:  American Health Information Community (AHIC)
  Spanish (SPAIN)  (From: Regenstrief-generated full translation based on part translation provided by the Clinical Laboratory Committee of SERVICIO EXTREMEÑO DE SALUD, with the support of BITAC MAP.)
 
  Panel de screening del recien nacido:  Propiedades mixtas (sólo paneles):  Punto temporal:  ^paciente:  -:  AHICPanel de screening del recien nacido:  Propiedades mixtas (sólo paneles):  Punto temporal:  ^paciente:  -:  AHICPanel de screening del recien nacido:  Propiedades mixtas (sólo paneles):  Punto temporal:  ^paciente:  -:  AHIC

RELATED NAMES
  Asympt New born Point in time
  Asymptomatic Pan Random
  Chemistry PANEL.CHEMISTRY Scn
  NB Screen Pnl Panl  
  NBS Pnl  

CHANGE HISTORY
  Change Type: MIN

INTERNAL FIELDS
  Attachment Units Required: N
  Long Common Name: Newborn screening panel American Health Information Community (AHIC)
  Shortname: NB Screen Pnl Patient AHIC
  Fully Specified Name: Newborn screening panel: -: Pt: ^Patient: -: AHIC
     
  Component Word Count: 3
  ID: 48375
  # of Panel Elements: 345
  Status (Raw): ACTIVE



Selected information about each LOINC that is part of this panel



57128-1   Newborn Screening Report summary panelNewborn Screening Report summary panelNewborn Screening Report summary panel: -: Pt: ^Patient: -:  

NAME
  Fully-Specified Name: 
Component   Property   Time   System   Scale   Method
Newborn Screening Report summary panel  Pt  ^Patient 
  Long Common Name:  Newborn Screening Report summary panel
  Shortname:  NBS report summary pnl Patient

TERM DEFINITION/DESCRIPTION(S)
  This panel includes a LOINC code that could carry a summary report as text , or PDF , the overall interpretation of the report to permit easy searching for abnormal , a list of the conditions suspected based on the marker results as codes - to make it easy for receiving systems to find cases requiring follow up.
 
 

QUESTION CARDINALITY
0..1

OBSERVATION REQUIRED IN PANEL
Conditional

BASIC ATTRIBUTES
  Class/Type: PANEL.CHEM/Lab
  Panel Type: Organizer
  First Released in Version: 2.29
  Last Updated in Version: 2.40
  Order vs. Obs.: Order
  Status: Active

MEMBER OF THESE PANELS
  54089-8   Newborn screening panel American Health Information Community (AHIC)Newborn screening panel American Health Information Community (AHIC)Newborn screening panel: -: Pt: ^Patient: -: AHIC

PARTS

Part Type    Part No.  Part Name   
Component   LP97103-3  Newborn Screening Report summary panel 
Property   LP6769-6 
Time   LP6960-1  Pt   [Point in time (spot)] 
Super System   LP6985-8  Patient 
Scale   LP7747-1 
Fragments for synonyms   LP21059-8  Panel 
Fragments for synonyms   LP91459-5  newborn 
Fragments for synonyms   LP34059-3  Screening 

LANGUAGE VARIANTS
  Chinese (CHINA)  (From: Regenstrief-generated full translation based on part translation provided by Bethune International Peace Hospital)
 
  新生儿筛查报告摘要组套:  -:  时间点:  ^患者:  -:  新生儿筛查报告摘要组套:  -:  时间点:  ^患者:  -:  新生儿筛查报告摘要组套:  -:  时间点:  ^患者:  -:  
  Dutch (NETHERLANDS)  (From: Regenstrief-generated full translation based on part translation provided by NVKC, Dutch Society for Clinical Chemistry and Laboratory Medicine, The Netherlands)
 
  Pasgeborene screening rapport samenvattend panel:  -:  Moment:  ^Patient:  -:  Pasgeborene screening rapport samenvattend panel:  -:  Moment:  ^Patient:  -:  Pasgeborene screening rapport samenvattend panel:  -:  Moment:  ^Patient:  -:  
  French (BELGIUM)  (From: Regenstrief-generated full translation based on part translation provided by Jean M. Prevost, MD, Biopathology)
 
  Rapport screening néonatal.Panel résumé:  -:  Temps ponctuel:  ^Patient:  -:  Rapport screening néonatal.Panel résumé:  -:  Temps ponctuel:  ^Patient:  -:  Rapport screening néonatal.Panel résumé:  -:  Temps ponctuel:  ^Patient:  -:  
  Italian (ITALY)  (From: Regenstrief-generated full translation based on part translation provided by Consiglio Nazionale delle Ricerche)
 
  Screening neonatale, panel riassuntivo di referto:  -:  Pt:  ^Paziente:  -:  Screening neonatale, panel riassuntivo di referto:  -:  Pt:  ^Paziente:  -:  Screening neonatale, panel riassuntivo di referto:  -:  Pt:  ^Paziente:  -:  
  Portuguese (BRAZIL)  (From: HL7 Brazil Institute)
 
  NBS report summary pnl PatientResumo de relatório da triagem Neonatal painel:  #N/​A:  Pt:  ^Paciente:  -:  Resumo de relatório da triagem Neonatal painel:  #N/​A:  Pt:  ^Paciente:  -:  
  Russian (RUSSIAN FEDERATION)  (From: Regenstrief-generated full translation based on part translation provided by Yaroslavl State Medical Academy)
 
  Новорождённый Скрининг Отчёт краткие сведения панель:  -:  ТчкВрм:  ^Пациент:  -:  Новорождённый Скрининг Отчёт краткие сведения панель:  -:  ТчкВрм:  ^Пациент:  -:  Новорождённый Скрининг Отчёт краткие сведения панель:  -:  ТчкВрм:  ^Пациент:  -:  
  Spanish (SPAIN)  (From: Regenstrief-generated full translation based on part translation provided by the Clinical Laboratory Committee of SERVICIO EXTREMEÑO DE SALUD, with the support of BITAC MAP.)
 
  Resumen de Informe del panel de cribado del recién nacido:  Propiedades mixtas (sólo paneles):  Punto temporal:  ^paciente:  -:  Resumen de Informe del panel de cribado del recién nacido:  Propiedades mixtas (sólo paneles):  Punto temporal:  ^paciente:  -:  Resumen de Informe del panel de cribado del recién nacido:  Propiedades mixtas (sólo paneles):  Punto temporal:  ^paciente:  -:  

RELATED NAMES
  Asympt Pan Random
  Asymptomatic PANEL.CHEMISTRY Rpt summ
  Chemistry Panl Scn
  NBS report summary pnl Pnl  
  New born Point in time  

CHANGE HISTORY
  Change Type: MIN

INTERNAL FIELDS
  Attachment Units Required: N
  Long Common Name: Newborn Screening Report summary panel
  Shortname: NBS report summary pnl Patient
  Fully Specified Name: Newborn Screening Report summary panel: -: Pt: ^Patient: -:
     
  Component Word Count: 5
  ID: 51760
  Status (Raw): ACTIVE


57721-3   Reason for lab test in Dried blood spotReason for lab test in Dried blood spotReason for lab test: Type: Pt: Bld.dot: Nom:  

NAME
  Fully-Specified Name: 
Component   Property   Time   System   Scale   Method
Reason for lab test  Type  Pt  Bld.dot  Nom 
  Long Common Name:  Reason for lab test in Dried blood spot
  Shortname:  Reason for lab test DBS

TERM DEFINITION/DESCRIPTION(S)
  Definitions of answer codes for reason for newborn screen lab test in dried blood spot:

Initial Screen: This answer code is used for the first screen performed on an infant after birth. When the first specimen obtained is of unacceptable quality and cannot be used, a replacement specimen is still considered the initial screen. When an initial screen is performed before 24 hrs because of a planned transfusion or an extremely ill infant, it is still considered the initial screen even though it may need to be repeated later.

Subsequent screen - required by law: This answer code is used for mandatory second screens as required by law and assumes that the first screen was normal and that the second screen was performed only because it was mandated by law. For example, [give name of state(s)] currently performs a second screen on every infant born in the state at a particular point in time, such as between 1 and 2 weeks. The purpose of identifying the reason for a subsequent screen is that it will change the expected time interval when the subsequent screen should be performed.

Subsequent screen - required by protocol: This answer code is used for subsequent screens that are performed because of clinical conditions in the newborn that require a repeat screen as specified by a protocol to assure valid test results. Many of these subsequent screens have abnormal or out-of-range results on the initial screen that can be explained by the clinical condition of the infant. Typical examples include premature infants, infants who receive blood product transfusions, and infants who are receiving intravenous alimentation. This category should not include abnormal tests that should be considered presumptive positives (which would require a diagnostic evaluation rather than a repeat screen by protocol). The purpose of identifying the reason for a subsequent screen is that it will change the expected time interval when the subsequent screen should be performed.


Subsequent screen - for clarification of initial results (not by law or protocol): When the results of the initial screen are abnormal or out of range, many states perform an "immediate" repeat screen to confirm the results before considering the test a presumptive positive that will require a diagnostic evaluation. Many of these results may be considered or reported as equivocal or borderline until a clear abnormality is confirmed on the subsequent screen. This category does not include abnormal or borderline results for which there is a clear clinical explanation, such as prematurity, for which there is a clear protocol for obtaining a second screen. The purpose of identifying the reason for a subsequent screen is that it will change the expected time interval when the subsequent screen should be performed.

Subsequent screen - reason unknown: The purpose of identifying the reason for a subsequent screen is that it will change the expected time interval when the subsequent screen should be performed. States should use this answer code if they are unable to identify the specific reason for a subsequent screen, but they are able to separate initial screens from subsequent screens. The reason for the second screen might be any of the above. A repeat initial screen because the first specimen was of unacceptable quality should not be considered a subsequent screen, but some states may use this code if they are unable to track that the reason for a second specimen was unacceptable quality of the first screen.

No sample collected due to parental refusal: This answer code is used to document parental refusal of newborn screening so that a report can be generated which will contain no test results because no specimen was submitted. This will enable complete matching of newborn screening results to all infants born even if no laboratory testing was performed.
 
 

ANSWER CARDINALITY
1..1

OBSERVATION REQUIRED IN PANEL
Required

BASIC ATTRIBUTES
  Class/Type: MISC/Lab
  First Released in Version: 2.29
  Last Updated in Version: 2.36
  Order vs. Obs.: Observation
  Status: Active

NORMATIVE ANSWER LIST    (LL831-9)  
  SEQ#        Answer        Answer ID    
  1       Initial screen       LA12421-6  
  2       Subsequent screen - required by law       LA12425-7  
  3       Subsequent screen - required by protocol       LA12426-5  
  4       Subsequent screen - for clarification of initial results (not by law or protocol)       LA12427-3  
  5       Subsequent screen - reason unknown       LA16473-3  
  6       No sample collected due to parental refusal       LA14132-7  

MEMBER OF THESE PANELS
  54089-8   Newborn screening panel American Health Information Community (AHIC)Newborn screening panel American Health Information Community (AHIC)Newborn screening panel: -: Pt: ^Patient: -: AHIC

PARTS

Part Type    Part No.  Part Name   
Component   LP97571-1  Reason for lab test 
Property   LP6886-8  Type 
Time   LP6960-1  Pt   [Point in time (spot)] 
System   LP21304-8  Bld.dot   [Dried blood spot] 
Scale   LP7750-5  Nom 

LANGUAGE VARIANTS
  Chinese (CHINA)  (From: Regenstrief-generated full translation based on part translation provided by Bethune International Peace Hospital)
 
  关于实验室检验项目的原因:  类型:  时间点:  全血.斑点:  名义型:  关于实验室检验项目的原因:  类型:  时间点:  全血.斑点:  名义型:  关于实验室检验项目的原因:  类型:  时间点:  全血.斑点:  名义型:  
  Dutch (NETHERLANDS)  (From: Regenstrief-generated full translation based on part translation provided by NVKC, Dutch Society for Clinical Chemistry and Laboratory Medicine, The Netherlands)
 
  Reden voor labtest:  Type:  Moment:  Gedroogde bloedspot:  Nominaal:  Reden voor labtest:  Type:  Moment:  Gedroogde bloedspot:  Nominaal:  Reden voor labtest:  Type:  Moment:  Gedroogde bloedspot:  Nominaal:  
  French (BELGIUM)  (From: Regenstrief-generated full translation based on part translation provided by Jean M. Prevost, MD, Biopathology)
 
  Justification des tests de labo:  Type:  Temps ponctuel:  Sang sur papier filtre:  Nominal:  Justification des tests de labo:  Type:  Temps ponctuel:  Sang sur papier filtre:  Nominal:  Justification des tests de labo:  Type:  Temps ponctuel:  Sang sur papier filtre:  Nominal:  
  French (CANADA)  (From: Regenstrief-generated full translation based on part translation provided by Canada Health Infoway Inc.)
 
  Indication de l'examen de laboratoire:  Type:  Temps ponctuel:  Sang sur papier filtre:  Nominal:  Indication de l'examen de laboratoire:  Type:  Temps ponctuel:  Sang sur papier filtre:  Nominal:  Indication de l'examen de laboratoire:  Type:  Temps ponctuel:  Sang sur papier filtre:  Nominal:  
  Italian (ITALY)  (From: Regenstrief-generated full translation based on part translation provided by Consiglio Nazionale delle Ricerche)
 
  Motivo di prova di laboratorio:  Tipo:  Pt:  Sangue.su carta da filtro:  Nom:  Motivo di prova di laboratorio:  Tipo:  Pt:  Sangue.su carta da filtro:  Nom:  Motivo di prova di laboratorio:  Tipo:  Pt:  Sangue.su carta da filtro:  Nom:  
  Portuguese (BRAZIL)  (From: HL7 Brazil Institute)
 
  Reason for lAc test DBSRazão para teste de laboratório:  Tipo:  Pt:  SgPapel:  Nom:  Razão para teste de laboratório:  Tipo:  Pt:  SgPapel:  Nom:  
  Russian (RUSSIAN FEDERATION)  (From: Regenstrief-generated full translation based on part translation provided by Yaroslavl State Medical Academy)
 
  Причина лабораторный тест:  Тип:  ТчкВрм:  Кр.Сух.капл:  Ном:  Причина лабораторный тест:  Тип:  ТчкВрм:  Кр.Сух.капл:  Ном:  Причина лабораторный тест:  Тип:  ТчкВрм:  Кр.Сух.капл:  Ном:  
  Spanish (SPAIN)  (From: Regenstrief-generated full translation based on part translation provided by the Clinical Laboratory Committee of SERVICIO EXTREMEÑO DE SALUD, with the support of BITAC MAP.)
 
  Motivo de la prueba de laboratorio:  Tipo:  Punto temporal:  Punto de sangre (papel de filtro):  Nom:  Motivo de la prueba de laboratorio:  Tipo:  Punto temporal:  Punto de sangre (papel de filtro):  Nom:  Motivo de la prueba de laboratorio:  Tipo:  Punto temporal:  Punto de sangre (papel de filtro):  Nom:  
  Turkish (TURKEY)  (From: Regenstrief-generated full translation based on part translation provided by LOINC Turkish Translation Group and the Turkish Ministry of Health)
 
  Sebep lab testi için:  Tip:  Zmlı:  Kan.nokta:  Snf:  Sebep lab testi için:  Tip:  Zmlı:  Kan.nokta:  Snf:  Sebep lab testi için:  Tip:  Zmlı:  Kan.nokta:  Snf:  

RELATED NAMES
  Blood MISC WB
  DBS Nominal Whole blood
  Dried blood spot Point in time  
  Filter paper Random  
  FP Typ  

CHANGE HISTORY
  Change Type: MIN

INTERNAL FIELDS
  Attachment Units Required: N
  Long Common Name: Reason for lab test in Dried blood spot
  Shortname: Reason for lab test DBS
  Fully Specified Name: Reason for lab test: Type: Pt: Bld.dot: Nom:
     
  Component Word Count: 4
  ID: 52394
  Status (Raw): ACTIVE


57718-9   Sample quality of Dried blood spotSample quality of Dried blood spotSample condition: Type: Pt: Bld.dot: Nom:  

NAME
  Fully-Specified Name: 
Component   Property   Time   System   Scale   Method
Sample condition  Type  Pt  Bld.dot  Nom 
  Long Common Name:  Sample quality of Dried blood spot
  Shortname:  Sample quality of DBS

ANSWER CARDINALITY
1..1

OBSERVATION REQUIRED IN PANEL
Required

BASIC ATTRIBUTES
  Class/Type: SPEC/Lab
  First Released in Version: 2.29
  Last Updated in Version: 2.56
  Order vs. Obs.: Observation
  Status: Active.
Change Reason: Changed answer list from "Normative" to "Preferred" to fit the current LOINC model.

PREFERRED ANSWER LIST    (LL832-7)  
  SEQ#        Answer        Answer ID    
  1       Acceptable       LA12432-3  
  2       No sample received       LA12433-1  
  3       Specimen damaged during transport       LA20623-7  
  4       Specimen received in sealed plastic container       LA20624-5  
  5       Specimen quantity insufficient due to incomplete saturation (blood did not soak through paper)       LA20625-2  
  6       Specimen quantity insufficient because blood did not completely fill specimen circles       LA20626-0  
  7       Specimen has uneven saturation       LA20627-8  
  8       Specimen appears scratched or abraded       LA12682-3  
  9       Specimen not dry before mailing       LA12683-1  
  10       Specimen appears supersaturated       LA12684-9  
  11       Specimen appears diluted, discolored or contaminated       LA12685-6  
  12       Specimen exhibits serum rings       LA12686-4  
  13       Specimen appears clotted or layered       LA12435-6  
  14       Specimen not eluting       LA20628-6  
  15       No blood       LA12687-2  
  16       Sample too old       LA12441-4  
  17       Testing of this specimen indicates more than one source of blood is present on the filter paper card       LA20630-2  
  18       Unsuitable for other reasons       LA20629-4  

MEMBER OF THESE PANELS
  54089-8   Newborn screening panel American Health Information Community (AHIC)Newborn screening panel American Health Information Community (AHIC)Newborn screening panel: -: Pt: ^Patient: -: AHIC
  74874-9   Metabolic disorder therapy monitoring panel - Dried blood spotMetabolic disorder therapy monitoring panel - Dried blood spotMetabolic disorder therapy monitoring panel: -: Pt: Bld.dot: -:

PARTS

Part Type    Part No.  Part Name   
Component   LP97568-7  Sample condition 
Property   LP6886-8  Type 
Time   LP6960-1  Pt   [Point in time (spot)] 
System   LP21304-8  Bld.dot   [Dried blood spot] 
Scale   LP7750-5  Nom 

LANGUAGE VARIANTS
  Chinese (CHINA)  (From: Regenstrief-generated full translation based on part translation provided by Bethune International Peace Hospital)
 
  样本状况:  类型:  时间点:  全血.斑点:  名义型:  样本状况:  类型:  时间点:  全血.斑点:  名义型:  样本状况:  类型:  时间点:  全血.斑点:  名义型:  
  Dutch (NETHERLANDS)  (From: Regenstrief-generated full translation based on part translation provided by NVKC, Dutch Society for Clinical Chemistry and Laboratory Medicine, The Netherlands)
 
  Monsterconditie:  Type:  Moment:  Gedroogde bloedspot:  Nominaal:  Monsterconditie:  Type:  Moment:  Gedroogde bloedspot:  Nominaal:  Monsterconditie:  Type:  Moment:  Gedroogde bloedspot:  Nominaal:  
  French (BELGIUM)  (From: Regenstrief-generated full translation based on part translation provided by Jean M. Prevost, MD, Biopathology)
 
  Condition échantillon:  Type:  Temps ponctuel:  Sang sur papier filtre:  Nominal:  Condition échantillon:  Type:  Temps ponctuel:  Sang sur papier filtre:  Nominal:  Condition échantillon:  Type:  Temps ponctuel:  Sang sur papier filtre:  Nominal:  
  French (FRANCE)  (From: ASIP Santé (Agence des systèmes d'information partagés de santé))
 
  Échantillon condition:  Type:  Ponctuel:  Sang buvard:  Résultat textuel:  Échantillon condition:  Type:  Ponctuel:  Sang buvard:  Résultat textuel:  Échantillon condition:  Type:  Ponctuel:  Sang buvard:  Résultat textuel:  
  Italian (ITALY)  (From: Regenstrief-generated full translation based on part translation provided by Consiglio Nazionale delle Ricerche)
 
  Campione, condizione:  Tipo:  Pt:  Sangue.su carta da filtro:  Nom:  Campione, condizione:  Tipo:  Pt:  Sangue.su carta da filtro:  Nom:  Campione, condizione:  Tipo:  Pt:  Sangue.su carta da filtro:  Nom:  
  Portuguese (BRAZIL)  (From: HL7 Brazil Institute)
 
  Sample quality of DBSCondição da amostra:  Tipo:  Pt:  SgPapel:  Nom:  Condição da amostra:  Tipo:  Pt:  SgPapel:  Nom:  
  Russian (RUSSIAN FEDERATION)  (From: Regenstrief-generated full translation based on part translation provided by Yaroslavl State Medical Academy)
 
  Образец состояние:  Тип:  ТчкВрм:  Кр.Сух.капл:  Ном:  Образец состояние:  Тип:  ТчкВрм:  Кр.Сух.капл:  Ном:  Образец состояние:  Тип:  ТчкВрм:  Кр.Сух.капл:  Ном:  
  Spanish (SPAIN)  (From: Regenstrief-generated full translation based on part translation provided by the Clinical Laboratory Committee of SERVICIO EXTREMEÑO DE SALUD, with the support of BITAC MAP.)
 
  Condición de la muestra:  Tipo:  Punto temporal:  Punto de sangre (papel de filtro):  Nom:  Condición de la muestra:  Tipo:  Punto temporal:  Punto de sangre (papel de filtro):  Nom:  Condición de la muestra:  Tipo:  Punto temporal:  Punto de sangre (papel de filtro):  Nom:  
  Turkish (TURKEY)  (From: Regenstrief-generated full translation based on part translation provided by LOINC Turkish Translation Group and the Turkish Ministry of Health)
 
  Örnek koşulu:  Tip:  Zmlı:  Kan.nokta:  Snf:  Örnek koşulu:  Tip:  Zmlı:  Kan.nokta:  Snf:  Örnek koşulu:  Tip:  Zmlı:  Kan.nokta:  Snf:  

RELATED NAMES
  Blood Nominal Typ
  DBS Point in time WB
  Dried blood spot Random Whole blood
  Filter paper SPEC  
  FP Specimen quality  

CHANGE HISTORY
  Change Type: MIN

INTERNAL FIELDS
  Attachment Units Required: N
  Long Common Name: Sample quality of Dried blood spot
  Shortname: Sample quality of DBS
  Fully Specified Name: Sample condition: Type: Pt: Bld.dot: Nom:
     
  Component Word Count: 2
  ID: 52391
  Status (Raw): ACTIVE


57130-7   Newborn screening report - overall interpretationNewborn screening report - overall interpretationNewborn screening report - overall interpretation: Imp: Pt: ^Patient: Nom:  

NAME
  Fully-Specified Name: 
Component   Property   Time   System   Scale   Method
Newborn screening report - overall interpretation  Imp  Pt  ^Patient  Nom 
  Long Common Name:  Newborn screening report - overall interpretation
  Shortname:  NBS report - overall interp

TERM DEFINITION/DESCRIPTION(S)
  Reports the summary interpretation of the screening test from a short list of specified codes (to be developed by the NBS community)
 
 

CONDITION FOR INCLUSION
If the state reports a summary impression.

ANSWER CARDINALITY
1..*

OBSERVATION REQUIRED IN PANEL
Conditional

BASIC ATTRIBUTES
  Class/Type: CHEM/Lab
  First Released in Version: 2.29
  Last Updated in Version: 2.36
  Order vs. Obs.: Observation
  Status: Active

EXAMPLE ANSWER LIST    (LL771-7)  
  SEQ#        Answer        Answer ID    
  1       All screening is in range for the conditions tested       LA12428-1  
  2       Screen is borderline for at least one condition       LA12429-9  
  3       Screen is indeterminate for at least one condition       LA18943-3  
  4       Screen is out of range for at least one condition       LA18944-1  
  5       Out of range requiring further dried blood spot testing for at least one condition       LA12430-7  
  6       Out of range requiring immediate referral       LA25817-0  
  7       Out of range requiring immediate second-tier testing for at least one condition       LA12431-5  
  8       Out of range requiring deferred follow-up for at least one condition       LA18594-4  
  9       Screening not done due to parental refusal       LA14133-5  
  10       One or more tests pending       LA16204-2  
  11       Specimen unsatisfactory for at least one condition       LA16205-9  

MEMBER OF THESE PANELS
  54089-8   Newborn screening panel American Health Information Community (AHIC)Newborn screening panel American Health Information Community (AHIC)Newborn screening panel: -: Pt: ^Patient: -: AHIC

PARTS

Part Type    Part No.  Part Name   
Component   LP97105-8  Newborn screening report - overall interpretation 
Property   LP6819-9  Imp   [Impression/interpretation of study] 
Time   LP6960-1  Pt   [Point in time (spot)] 
Super System   LP6985-8  Patient 
Scale   LP7750-5  Nom 
Fragments for synonyms   LP34059-3  Screening 
Fragments for synonyms   LP91459-5  newborn 

LANGUAGE VARIANTS
  Chinese (CHINA)  (From: Regenstrief-generated full translation based on part translation provided by Bethune International Peace Hospital)
 
  新生儿筛查报告 - 总体解释:  印象:  时间点:  ^患者:  名义型:  新生儿筛查报告 - 总体解释:  印象:  时间点:  ^患者:  名义型:  新生儿筛查报告 - 总体解释:  印象:  时间点:  ^患者:  名义型:  
  Dutch (NETHERLANDS)  (From: Regenstrief-generated full translation based on part translation provided by NVKC, Dutch Society for Clinical Chemistry and Laboratory Medicine, The Netherlands)
 
  Pasgeborene screening rapport - overall interpretatie:  Indruk/​interpretatie van het onderzoek:  Moment:  ^Patient:  Nominaal:  Pasgeborene screening rapport - overall interpretatie:  Indruk/​interpretatie van het onderzoek:  Moment:  ^Patient:  Nominaal:  Pasgeborene screening rapport - overall interpretatie:  Indruk/​interpretatie van het onderzoek:  Moment:  ^Patient:  Nominaal:  
  French (BELGIUM)  (From: Regenstrief-generated full translation based on part translation provided by Jean M. Prevost, MD, Biopathology)
 
  Rapport screening néonatal - interprétation générale:  Impression/​interprétation d'étude:  Temps ponctuel:  ^Patient:  Nominal:  Rapport screening néonatal - interprétation générale:  Impression/​interprétation d'étude:  Temps ponctuel:  ^Patient:  Nominal:  Rapport screening néonatal - interprétation générale:  Impression/​interprétation d'étude:  Temps ponctuel:  ^Patient:  Nominal:  
  French (FRANCE)  (From: ASIP Santé (Agence des systèmes d'information partagés de santé))
 
  Compte rendu dépistage néonatal - Interprétation:  Interprétation:  Ponctuel:  Patient:  Résultat textuel:  Compte rendu dépistage néonatal - Interprétation:  Interprétation:  Ponctuel:  Patient:  Résultat textuel:  Compte rendu dépistage néonatal - Interprétation:  Interprétation:  Ponctuel:  Patient:  Résultat textuel:  
  Italian (ITALY)  (From: Regenstrief-generated full translation based on part translation provided by Consiglio Nazionale delle Ricerche)
 
  Screening neonatale, referto - interpretazione generale:  Imp:  Pt:  ^Paziente:  Nom:  Screening neonatale, referto - interpretazione generale:  Imp:  Pt:  ^Paziente:  Nom:  Screening neonatale, referto - interpretazione generale:  Imp:  Pt:  ^Paziente:  Nom:  
  Portuguese (BRAZIL)  (From: HL7 Brazil Institute)
 
  NBS report - overall interpRelatório de triagem neonatal - interpretação global:  #N/​A:  Pt:  ^Paciente:  Nom:  Relatório de triagem neonatal - interpretação global:  #N/​A:  Pt:  ^Paciente:  Nom:  
  Russian (RUSSIAN FEDERATION)  (From: Regenstrief-generated full translation based on part translation provided by Yaroslavl State Medical Academy)
 
  Новорождённый скрининг отчёт - общая интерпретация:  Впчт:  ТчкВрм:  ^Пациент:  Ном:  Новорождённый скрининг отчёт - общая интерпретация:  Впчт:  ТчкВрм:  ^Пациент:  Ном:  Новорождённый скрининг отчёт - общая интерпретация:  Впчт:  ТчкВрм:  ^Пациент:  Ном:  
  Spanish (SPAIN)  (From: Regenstrief-generated full translation based on part translation provided by the Clinical Laboratory Committee of SERVICIO EXTREMEÑO DE SALUD, with the support of BITAC MAP.)
 
  Informe del cribado del recién nacido-interpretación general:  Impresión/​interpretación del estudio:  Punto temporal:  ^paciente:  Nom:  Informe del cribado del recién nacido-interpretación general:  Impresión/​interpretación del estudio:  Punto temporal:  ^paciente:  Nom:  Informe del cribado del recién nacido-interpretación general:  Impresión/​interpretación del estudio:  Punto temporal:  ^paciente:  Nom:  
  Turkish (TURKEY)  (From: Regenstrief-generated full translation based on part translation provided by LOINC Turkish Translation Group and the Turkish Ministry of Health)
 
  Yenidoğan tarama raporu - genel yorum:  İzlnm:  Zmlı:  ^Hasta:  Snf:  Yenidoğan tarama raporu - genel yorum:  İzlnm:  Zmlı:  ^Hasta:  Snf:  Yenidoğan tarama raporu - genel yorum:  İzlnm:  Zmlı:  ^Hasta:  Snf:  

RELATED NAMES
  Asympt Interp New born
  Asymptomatic Interpret Nominal
  Chemistry Interpretation Point in time
  Impression Interpt Random
  Impression/interpretation of study Intrp Scn
  Impressions NBS report - overall interp  

CHANGE HISTORY
  Change Type: MIN

INTERNAL FIELDS
  Attachment Units Required: N
  Long Common Name: Newborn screening report - overall interpretation
  Shortname: NBS report - overall interp
  Fully Specified Name: Newborn screening report - overall interpretation: Imp: Pt: ^Patient: Nom:
     
  Component Word Count: 5
  ID: 51762
  Status (Raw): ACTIVE


57131-5   Newborn conditions with positive markers [Identifier] in Dried blood spotNewborn conditions with positive markers [Identifier] in Dried blood spotNewborn conditions with positive markers: Prid: Pt: Bld.dot: Nom:  

NAME
  Fully-Specified Name: 
Component   Property   Time   System   Scale   Method
Newborn conditions with positive markers  Prid  Pt  Bld.dot  Nom 
  Long Common Name:  Newborn conditions with positive markers [Identifier] in Dried blood spot
  Shortname:  NB conditions positive DBS

TERM DEFINITION/DESCRIPTION(S)
  This variable list the conditions that that the markers suggest may be present. It is a coded result intended for easy access by decision support systems to identify the cases that need special attention. The LOINC code will include an answer list that covers all of the conditions screened for by any state. States would only make statements about the conditions they screen for. (This item is still under discussion by the NBS community and subject to change)
 
 

ANSWER CARDINALITY
1..*

OBSERVATION REQUIRED IN PANEL
Required

BASIC ATTRIBUTES
  Class/Type: CHEM/Lab
  First Released in Version: 2.29
  Last Updated in Version: 2.56
  Order vs. Obs.: Observation
  Status: Active.
Change Reason: Changed answer list from "Normative" to "Preferred" to fit the current LOINC model.

PREFERRED ANSWER LIST    (LL835-0)  
  SEQ#        Answer        Global ID        Global ID
Code System
   
    Answer ID    
  0       None               LA137-2  
  1       HEAR       15188001       SCT       LA12463-8  
  2       2M3HBA       791000124107       SCT       LA12464-6  
  3       2MBG       445596006       SCT       LA12465-3  
  4       3-MCC       13144005       SCT       LA12466-1  
  5       3-MCC (mat)       206001006       SCT       LA12467-9  
  6       3MGA       297235006       SCT       LA12468-7  
  7       5-OXO       39112005       SCT       LA12469-5  
  8       ARG       23501004       SCT       LA12470-3  
  9       ASA       41013004       SCT       LA12471-1  
  10       BIOPT-BS       237914002       SCT       LA12472-9  
  11       BIOPT-REG       58256000       SCT       LA12473-7  
  12       BKT       237953006       SCT       LA12474-5  
  13       CACT       238003000       SCT       LA12475-2  
  14       CBL A       73843004       SCT       LA12476-0  
  15       CBL B       82245003       SCT       LA12477-8  
  16       CBL C       74653006       SCT       LA12478-6  
  17       CBL D       31220004       SCT       LA12479-4  
  18       CBL E       360373000       SCT       LA12480-2  
  19       CBL G       237938003       SCT       LA12481-0  
  20       CIT-I       398680004       SCT       LA12482-8  
  21       CIT-II       30529005       SCT       LA12483-6  
  22       CPS       62522004       SCT       LA12484-4  
  23       CPT-Ia       238001003       SCT       LA12485-1  
  24       CPT-II       238002005       SCT       LA12486-9  
  25       CUD       21764004       SCT       LA12487-7  
  26       CUD (mat)       206001006       SCT       LA12488-5  
  27       De-Red       444944006       SCT       LA12489-3  
  28       E3       29914000       SCT       LA12490-1  
  29       EMA       811000124106       SCT       LA12491-9  
  30       FIGLU       59761008       SCT       LA12492-7  
  31       GA-1       76175005       SCT       LA12493-5  
  32       GA-1 (mat)       206001006       SCT       LA12494-3  
  33       GA-2       22886006       SCT       LA12495-0  
  34       HCY       11282001       SCT       LA12496-8  
  35       HHH       30287008       SCT       LA12497-6  
  36       HIS       410058007       SCT       LA12498-4  
  37       HMG       410059004       SCT       LA12499-2  
  38       H-PHE       68528007       SCT       LA12500-7  
  39       Hyper LYS       58558003       SCT       LA12501-5  
  40       Hyper ORN       314467007       SCT       LA12502-3  
  41       Hyper VAL       47719001       SCT       LA12503-1  
  42       IBG       445571008       SCT       LA12504-9  
  43       IVA       87827003       SCT       LA12505-6  
  44       LACTIC       190882007       SCT       LA12506-4  
  45       LCHAD       307127004       SCT       LA12507-2  
  46       MAL       124594007       SCT       LA12508-0  
  47       MCAD       128596003       SCT       LA12509-8  
  48       MCD       360369003       SCT       LA12510-6  
  49       MCKAT       124265004       SCT       LA12511-4  
  50       MET       43123004       SCT       LA12512-2  
  51       MSUD       27718001       SCT       LA12513-0  
  52       MTHFR       41797007       SCT       LA12514-8  
  53       MUT       124680001       SCT       LA12515-5  
  54       NKHG       237939006       SCT       LA12516-3  
  55       OH PRO       25739007       SCT       LA12517-1  
  56       OTC       80908008       SCT       LA12518-9  
  57       PC       87694001       SCT       LA12519-7  
  58       PKU       7573000       SCT       LA12520-5  
  59       PRO I       61071003       SCT       LA12521-3  
  60       PRO II       124177001       SCT       LA12522-1  
  61       PROP       69080001       SCT       LA12523-9  
  62       SCAD       124166007       SCT       LA12524-7  
  63       SCHAD       237998000       SCT       LA12525-4  
  64       SUCLA2       445275003       SCT       LA12526-2  
  65       TFP       237999008       SCT       LA12527-0  
  66       TYR-1       410056006       SCT       LA12528-8  
  67       TYR-II       4887000       SCT       LA12529-6  
  68       TYR-III       415764005       SCT       LA12530-4  
  69       VLCAD       237997005       SCT       LA12531-2  
  70       BIO       8808004       SCT       LA12532-0  
  71       CAH       124214007       SCT       LA12533-8  
  72       CF       190905008       SCT       LA12537-9  
  73       CH       190268003       SCT       LA12538-7  
  74       CH2       82598004       SCT       LA12539-5  
  75       G6PD       62403005       SCT       LA12540-3  
  76       GALE       8849004       SCT       LA12541-1  
  77       GALK       124302001       SCT       LA12542-9  
  78       GALT       398664009       SCT       LA12543-7  
  79       Hb C-carrier       76050008       SCT       LA12602-1  
  80       Hb D-carrier       7391009       SCT       LA12603-9  
  81       Hb E-carrier       46248003       SCT       LA12604-7  
  82       Hb O-Arab carrier               LA12605-4  
  83       Hb S (sickle)-carrier       16402000       SCT       LA12606-2  
  84       Hb C-disease       51053007       SCT       LA12607-0  
  85       Hb C beta-thalassemia       61777009       SCT       LA12608-8  
  86       Hb D-disease               LA12609-6  
  87       Hb D beta-thalassemia       47047009       SCT       LA12610-4  
  88       Hb beta zero-thalassemia       86715000       SCT       LA12611-2  
  89       Hb E-disease       25065001       SCT       LA12612-0  
  90       Hb E beta-thalassemia       234392002       SCT       LA12613-8  
  91       Hb SS-disease (sickle cell anemia)       127040003       SCT       LA12614-6  
  92       Hb S beta-thalassemia       127041004       SCT       LA12615-3  
  93       Hb SC-disease       35434009       SCT       LA12616-1  
  94       Hb SD-disease       25472008       SCT       LA12617-9  
  95       Hb SE-disease       47024008       SCT       LA12618-7  
  96       Hb S O-Arab disease       127048005       SCT       LA12619-5  
  97       Hb S plus Hb other than A,C,D,E,O-Arab disease       23269001       SCT       LA12620-3  
  98       Hb disease other than A, C, D, E, H,O-Arab, S       80141007       SCT       LA12621-1  
  99       Hb carrier other than C, D, E, S ,O-Arab       123773003       SCT       LA12622-9  
  100       HIV       52079000       SCT       LA12565-0  
  101       SCID
Description: Severe combined immunodeficiency (SCID) is an inherited disorder of the immune system resulting from a defect in both T and B lymphocytes. Beginning in the first few months of life, affected individuals are prone to recurrent and persistent infections caused by opportunistic bacteria, viruses, and fungi. These infections are often serious or life-threatening. Researchers have described several different types of severe combined immunodeficiency, which are caused by mutations in multiple genes.
  31323000       SCT       LA12566-8  
  102       TBG       237544006       SCT       LA12567-6  
  103       TOXO       73893000       SCT       LA12568-4  
  104       CIT-I or CIT-II or ASA               LA12569-2  
  105       HCY or MET or CBL C               LA12570-0  
  106       PKU or BIPT-BS or BIOPT-REG or H-PHE               LA12571-8  
  107       TYR-1 or TYR-II or TYR-III               LA12572-6  
  108       CPT-II or CACT               LA12573-4  
  109       LCHAD or TFP               LA12574-2  
  110       MCAD or SCAD or GA-2(MADD)               LA12575-9  
  111       SCAD or EMA or IBG or GA-2 (MADD)               LA12576-7  
  112       2M3HBA or BKT-2               LA12577-5  
  113       IVA or 2MBG or GA-2 or EMA               LA12578-3  
  114       PROP or CBL A or CBL B or MUT or CBL C or MCD               LA12579-1  
  115       3-MCC or 3-MCC (mat) or 3MGA or BKT or HMG or MCD or BIO               LA12915-7  
  116       CUD or CUD (mat) or CPT-Ia               LA12916-5  
  117       GA-1 or GA-2               LA12917-3  
  118       GLA
Description: Fabry disease is an inherited disorder that results from the buildup of a fatty substance called globotriaosylceramide in the body's cells. This buildup leads to episodes of pain, particularly in the hands and feet; small, dark red spots on the skin called angiokeratomas; decreased sweating (hypohidrosis); corneal opacity; and hearing loss. Fabry disease can also involve potentially life-threatening complications such as progressive kidney damage, heart attack, and stroke. This disorder is caused by mutations in the GLA gene; it has an X-linked pattern of inheritance.
  16652001       SCT       LA14036-0  
  119       GAA
Description: Pompe disease is an inherited disorder caused by the buildup of a complex sugar called glycogen in the body's cells. The accumulation of glycogen in certain organs and tissues, especially in muscles, impairs their ability to function normally. Major features of Pompe disease include muscle weakness, heart abnormalities, and breathing problems. This disorder is caused by mutations in the GAA gene; it has an autosomal recessive pattern of inheritance.
  237968007       SCT       LA14037-8  
  120       GALC
Description: Krabbe disease is an inherited disorder that affects the nervous system.  This condition is characterized by severe muscle weakness, slow mental and physical development, vision loss, and seizures. Mutations in the GALC gene cause Krabbe disease; it has an autosomal recessive pattern of inheritance.
  192782005       SCT       LA14038-6  
  121       GBA
Description: Gaucher disease is an inherited disorder that affects many of the body's organs and tissues. Common signs and symptoms include hepatosplenomegaly, anemia, thrombocytopenia, lung disease, and bone abnormalities. The severe types of the disease also involve the central nervous system, causing neurological problems such as abnormal eye movements, seizures, and brain damage. Gaucher disease results from mutations in the GBA gene; it has an autosomal recessive pattern of inheritance.
  190794006       SCT       LA14039-4  
  122       ASM
Description: Niemann-Pick disease is an inherited disorder in which the body in unable to process fats and cholesterol properly.  People with this condition have some combination of the following features: failure to thrive, an enlarged liver and spleen, neurological problems, frequent lung infections, an increased risk of abnormal blood clots, developmental delay, seizures, and poor muscle tone.  Mutations in the SMPD1 gene causes Niemann-Pick disease; it has an autosomal recessive pattern of inheritance.
  58459009       SCT       LA14040-2  
  123       Hb H-disease       48553001       SCT       LA16007-9  
  124       Hemoglobinopathies       80141007       SCT       LA16207-5  
  125       CCHD
Description: Critical congenital heart disease (CCHD) is a term that refers to a group of serious heart defects that are present from birth. These abnormalities result from problems with the formation of one or more parts of the heart during the early stages of embryonic development. CCHD prevents the heart from pumping blood effectively or reduces the amount of oxygen in the blood. As a result, organs and tissues throughout the body do not receive enough oxygen, which can lead to organ damage and life-threatening complications. Individuals with CCHD usually require surgery soon after birth.
          LA20349-9  
  126       X-ALD       65389002       SCT       LA25796-6  
  127       MPS I       11380006       SCT       LA25797-4  

MEMBER OF THESE PANELS
  54089-8   Newborn screening panel American Health Information Community (AHIC)Newborn screening panel American Health Information Community (AHIC)Newborn screening panel: -: Pt: ^Patient: -: AHIC

PARTS

Part Type    Part No.  Part Name   
Component   LP97106-6  Newborn conditions with positive markers 
Property   LP6850-4  Prid   [Presence or Identity] 
Time   LP6960-1  Pt   [Point in time (spot)] 
System   LP21304-8  Bld.dot   [Dried blood spot] 
Scale   LP7750-5  Nom 
Fragments for synonyms   LP21065-5  Positive 
Fragments for synonyms   LP91459-5  newborn 

LANGUAGE VARIANTS
  Chinese (CHINA)  (From: Regenstrief-generated full translation based on part translation provided by Bethune International Peace Hospital)
 
  带有阳性标志的新生儿健康状况:  存在与否或特征标识:  时间点:  全血.斑点:  名义型:  带有阳性标志的新生儿健康状况:  存在与否或特征标识:  时间点:  全血.斑点:  名义型:  带有阳性标志的新生儿健康状况:  存在与否或特征标识:  时间点:  全血.斑点:  名义型:  
  French (BELGIUM)  (From: Regenstrief-generated full translation based on part translation provided by Jean M. Prevost, MD, Biopathology)
 
  Conditions néonatales avec marqueurs positifs:  Présence ou identité:  Temps ponctuel:  Sang sur papier filtre:  Nominal:  Conditions néonatales avec marqueurs positifs:  Présence ou identité:  Temps ponctuel:  Sang sur papier filtre:  Nominal:  Conditions néonatales avec marqueurs positifs:  Présence ou identité:  Temps ponctuel:  Sang sur papier filtre:  Nominal:  
  French (FRANCE)  (From: ASIP Santé (Agence des systèmes d'information partagés de santé))
 
  Conditions néonatales avec marqueurs présents:  Identification:  Ponctuel:  Sang buvard:  Résultat textuel:  Conditions néonatales avec marqueurs présents:  Identification:  Ponctuel:  Sang buvard:  Résultat textuel:  Conditions néonatales avec marqueurs présents:  Identification:  Ponctuel:  Sang buvard:  Résultat textuel:  
  Italian (ITALY)  (From: Regenstrief-generated full translation based on part translation provided by Consiglio Nazionale delle Ricerche)
 
  Neonato, condizioni con marcatori positivi:  Prid:  Pt:  Sangue.su carta da filtro:  Nom:  Neonato, condizioni con marcatori positivi:  Prid:  Pt:  Sangue.su carta da filtro:  Nom:  Neonato, condizioni con marcatori positivi:  Prid:  Pt:  Sangue.su carta da filtro:  Nom:  
  Portuguese (BRAZIL)  (From: HL7 Brazil Institute)
 
  NB conditions positive DBSCondições de recém-nascidos com marcadores positivos:  Ident:  Pt:  SgPapel:  Nom:  Condições de recém-nascidos com marcadores positivos:  Ident:  Pt:  SgPapel:  Nom:  
  Russian (RUSSIAN FEDERATION)  (From: Regenstrief-generated full translation based on part translation provided by Yaroslavl State Medical Academy)
 
  Новорождённый состояния с позитивными маркерами:  ПрИд:  ТчкВрм:  Кр.Сух.капл:  Ном:  Новорождённый состояния с позитивными маркерами:  ПрИд:  ТчкВрм:  Кр.Сух.капл:  Ном:  Новорождённый состояния с позитивными маркерами:  ПрИд:  ТчкВрм:  Кр.Сух.капл:  Ном:  
  Spanish (SPAIN)  (From: Regenstrief-generated full translation based on part translation provided by the Clinical Laboratory Committee of SERVICIO EXTREMEÑO DE SALUD, with the support of BITAC MAP.)
 
  Estado del recién nacido con marcadores positivos:  Presencia o identidad:  Punto temporal:  Punto de sangre (papel de filtro):  Nom:  Estado del recién nacido con marcadores positivos:  Presencia o identidad:  Punto temporal:  Punto de sangre (papel de filtro):  Nom:  Estado del recién nacido con marcadores positivos:  Presencia o identidad:  Punto temporal:  Punto de sangre (papel de filtro):  Nom:  
  Turkish (TURKEY)  (From: Regenstrief-generated full translation based on part translation provided by LOINC Turkish Translation Group and the Turkish Ministry of Health)
 
  Pozitif belirteçli yenidoğan durumları:  MevcKimlik:  Zmlı:  Kan.nokta:  Snf:  Pozitif belirteçli yenidoğan durumları:  MevcKimlik:  Zmlı:  Kan.nokta:  Snf:  Pozitif belirteçli yenidoğan durumları:  MevcKimlik:  Zmlı:  Kan.nokta:  Snf:  

RELATED NAMES
  Blood Identity or presence Random
  Chemistry NB conditions positive WB
  DBS New born Whole blood
  Dried blood spot Nominal  
  Filter paper Point in time  
  FP Pos  

CHANGE HISTORY
  Change Type: MIN

INTERNAL FIELDS
  Attachment Units Required: N
  Long Common Name: Newborn conditions with positive markers [Identifier] in Dried blood spot
  Shortname: NB conditions positive DBS
  Fully Specified Name: Newborn conditions with positive markers: Prid: Pt: Bld.dot: Nom:
     
  Component Word Count: 5
  ID: 51763
  Status (Raw): ACTIVE


57720-5   Newborn conditions with equivocal markers [Identifier] in Dried blood spotNewborn conditions with equivocal markers [Identifier] in Dried blood spotNewborn conditions with equivocal markers: Prid: Pt: Bld.dot: Nom:  

NAME
  Fully-Specified Name: 
Component   Property   Time   System   Scale   Method
Newborn conditions with equivocal markers  Prid  Pt  Bld.dot  Nom 
  Long Common Name:  Newborn conditions with equivocal markers [Identifier] in Dried blood spot
  Shortname:  NB conditions with equivocal markers

ANSWER CARDINALITY
1..*

OBSERVATION REQUIRED IN PANEL
Required

BASIC ATTRIBUTES
  Class/Type: CHEM/Lab
  First Released in Version: 2.29
  Last Updated in Version: 2.56
  Order vs. Obs.: Observation
  Status: Active.
Change Reason: Changed answer list from "Normative" to "Preferred" to fit the current LOINC model.

PREFERRED ANSWER LIST    (LL835-0)  
  SEQ#        Answer        Global ID        Global ID
Code System
   
    Answer ID    
  0       None               LA137-2  
  1       HEAR       15188001       SCT       LA12463-8  
  2       2M3HBA       791000124107       SCT       LA12464-6  
  3       2MBG       445596006       SCT       LA12465-3  
  4       3-MCC       13144005       SCT       LA12466-1  
  5       3-MCC (mat)       206001006       SCT       LA12467-9  
  6       3MGA       297235006       SCT       LA12468-7  
  7       5-OXO       39112005       SCT       LA12469-5  
  8       ARG       23501004       SCT       LA12470-3  
  9       ASA       41013004       SCT       LA12471-1  
  10       BIOPT-BS       237914002       SCT       LA12472-9  
  11       BIOPT-REG       58256000       SCT       LA12473-7  
  12       BKT       237953006       SCT       LA12474-5  
  13       CACT       238003000       SCT       LA12475-2  
  14       CBL A       73843004       SCT       LA12476-0  
  15       CBL B       82245003       SCT       LA12477-8  
  16       CBL C       74653006       SCT       LA12478-6  
  17       CBL D       31220004       SCT       LA12479-4  
  18       CBL E       360373000       SCT       LA12480-2  
  19       CBL G       237938003       SCT       LA12481-0  
  20       CIT-I       398680004       SCT       LA12482-8  
  21       CIT-II       30529005       SCT       LA12483-6  
  22       CPS       62522004       SCT       LA12484-4  
  23       CPT-Ia       238001003       SCT       LA12485-1  
  24       CPT-II       238002005       SCT       LA12486-9  
  25       CUD       21764004       SCT       LA12487-7  
  26       CUD (mat)       206001006       SCT       LA12488-5  
  27       De-Red       444944006       SCT       LA12489-3  
  28       E3       29914000       SCT       LA12490-1  
  29       EMA       811000124106       SCT       LA12491-9  
  30       FIGLU       59761008       SCT       LA12492-7  
  31       GA-1       76175005       SCT       LA12493-5  
  32       GA-1 (mat)       206001006       SCT       LA12494-3  
  33       GA-2       22886006       SCT       LA12495-0  
  34       HCY       11282001       SCT       LA12496-8  
  35       HHH       30287008       SCT       LA12497-6  
  36       HIS       410058007       SCT       LA12498-4  
  37       HMG       410059004       SCT       LA12499-2  
  38       H-PHE       68528007       SCT       LA12500-7  
  39       Hyper LYS       58558003       SCT       LA12501-5  
  40       Hyper ORN       314467007       SCT       LA12502-3  
  41       Hyper VAL       47719001       SCT       LA12503-1  
  42       IBG       445571008       SCT       LA12504-9  
  43       IVA       87827003       SCT       LA12505-6  
  44       LACTIC       190882007       SCT       LA12506-4  
  45       LCHAD       307127004       SCT       LA12507-2  
  46       MAL       124594007       SCT       LA12508-0  
  47       MCAD       128596003       SCT       LA12509-8  
  48       MCD       360369003       SCT       LA12510-6  
  49       MCKAT       124265004       SCT       LA12511-4  
  50       MET       43123004       SCT       LA12512-2  
  51       MSUD       27718001       SCT       LA12513-0  
  52       MTHFR       41797007       SCT       LA12514-8  
  53       MUT       124680001       SCT       LA12515-5  
  54       NKHG       237939006       SCT       LA12516-3  
  55       OH PRO       25739007       SCT       LA12517-1  
  56       OTC       80908008       SCT       LA12518-9  
  57       PC       87694001       SCT       LA12519-7  
  58       PKU       7573000       SCT       LA12520-5  
  59       PRO I       61071003       SCT       LA12521-3  
  60       PRO II       124177001       SCT       LA12522-1  
  61       PROP       69080001       SCT       LA12523-9  
  62       SCAD       124166007       SCT       LA12524-7  
  63       SCHAD       237998000       SCT       LA12525-4  
  64       SUCLA2       445275003       SCT       LA12526-2  
  65       TFP       237999008       SCT       LA12527-0  
  66       TYR-1       410056006       SCT       LA12528-8  
  67       TYR-II       4887000       SCT       LA12529-6  
  68       TYR-III       415764005       SCT       LA12530-4  
  69       VLCAD       237997005       SCT       LA12531-2  
  70       BIO       8808004       SCT       LA12532-0  
  71       CAH       124214007       SCT       LA12533-8  
  72       CF       190905008       SCT       LA12537-9  
  73       CH       190268003       SCT       LA12538-7  
  74       CH2       82598004       SCT       LA12539-5  
  75       G6PD       62403005       SCT       LA12540-3  
  76       GALE       8849004       SCT       LA12541-1  
  77       GALK       124302001       SCT       LA12542-9  
  78       GALT       398664009       SCT       LA12543-7  
  79       Hb C-carrier       76050008       SCT       LA12602-1  
  80       Hb D-carrier       7391009       SCT       LA12603-9  
  81       Hb E-carrier       46248003       SCT       LA12604-7  
  82       Hb O-Arab carrier               LA12605-4  
  83       Hb S (sickle)-carrier       16402000       SCT       LA12606-2  
  84       Hb C-disease       51053007       SCT       LA12607-0  
  85       Hb C beta-thalassemia       61777009       SCT       LA12608-8  
  86       Hb D-disease               LA12609-6  
  87       Hb D beta-thalassemia       47047009       SCT       LA12610-4  
  88       Hb beta zero-thalassemia       86715000       SCT       LA12611-2  
  89       Hb E-disease       25065001       SCT       LA12612-0  
  90       Hb E beta-thalassemia       234392002       SCT       LA12613-8  
  91       Hb SS-disease (sickle cell anemia)       127040003       SCT       LA12614-6  
  92       Hb S beta-thalassemia       127041004       SCT       LA12615-3  
  93       Hb SC-disease       35434009       SCT       LA12616-1  
  94       Hb SD-disease       25472008       SCT       LA12617-9  
  95       Hb SE-disease       47024008       SCT       LA12618-7  
  96       Hb S O-Arab disease       127048005       SCT       LA12619-5  
  97       Hb S plus Hb other than A,C,D,E,O-Arab disease       23269001       SCT       LA12620-3  
  98       Hb disease other than A, C, D, E, H,O-Arab, S       80141007       SCT       LA12621-1  
  99       Hb carrier other than C, D, E, S ,O-Arab       123773003       SCT       LA12622-9  
  100       HIV       52079000       SCT       LA12565-0  
  101       SCID
Description: Severe combined immunodeficiency (SCID) is an inherited disorder of the immune system resulting from a defect in both T and B lymphocytes. Beginning in the first few months of life, affected individuals are prone to recurrent and persistent infections caused by opportunistic bacteria, viruses, and fungi. These infections are often serious or life-threatening. Researchers have described several different types of severe combined immunodeficiency, which are caused by mutations in multiple genes.
  31323000       SCT       LA12566-8  
  102       TBG       237544006       SCT       LA12567-6  
  103       TOXO       73893000       SCT       LA12568-4  
  104       CIT-I or CIT-II or ASA               LA12569-2  
  105       HCY or MET or CBL C               LA12570-0  
  106       PKU or BIPT-BS or BIOPT-REG or H-PHE               LA12571-8  
  107       TYR-1 or TYR-II or TYR-III               LA12572-6  
  108       CPT-II or CACT               LA12573-4  
  109       LCHAD or TFP               LA12574-2  
  110       MCAD or SCAD or GA-2(MADD)               LA12575-9  
  111       SCAD or EMA or IBG or GA-2 (MADD)               LA12576-7  
  112       2M3HBA or BKT-2               LA12577-5  
  113       IVA or 2MBG or GA-2 or EMA               LA12578-3  
  114       PROP or CBL A or CBL B or MUT or CBL C or MCD               LA12579-1  
  115       3-MCC or 3-MCC (mat) or 3MGA or BKT or HMG or MCD or BIO               LA12915-7  
  116       CUD or CUD (mat) or CPT-Ia               LA12916-5  
  117       GA-1 or GA-2               LA12917-3  
  118       GLA
Description: Fabry disease is an inherited disorder that results from the buildup of a fatty substance called globotriaosylceramide in the body's cells. This buildup leads to episodes of pain, particularly in the hands and feet; small, dark red spots on the skin called angiokeratomas; decreased sweating (hypohidrosis); corneal opacity; and hearing loss. Fabry disease can also involve potentially life-threatening complications such as progressive kidney damage, heart attack, and stroke. This disorder is caused by mutations in the GLA gene; it has an X-linked pattern of inheritance.
  16652001       SCT       LA14036-0  
  119       GAA
Description: Pompe disease is an inherited disorder caused by the buildup of a complex sugar called glycogen in the body's cells. The accumulation of glycogen in certain organs and tissues, especially in muscles, impairs their ability to function normally. Major features of Pompe disease include muscle weakness, heart abnormalities, and breathing problems. This disorder is caused by mutations in the GAA gene; it has an autosomal recessive pattern of inheritance.
  237968007       SCT       LA14037-8  
  120       GALC
Description: Krabbe disease is an inherited disorder that affects the nervous system.  This condition is characterized by severe muscle weakness, slow mental and physical development, vision loss, and seizures. Mutations in the GALC gene cause Krabbe disease; it has an autosomal recessive pattern of inheritance.
  192782005       SCT       LA14038-6  
  121       GBA
Description: Gaucher disease is an inherited disorder that affects many of the body's organs and tissues. Common signs and symptoms include hepatosplenomegaly, anemia, thrombocytopenia, lung disease, and bone abnormalities. The severe types of the disease also involve the central nervous system, causing neurological problems such as abnormal eye movements, seizures, and brain damage. Gaucher disease results from mutations in the GBA gene; it has an autosomal recessive pattern of inheritance.
  190794006       SCT       LA14039-4  
  122       ASM
Description: Niemann-Pick disease is an inherited disorder in which the body in unable to process fats and cholesterol properly.  People with this condition have some combination of the following features: failure to thrive, an enlarged liver and spleen, neurological problems, frequent lung infections, an increased risk of abnormal blood clots, developmental delay, seizures, and poor muscle tone.  Mutations in the SMPD1 gene causes Niemann-Pick disease; it has an autosomal recessive pattern of inheritance.
  58459009       SCT       LA14040-2  
  123       Hb H-disease       48553001       SCT       LA16007-9  
  124       Hemoglobinopathies       80141007       SCT       LA16207-5  
  125       CCHD
Description: Critical congenital heart disease (CCHD) is a term that refers to a group of serious heart defects that are present from birth. These abnormalities result from problems with the formation of one or more parts of the heart during the early stages of embryonic development. CCHD prevents the heart from pumping blood effectively or reduces the amount of oxygen in the blood. As a result, organs and tissues throughout the body do not receive enough oxygen, which can lead to organ damage and life-threatening complications. Individuals with CCHD usually require surgery soon after birth.
          LA20349-9  
  126       X-ALD       65389002       SCT       LA25796-6  
  127       MPS I       11380006       SCT       LA25797-4  

MEMBER OF THESE PANELS
  54089-8   Newborn screening panel American Health Information Community (AHIC)Newborn screening panel American Health Information Community (AHIC)Newborn screening panel: -: Pt: ^Patient: -: AHIC

PARTS

Part Type    Part No.  Part Name   
Component   LP97570-3  Newborn conditions with equivocal markers 
Property   LP6850-4  Prid   [Presence or Identity] 
Time   LP6960-1  Pt   [Point in time (spot)] 
System   LP21304-8  Bld.dot   [Dried blood spot] 
Scale   LP7750-5  Nom 
Fragments for synonyms   LP91459-5  newborn 

LANGUAGE VARIANTS
  Chinese (CHINA)  (From: Regenstrief-generated full translation based on part translation provided by Bethune International Peace Hospital)
 
  带有模糊标志的新生儿健康状况:  存在与否或特征标识:  时间点:  全血.斑点:  名义型:  带有模糊标志的新生儿健康状况:  存在与否或特征标识:  时间点:  全血.斑点:  名义型:  带有模糊标志的新生儿健康状况:  存在与否或特征标识:  时间点:  全血.斑点:  名义型:  
  French (BELGIUM)  (From: Regenstrief-generated full translation based on part translation provided by Jean M. Prevost, MD, Biopathology)
 
  Conditions néonatales avec marqueurs équivoques:  Présence ou identité:  Temps ponctuel:  Sang sur papier filtre:  Nominal:  Conditions néonatales avec marqueurs équivoques:  Présence ou identité:  Temps ponctuel:  Sang sur papier filtre:  Nominal:  Conditions néonatales avec marqueurs équivoques:  Présence ou identité:  Temps ponctuel:  Sang sur papier filtre:  Nominal:  
  French (FRANCE)  (From: ASIP Santé (Agence des systèmes d'information partagés de santé))
 
  Conditions néonatales avec marqueurs équivoques:  Identification:  Ponctuel:  Sang buvard:  Résultat textuel:  Conditions néonatales avec marqueurs équivoques:  Identification:  Ponctuel:  Sang buvard:  Résultat textuel:  Conditions néonatales avec marqueurs équivoques:  Identification:  Ponctuel:  Sang buvard:  Résultat textuel:  
  Italian (ITALY)  (From: Regenstrief-generated full translation based on part translation provided by Consiglio Nazionale delle Ricerche)
 
  Neonato, condizioni con marcatori sospetti:  Prid:  Pt:  Sangue.su carta da filtro:  Nom:  Neonato, condizioni con marcatori sospetti:  Prid:  Pt:  Sangue.su carta da filtro:  Nom:  Neonato, condizioni con marcatori sospetti:  Prid:  Pt:  Sangue.su carta da filtro:  Nom:  
  Portuguese (BRAZIL)  (From: HL7 Brazil Institute)
 
  NB conditions with equivocal markersCondições de recém-nascidos com marcadores equívocos:  Ident:  Pt:  SgPapel:  Nom:  Condições de recém-nascidos com marcadores equívocos:  Ident:  Pt:  SgPapel:  Nom:  
  Russian (RUSSIAN FEDERATION)  (From: Regenstrief-generated full translation based on part translation provided by Yaroslavl State Medical Academy)
 
  Новорождённый состояние с неопределённые маркеры:  ПрИд:  ТчкВрм:  Кр.Сух.капл:  Ном:  Новорождённый состояние с неопределённые маркеры:  ПрИд:  ТчкВрм:  Кр.Сух.капл:  Ном:  Новорождённый состояние с неопределённые маркеры:  ПрИд:  ТчкВрм:  Кр.Сух.капл:  Ном:  
  Spanish (SPAIN)  (From: Regenstrief-generated full translation based on part translation provided by the Clinical Laboratory Committee of SERVICIO EXTREMEÑO DE SALUD, with the support of BITAC MAP.)
 
  Estado del recién nacido con marcadores equívocos:  Presencia o identidad:  Punto temporal:  Punto de sangre (papel de filtro):  Nom:  Estado del recién nacido con marcadores equívocos:  Presencia o identidad:  Punto temporal:  Punto de sangre (papel de filtro):  Nom:  Estado del recién nacido con marcadores equívocos:  Presencia o identidad:  Punto temporal:  Punto de sangre (papel de filtro):  Nom:  
  Turkish (TURKEY)  (From: Regenstrief-generated full translation based on part translation provided by LOINC Turkish Translation Group and the Turkish Ministry of Health)
 
  Kuşkulu belirteçli yenidoğan şartları:  MevcKimlik:  Zmlı:  Kan.nokta:  Snf:  Kuşkulu belirteçli yenidoğan şartları:  MevcKimlik:  Zmlı:  Kan.nokta:  Snf:  Kuşkulu belirteçli yenidoğan şartları:  MevcKimlik:  Zmlı:  Kan.nokta:  Snf:  

RELATED NAMES
  Blood FP Point in time
  Chemistry Identity or presence Random
  DBS NB conditions with equivocal markers WB
  Dried blood spot New born Whole blood
  Filter paper Nominal  

CHANGE HISTORY
  Change Type: MIN

INTERNAL FIELDS
  Attachment Units Required: N
  Long Common Name: Newborn conditions with equivocal markers [Identifier] in Dried blood spot
  Shortname: NB conditions with equivocal markers
  Fully Specified Name: Newborn conditions with equivocal markers: Prid: Pt: Bld.dot: Nom:
     
  Component Word Count: 5
  ID: 52393
  Status (Raw): ACTIVE


57724-7   Newborn screening short narrative summaryNewborn screening short narrative summaryNewborn screening short narrative summary: Txt: Pt: ^Patient: Nar:  

NAME
  Fully-Specified Name: 
Component   Property   Time   System   Scale   Method
Newborn screening short narrative summary  Txt  Pt  ^Patient  Nar 
  Long Common Name:  Newborn screening short narrative summary
  Shortname:  NBS short summary

ANSWER CARDINALITY
0..1

OBSERVATION REQUIRED IN PANEL
Optional

BASIC ATTRIBUTES
  Class/Type: CHEM/Lab
  First Released in Version: 2.29
  Last Updated in Version: 2.40
  Order vs. Obs.: Observation
  Status: Active

MEMBER OF THESE PANELS
  54089-8   Newborn screening panel American Health Information Community (AHIC)Newborn screening panel American Health Information Community (AHIC)Newborn screening panel: -: Pt: ^Patient: -: AHIC

PARTS

Part Type    Part No.  Part Name   
Component   LP97576-0  Newborn screening short narrative summary 
Property   LP6885-0  Txt   [Text] 
Time   LP6960-1  Pt   [Point in time (spot)] 
Super System   LP6985-8  Patient 
Scale   LP7749-7  Nar 
Fragments for synonyms   LP34059-3  Screening 
Fragments for synonyms   LP91459-5  newborn 

LANGUAGE VARIANTS
  Chinese (CHINA)  (From: Regenstrief-generated full translation based on part translation provided by Bethune International Peace Hospital)
 
  新生儿筛查简述摘要:  文本型属性:  时间点:  ^患者:  叙述型:  新生儿筛查简述摘要:  文本型属性:  时间点:  ^患者:  叙述型:  新生儿筛查简述摘要:  文本型属性:  时间点:  ^患者:  叙述型:  
  Dutch (NETHERLANDS)  (From: Regenstrief-generated full translation based on part translation provided by NVKC, Dutch Society for Clinical Chemistry and Laboratory Medicine, The Netherlands)
 
  Pasgeborene screening korte tekstuele samnvatting:  Tekst:  Moment:  ^Patient:  Tekstueel:  Pasgeborene screening korte tekstuele samnvatting:  Tekst:  Moment:  ^Patient:  Tekstueel:  Pasgeborene screening korte tekstuele samnvatting:  Tekst:  Moment:  ^Patient:  Tekstueel:  
  French (BELGIUM)  (From: Regenstrief-generated full translation based on part translation provided by Jean M. Prevost, MD, Biopathology)
 
  Screening Nouveau-né. Résumé court:  Texte:  Temps ponctuel:  ^Patient:  Narratif:  Screening Nouveau-né. Résumé court:  Texte:  Temps ponctuel:  ^Patient:  Narratif:  Screening Nouveau-né. Résumé court:  Texte:  Temps ponctuel:  ^Patient:  Narratif:  
  French (FRANCE)  (From: ASIP Santé (Agence des systèmes d'information partagés de santé))
 
  Dépistage néonatal résumé compte rendu:  Texte:  Ponctuel:  Patient:  Commentaire:  Dépistage néonatal résumé compte rendu:  Texte:  Ponctuel:  Patient:  Commentaire:  Dépistage néonatal résumé compte rendu:  Texte:  Ponctuel:  Patient:  Commentaire:  
  Italian (ITALY)  (From: Regenstrief-generated full translation based on part translation provided by Consiglio Nazionale delle Ricerche)
 
  Screening neonatale, breve resoconto:  Txt:  Pt:  ^Paziente:  Nar:  Screening neonatale, breve resoconto:  Txt:  Pt:  ^Paziente:  Nar:  Screening neonatale, breve resoconto:  Txt:  Pt:  ^Paziente:  Nar:  
  Portuguese (BRAZIL)  (From: HL7 Brazil Institute)
 
  NBSshort summary PatientTriagem neonatal pequeno sumário narrativo:  #N/​A:  Pt:  ^Paciente:  Nar:  Triagem neonatal pequeno sumário narrativo:  #N/​A:  Pt:  ^Paciente:  Nar:  
  Russian (RUSSIAN FEDERATION)  (From: Regenstrief-generated full translation based on part translation provided by Yaroslavl State Medical Academy)
 
  Новорождённый скрининг краткий описательный краткие сведения:  Txt:  ТчкВрм:  ^Пациент:  Опис:  Новорождённый скрининг краткий описательный краткие сведения:  Txt:  ТчкВрм:  ^Пациент:  Опис:  Новорождённый скрининг краткий описательный краткие сведения:  Txt:  ТчкВрм:  ^Пациент:  Опис:  
  Spanish (SPAIN)  (From: Regenstrief-generated full translation based on part translation provided by the Clinical Laboratory Committee of SERVICIO EXTREMEÑO DE SALUD, with the support of BITAC MAP.)
 
  Resumen narrativo corto del cribado del recién nacido:  Texto:  Punto temporal:  ^paciente:  Narrativo:  Resumen narrativo corto del cribado del recién nacido:  Texto:  Punto temporal:  ^paciente:  Narrativo:  Resumen narrativo corto del cribado del recién nacido:  Texto:  Punto temporal:  ^paciente:  Narrativo:  
  Turkish (TURKEY)  (From: Regenstrief-generated full translation based on part translation provided by LOINC Turkish Translation Group and the Turkish Ministry of Health)
 
  Yenidoğan tarama kısa yazılı özet:  Metin:  Zmlı:  ^Hasta:  Öykü:  Yenidoğan tarama kısa yazılı özet:  Metin:  Zmlı:  ^Hasta:  Öykü:  Yenidoğan tarama kısa yazılı özet:  Metin:  Zmlı:  ^Hasta:  Öykü:  

RELATED NAMES
  Asympt NBS short summary Report
  Asymptomatic New born Scn
  Chemistry Point in time Text
  Narrative Random  

CHANGE HISTORY
  Change Type: MIN

INTERNAL FIELDS
  Attachment Units Required: N
  Long Common Name: Newborn screening short narrative summary
  Shortname: NBS short summary
  Fully Specified Name: Newborn screening short narrative summary: Txt: Pt: ^Patient: Nar:
     
  Component Word Count: 5
  ID: 52397
  Status (Raw): ACTIVE


57129-9   Full newborn screening summary report for display or printingFull newborn screening summary report for display or printingFull newborn screening summary report for display or printing: -: Pt: ^Patient: Doc:  

NAME
  Fully-Specified Name: 
Component   Property   Time   System   Scale   Method
Full newborn screening summary report for display or printing  Pt  ^Patient  Doc 
  Long Common Name:  Full newborn screening summary report for display or printing
  Shortname:  Full NBS summary for display/printing

TERM DEFINITION/DESCRIPTION(S)
  This code indicates that the OBX-5 carries a summary new born screen report as formatted text. Use HL7 type FT or if you want to see as PDF use HL7 encoded data type (ED) and send as binary data in the OBX-5. It is an option entry that provides a convenient way for laboratories to send reports for display and/or printing to clinicians with whatever format they now deliver. If sent as a PDF it could include letter head, water marks etc.
 
 

ANSWER CARDINALITY
0..1

OBSERVATION REQUIRED IN PANEL
Optional

BASIC ATTRIBUTES
  Class/Type: CHEM/Lab
  First Released in Version: 2.29
  Last Updated in Version: 2.38
  Order vs. Obs.: Observation
  Status: Active

MEMBER OF THESE PANELS
  54089-8   Newborn screening panel American Health Information Community (AHIC)Newborn screening panel American Health Information Community (AHIC)Newborn screening panel: -: Pt: ^Patient: -: AHIC

PARTS

Part Type    Part No.  Part Name   
Component   LP97104-1  Full newborn screening summary report for display or printing 
Property   LP6769-6 
Time   LP6960-1  Pt   [Point in time (spot)] 
Super System   LP6985-8  Patient 
Scale   LP32888-7  Doc 
Fragments for synonyms   LP34059-3  Screening 
Fragments for synonyms   LP91459-5  newborn 

LANGUAGE VARIANTS
  Chinese (CHINA)  (From: Regenstrief-generated full translation based on part translation provided by Bethune International Peace Hospital)
 
  适用于显示或打印的全面新生儿筛查摘要报告:  -:  时间点:  ^患者:  文档型:  适用于显示或打印的全面新生儿筛查摘要报告:  -:  时间点:  ^患者:  文档型:  适用于显示或打印的全面新生儿筛查摘要报告:  -:  时间点:  ^患者:  文档型:  
  Dutch (NETHERLANDS)  (From: Regenstrief-generated full translation based on part translation provided by NVKC, Dutch Society for Clinical Chemistry and Laboratory Medicine, The Netherlands)
 
  Volledige pasgeborene screening samenvattend rapport voor weergave of om te printen:  -:  Moment:  ^Patient:  Document:  Volledige pasgeborene screening samenvattend rapport voor weergave of om te printen:  -:  Moment:  ^Patient:  Document:  Volledige pasgeborene screening samenvattend rapport voor weergave of om te printen:  -:  Moment:  ^Patient:  Document:  
  Italian (ITALY)  (From: Regenstrief-generated full translation based on part translation provided by Consiglio Nazionale delle Ricerche)
 
  Screening neonatale completo, referto generale per la visualizzazione o la stampa:  -:  Pt:  ^Paziente:  Doc:  Screening neonatale completo, referto generale per la visualizzazione o la stampa:  -:  Pt:  ^Paziente:  Doc:  Screening neonatale completo, referto generale per la visualizzazione o la stampa:  -:  Pt:  ^Paziente:  Doc:  
  Portuguese (BRAZIL)  (From: HL7 Brazil Institute)
 
  Full NBS summary for display & printingRelatório completo de síntese de Triagem Neonatal para exibição ou impressão:  #N/​A:  Pt:  ^Paciente:  Doc:  Relatório completo de síntese de Triagem Neonatal para exibição ou impressão:  #N/​A:  Pt:  ^Paciente:  Doc:  
  Russian (RUSSIAN FEDERATION)  (From: Regenstrief-generated full translation based on part translation provided by Yaroslavl State Medical Academy)
 
  Полный новорождённый скрининг краткие сведения отчёт для вывода на экран или печати:  -:  ТчкВрм:  ^Пациент:  Док:  Полный новорождённый скрининг краткие сведения отчёт для вывода на экран или печати:  -:  ТчкВрм:  ^Пациент:  Док:  Полный новорождённый скрининг краткие сведения отчёт для вывода на экран или печати:  -:  ТчкВрм:  ^Пациент:  Док:  
  Spanish (SPAIN)  (From: Regenstrief-generated full translation based on part translation provided by the Clinical Laboratory Committee of SERVICIO EXTREMEÑO DE SALUD, with the support of BITAC MAP.)
 
  Informe de cribado total en el recién nacido para su visualización o impresión:  Propiedades mixtas (sólo paneles):  Punto temporal:  ^paciente:  Doc:  Informe de cribado total en el recién nacido para su visualización o impresión:  Propiedades mixtas (sólo paneles):  Punto temporal:  ^paciente:  Doc:  Informe de cribado total en el recién nacido para su visualización o impresión:  Propiedades mixtas (sólo paneles):  Punto temporal:  ^paciente:  Doc:  
  Turkish (TURKEY)  (From: Regenstrief-generated full translation based on part translation provided by LOINC Turkish Translation Group and the Turkish Ministry of Health)
 
  Tam yenidoğan tarama özet raporu görüntü veya baskı için:  -:  Zmlı:  ^Hasta:  Dokm:  Tam yenidoğan tarama özet raporu görüntü veya baskı için:  -:  Zmlı:  ^Hasta:  Dokm:  Tam yenidoğan tarama özet raporu görüntü veya baskı için:  -:  Zmlı:  ^Hasta:  Dokm:  

RELATED NAMES
  Asympt Document Point in time
  Asymptomatic Full NBS summary for display & print Random
  Chemistry New born Scn

CHANGE HISTORY
  Change Type: MIN

INTERNAL FIELDS
  Attachment Units Required: N
  Long Common Name: Full newborn screening summary report for display or printing
  Shortname: Full NBS summary for display/printing
  Fully Specified Name: Full newborn screening summary report for display or printing: -: Pt: ^Patient: Doc:
     
  Component Word Count: 9
  ID: 51761
  Status (Raw): ACTIVE


57719-7   Conditions tested for in this newborn screening study [Identifier] in Dried blood spotConditions tested for in this newborn screening study [Identifier] in Dried blood spotConditions tested for in this newborn screening study: ID: Pt: Bld.dot: Nom:  

NAME
  Fully-Specified Name: 
Component   Property   Time   System   Scale   Method
Conditions tested for in this newborn screening study  ID  Pt  Bld.dot  Nom 
  Long Common Name:  Conditions tested for in this newborn screening study [Identifier] in Dried blood spot
  Shortname:  Conditions tested for in NBS study DBS

ANSWER CARDINALITY
1..*

OBSERVATION REQUIRED IN PANEL
Required

BASIC ATTRIBUTES
  Class/Type: CHEM/Lab
  First Released in Version: 2.29
  Last Updated in Version: 2.56
  Order vs. Obs.: Observation
  Status: Active.
Change Reason: Changed answer list from "Normative" to "Preferred" to fit the current LOINC model.

PREFERRED ANSWER LIST    (LL841-8)  
  SEQ#        Answer        Global ID        Global ID
Code System
   
    Answer ID    
  0       Hemoglobin C crystals               LA11231-0  
  1       HEAR       15188001       SCT       LA12463-8  
  2       2M3HBA       791000124107       SCT       LA12464-6  
  3       2MBG       445596006       SCT       LA12465-3  
  4       3-MCC       13144005       SCT       LA12466-1  
  5       3-MCC (mat)       206001006       SCT       LA12467-9  
  6       3MGA       297235006       SCT       LA12468-7  
  7       5-OXO       39112005       SCT       LA12469-5  
  8       ARG       23501004       SCT       LA12470-3  
  9       ASA       41013004       SCT       LA12471-1  
  10       BIOPT-BS       237914002       SCT       LA12472-9  
  11       BIOPT-REG       58256000       SCT       LA12473-7  
  12       BKT       237953006       SCT       LA12474-5  
  13       CACT       238003000       SCT       LA12475-2  
  14       CBL A       73843004       SCT       LA12476-0  
  15       CBL B       82245003       SCT       LA12477-8  
  16       CBL C       74653006       SCT       LA12478-6  
  17       CBL D       31220004       SCT       LA12479-4  
  18       CBL E       360373000       SCT       LA12480-2  
  19       CBL G       237938003       SCT       LA12481-0  
  20       CIT-I       398680004       SCT       LA12482-8  
  21       CIT-II       30529005       SCT       LA12483-6  
  22       CPS       62522004       SCT       LA12484-4  
  23       CPT-Ia       238001003       SCT       LA12485-1  
  24       CPT-II       238002005       SCT       LA12486-9  
  25       CUD       21764004       SCT       LA12487-7  
  26       CUD (mat)       206001006       SCT       LA12488-5  
  27       De-Red       444944006       SCT       LA12489-3  
  28       E3       29914000       SCT       LA12490-1  
  29       EMA       811000124106       SCT       LA12491-9  
  30       FIGLU       59761008       SCT       LA12492-7  
  31       GA-1       76175005       SCT       LA12493-5  
  32       GA-1 (mat)       206001006       SCT       LA12494-3  
  33       GA-2       22886006       SCT       LA12495-0  
  34       HCY       11282001       SCT       LA12496-8  
  35       HHH       30287008       SCT       LA12497-6  
  36       HIS       410058007       SCT       LA12498-4  
  37       HMG       410059004       SCT       LA12499-2  
  38       H-PHE       68528007       SCT       LA12500-7  
  39       Hyper LYS       58558003       SCT       LA12501-5  
  40       Hyper ORN       314467007       SCT       LA12502-3  
  41       Hyper VAL       47719001       SCT       LA12503-1  
  42       IBG       445571008       SCT       LA12504-9  
  43       IVA       87827003       SCT       LA12505-6  
  44       LACTIC       190882007       SCT       LA12506-4  
  45       LCHAD       307127004       SCT       LA12507-2  
  46       MAL       124594007       SCT       LA12508-0  
  47       MCAD       128596003       SCT       LA12509-8  
  48       MCD       360369003       SCT       LA12510-6  
  49       MCKAT       124265004       SCT       LA12511-4  
  50       MET       43123004       SCT       LA12512-2  
  51       MSUD       27718001       SCT       LA12513-0  
  52       MTHFR       41797007       SCT       LA12514-8  
  53       MUT       124680001       SCT       LA12515-5  
  54       NKHG       237939006       SCT       LA12516-3  
  55       OH PRO       25739007       SCT       LA12517-1  
  56       OTC       80908008       SCT       LA12518-9  
  57       PC       87694001       SCT       LA12519-7  
  58       PKU       7573000       SCT       LA12520-5  
  59       PRO I       61071003       SCT       LA12521-3  
  60       PRO II       124177001       SCT       LA12522-1  
  61       PROP       69080001       SCT       LA12523-9  
  62       SCAD       124166007       SCT       LA12524-7  
  63       SCHAD       237998000       SCT       LA12525-4  
  64       SUCLA2       445275003       SCT       LA12526-2  
  65       TFP       237999008       SCT       LA12527-0  
  66       TYR-1       410056006       SCT       LA12528-8  
  67       TYR-II       4887000       SCT       LA12529-6  
  68       TYR-III       415764005       SCT       LA12530-4  
  69       VLCAD       237997005       SCT       LA12531-2  
  70       BIO       8808004       SCT       LA12532-0  
  71       CAH       124214007       SCT       LA12533-8  
  72       CF       190905008       SCT       LA12537-9  
  73       CH       190268003       SCT       LA12538-7  
  74       CH2       82598004       SCT       LA12539-5  
  75       G6PD       62403005       SCT       LA12540-3  
  76       GALE       8849004       SCT       LA12541-1  
  77       GALK       124302001       SCT       LA12542-9  
  78       GALT       398664009       SCT       LA12543-7  
  79       Hb C-carrier       76050008       SCT       LA12602-1  
  80       Hb D-carrier       7391009       SCT       LA12603-9  
  81       Hb E-carrier       46248003       SCT       LA12604-7  
  82       Hb O-Arab carrier               LA12605-4  
  83       Hb S (sickle)-carrier       16402000       SCT       LA12606-2  
  84       Hb C-disease       51053007       SCT       LA12607-0  
  85       Hb C beta-thalassemia       61777009       SCT       LA12608-8  
  86       Hb D-disease               LA12609-6  
  87       Hb D beta-thalassemia       47047009       SCT       LA12610-4  
  88       Hb beta zero-thalassemia       86715000       SCT       LA12611-2  
  89       Hb E-disease       25065001       SCT       LA12612-0  
  90       Hb E beta-thalassemia       234392002       SCT       LA12613-8  
  91       Hb SS-disease (sickle cell anemia)       127040003       SCT       LA12614-6  
  92       Hb S beta-thalassemia       127041004       SCT       LA12615-3  
  93       Hb SC-disease       35434009       SCT       LA12616-1  
  94       Hb SD-disease       25472008       SCT       LA12617-9  
  95       Hb SE-disease       47024008       SCT       LA12618-7  
  96       Hb S O-Arab disease       127048005       SCT       LA12619-5  
  97       Hb S plus Hb other than A,C,D,E,O-Arab disease       23269001       SCT       LA12620-3  
  98       Hb disease other than A, C, D, E, H,O-Arab, S       80141007       SCT       LA12621-1  
  99       Hb carrier other than C, D, E, S ,O-Arab       123773003       SCT       LA12622-9  
  100       HIV       52079000       SCT       LA12565-0  
  101       SCID
Description: Severe combined immunodeficiency (SCID) is an inherited disorder of the immune system resulting from a defect in both T and B lymphocytes. Beginning in the first few months of life, affected individuals are prone to recurrent and persistent infections caused by opportunistic bacteria, viruses, and fungi. These infections are often serious or life-threatening. Researchers have described several different types of severe combined immunodeficiency, which are caused by mutations in multiple genes.
  31323000       SCT       LA12566-8  
  102       TBG       237544006       SCT       LA12567-6  
  103       TOXO       73893000       SCT       LA12568-4  
  104       GLA
Description: Fabry disease is an inherited disorder that results from the buildup of a fatty substance called globotriaosylceramide in the body's cells. This buildup leads to episodes of pain, particularly in the hands and feet; small, dark red spots on the skin called angiokeratomas; decreased sweating (hypohidrosis); corneal opacity; and hearing loss. Fabry disease can also involve potentially life-threatening complications such as progressive kidney damage, heart attack, and stroke. This disorder is caused by mutations in the GLA gene; it has an X-linked pattern of inheritance.
  16652001       SCT       LA14036-0  
  105       GAA
Description: Pompe disease is an inherited disorder caused by the buildup of a complex sugar called glycogen in the body's cells. The accumulation of glycogen in certain organs and tissues, especially in muscles, impairs their ability to function normally. Major features of Pompe disease include muscle weakness, heart abnormalities, and breathing problems. This disorder is caused by mutations in the GAA gene; it has an autosomal recessive pattern of inheritance.
  237968007       SCT       LA14037-8  
  106       GALC
Description: Krabbe disease is an inherited disorder that affects the nervous system.  This condition is characterized by severe muscle weakness, slow mental and physical development, vision loss, and seizures. Mutations in the GALC gene cause Krabbe disease; it has an autosomal recessive pattern of inheritance.
  192782005       SCT       LA14038-6  
  107       GBA
Description: Gaucher disease is an inherited disorder that affects many of the body's organs and tissues. Common signs and symptoms include hepatosplenomegaly, anemia, thrombocytopenia, lung disease, and bone abnormalities. The severe types of the disease also involve the central nervous system, causing neurological problems such as abnormal eye movements, seizures, and brain damage. Gaucher disease results from mutations in the GBA gene; it has an autosomal recessive pattern of inheritance.
  190794006       SCT       LA14039-4  
  108       ASM
Description: Niemann-Pick disease is an inherited disorder in which the body in unable to process fats and cholesterol properly.  People with this condition have some combination of the following features: failure to thrive, an enlarged liver and spleen, neurological problems, frequent lung infections, an increased risk of abnormal blood clots, developmental delay, seizures, and poor muscle tone.  Mutations in the SMPD1 gene causes Niemann-Pick disease; it has an autosomal recessive pattern of inheritance.
  58459009       SCT       LA14040-2  
  109       Hb H-disease       48553001       SCT       LA16007-9  
  110       Hemoglobinopathies       80141007       SCT       LA16207-5  
  111       CCHD
Description: Critical congenital heart disease (CCHD) is a term that refers to a group of serious heart defects that are present from birth. These abnormalities result from problems with the formation of one or more parts of the heart during the early stages of embryonic development. CCHD prevents the heart from pumping blood effectively or reduces the amount of oxygen in the blood. As a result, organs and tissues throughout the body do not receive enough oxygen, which can lead to organ damage and life-threatening complications. Individuals with CCHD usually require surgery soon after birth.
          LA20349-9  
  112       X-ALD       65389002       SCT       LA25796-6  
  113       MPS I       11380006       SCT       LA25797-4  

MEMBER OF THESE PANELS
  54089-8   Newborn screening panel American Health Information Community (AHIC)Newborn screening panel American Health Information Community (AHIC)Newborn screening panel: -: Pt: ^Patient: -: AHIC

PARTS

Part Type    Part No.  Part Name   
Component   LP97569-5  Conditions tested for in this newborn screening study 
Property   LP6818-1  ID   [Identifier] 
Time   LP6960-1  Pt   [Point in time (spot)] 
System   LP21304-8  Bld.dot   [Dried blood spot] 
Scale   LP7750-5  Nom 
Fragments for synonyms   LP34059-3  Screening 
Fragments for synonyms   LP91459-5  newborn 

LANGUAGE VARIANTS
  Chinese (CHINA)  (From: Regenstrief-generated full translation based on part translation provided by Bethune International Peace Hospital)
 
  这项新生儿筛查检查当中的试验所针对的情况:  标识符:  时间点:  全血.斑点:  名义型:  这项新生儿筛查检查当中的试验所针对的情况:  标识符:  时间点:  全血.斑点:  名义型:  这项新生儿筛查检查当中的试验所针对的情况:  标识符:  时间点:  全血.斑点:  名义型:  
  Dutch (NETHERLANDS)  (From: Regenstrief-generated full translation based on part translation provided by NVKC, Dutch Society for Clinical Chemistry and Laboratory Medicine, The Netherlands)
 
  Geteste aandoeningen in deze pasgeborene screeningsonderzoek:  identificator:  Moment:  Gedroogde bloedspot:  Nominaal:  Geteste aandoeningen in deze pasgeborene screeningsonderzoek:  identificator:  Moment:  Gedroogde bloedspot:  Nominaal:  Geteste aandoeningen in deze pasgeborene screeningsonderzoek:  identificator:  Moment:  Gedroogde bloedspot:  Nominaal:  
  French (FRANCE)  (From: ASIP Santé (Agence des systèmes d'information partagés de santé))
 
  Conditions requises pour le dépistage néonatal:  Identifiant:  Ponctuel:  Sang buvard:  Résultat textuel:  Conditions requises pour le dépistage néonatal:  Identifiant:  Ponctuel:  Sang buvard:  Résultat textuel:  Conditions requises pour le dépistage néonatal:  Identifiant:  Ponctuel:  Sang buvard:  Résultat textuel:  
  Italian (ITALY)  (From: Regenstrief-generated full translation based on part translation provided by Consiglio Nazionale delle Ricerche)
 
  Condizioni analizzate in questo studio di screening neonatale:  ID:  Pt:  Sangue.su carta da filtro:  Nom:  Condizioni analizzate in questo studio di screening neonatale:  ID:  Pt:  Sangue.su carta da filtro:  Nom:  Condizioni analizzate in questo studio di screening neonatale:  ID:  Pt:  Sangue.su carta da filtro:  Nom:  
  Portuguese (BRAZIL)  (From: HL7 Brazil Institute)
 
  Conditions tested for in this NBS studyCondições testadas no presente estudo de triagem neonatal:  #N/​A:  Pt:  SgPapel:  Nom:  Condições testadas no presente estudo de triagem neonatal:  #N/​A:  Pt:  SgPapel:  Nom:  
  Russian (RUSSIAN FEDERATION)  (From: Regenstrief-generated full translation based on part translation provided by Yaroslavl State Medical Academy)
 
  Состояния тестированные в данное новорождённый скрининг исследование:  ID:  ТчкВрм:  Кр.Сух.капл:  Ном:  Состояния тестированные в данное новорождённый скрининг исследование:  ID:  ТчкВрм:  Кр.Сух.капл:  Ном:  Состояния тестированные в данное новорождённый скрининг исследование:  ID:  ТчкВрм:  Кр.Сух.капл:  Ном:  
  Spanish (SPAIN)  (From: Regenstrief-generated full translation based on part translation provided by the Clinical Laboratory Committee of SERVICIO EXTREMEÑO DE SALUD, with the support of BITAC MAP.)
 
  Condiciones probadas en este estudio de cribado neonatal:  Código identificador:  Punto temporal:  Punto de sangre (papel de filtro):  Nom:  Condiciones probadas en este estudio de cribado neonatal:  Código identificador:  Punto temporal:  Punto de sangre (papel de filtro):  Nom:  Condiciones probadas en este estudio de cribado neonatal:  Código identificador:  Punto temporal:  Punto de sangre (papel de filtro):  Nom:  
  Turkish (TURKEY)  (From: Regenstrief-generated full translation based on part translation provided by LOINC Turkish Translation Group and the Turkish Ministry of Health)
 
  Koşullar yenidoğan tarama çalışmasında test edilen:  Tnmlyc:  Zmlı:  Kan.nokta:  Snf:  Koşullar yenidoğan tarama çalışmasında test edilen:  Tnmlyc:  Zmlı:  Kan.nokta:  Snf:  Koşullar yenidoğan tarama çalışmasında test edilen:  Tnmlyc:  Zmlı:  Kan.nokta:  Snf:  

RELATED NAMES
  Asympt Filter paper Random
  Asymptomatic FP Scn
  Blood Ident Study report
  Chemistry Identifier WB
  Conditions tested for in NBS study New born Whole blood
  DBS Nominal  
  Dried blood spot Point in time  

CHANGE HISTORY
  Change Type: MIN

INTERNAL FIELDS
  Attachment Units Required: N
  Long Common Name: Conditions tested for in this newborn screening study [Identifier] in Dried blood spot
  Shortname: Conditions tested for in NBS study DBS
  Fully Specified Name: Conditions tested for in this newborn screening study: ID: Pt: Bld.dot: Nom:
     
  Component Word Count: 8
  ID: 52392
  Status (Raw): ACTIVE


69969-4   Newborn screening report overall laboratory commentNewborn screening report overall laboratory commentNewborn screening report overall laboratory comment: Txt: Pt: ^Patient: Nar:  

NAME
  Fully-Specified Name: 
Component   Property   Time   System   Scale   Method
Newborn screening report overall laboratory comment  Txt  Pt  ^Patient  Nar 
  Long Common Name:  Newborn screening report overall laboratory comment
  Shortname:  NBS report overall lab comment

TERM DEFINITION/DESCRIPTION(S)
  The use of ZNB or NTE segments for report boilerplate information, such as the list of conditions tested, is not recommended because receiving organizations may not know how to process the data. This LOINC code for Newborn Screening Report Overall Laboratory Comment enables sending this data in an OBX segment. If you send a list of conditions tested or another list, we suggest you use semicolons instead of commas to separate conditions in a list to avoid problems if the condition names contain commas.
 
 

ANSWER CARDINALITY
0..*

OBSERVATION REQUIRED IN PANEL
Optional

BASIC ATTRIBUTES
  Class/Type: CHEM/Lab
  First Released in Version: 2.40
  Last Updated in Version: 2.40
  Order vs. Obs.: Observation
  Status: Active

MEMBER OF THESE PANELS
  54089-8   Newborn screening panel American Health Information Community (AHIC)Newborn screening panel American Health Information Community (AHIC)Newborn screening panel: -: Pt: ^Patient: -: AHIC

PARTS

Part Type    Part No.  Part Name   
Component   LP145593-2  Newborn screening report overall laboratory comment 
Property   LP6885-0  Txt   [Text] 
Time   LP6960-1  Pt   [Point in time (spot)] 
Super System   LP6985-8  Patient 
Scale   LP7749-7  Nar 
Fragments for synonyms   LP91459-5  newborn 
Fragments for synonyms   LP20987-1  Comment 
Fragments for synonyms   LP34059-3  Screening 

LANGUAGE VARIANTS
  Chinese (CHINA)  (From: Regenstrief-generated full translation based on part translation provided by Bethune International Peace Hospital)
 
  新生儿筛查报告总体实验室注释:  文本型属性:  时间点:  ^患者:  叙述型:  新生儿筛查报告总体实验室注释:  文本型属性:  时间点:  ^患者:  叙述型:  新生儿筛查报告总体实验室注释:  文本型属性:  时间点:  ^患者:  叙述型:  
  Dutch (NETHERLANDS)  (From: Regenstrief-generated full translation based on part translation provided by NVKC, Dutch Society for Clinical Chemistry and Laboratory Medicine, The Netherlands)
 
  Pasgeborene screening rapport overall laboratoriumopmerkingen:  Tekst:  Moment:  ^Patient:  Tekstueel:  Pasgeborene screening rapport overall laboratoriumopmerkingen:  Tekst:  Moment:  ^Patient:  Tekstueel:  Pasgeborene screening rapport overall laboratoriumopmerkingen:  Tekst:  Moment:  ^Patient:  Tekstueel:  
  French (FRANCE)  (From: ASIP Santé (Agence des systèmes d'information partagés de santé))
 
  Compte rendu dépistage néonatal - Commentaire:  Texte:  Ponctuel:  Patient:  Commentaire:  Compte rendu dépistage néonatal - Commentaire:  Texte:  Ponctuel:  Patient:  Commentaire:  Compte rendu dépistage néonatal - Commentaire:  Texte:  Ponctuel:  Patient:  Commentaire:  
  Italian (ITALY)  (From: Regenstrief-generated full translation based on part translation provided by Consiglio Nazionale delle Ricerche)
 
  Screening neonatale, referto di commento complessivo risultati di laboratorio:  Txt:  Pt:  ^Paziente:  Nar:  Screening neonatale, referto di commento complessivo risultati di laboratorio:  Txt:  Pt:  ^Paziente:  Nar:  Screening neonatale, referto di commento complessivo risultati di laboratorio:  Txt:  Pt:  ^Paziente:  Nar:  
  Russian (RUSSIAN FEDERATION)  (From: Regenstrief-generated full translation based on part translation provided by Yaroslavl State Medical Academy)
 
  Новорождённых скрининг отчёт полный лаборатории комментарий:  Txt:  ТчкВрм:  ^Пациент:  Опис:  Новорождённых скрининг отчёт полный лаборатории комментарий:  Txt:  ТчкВрм:  ^Пациент:  Опис:  Новорождённых скрининг отчёт полный лаборатории комментарий:  Txt:  ТчкВрм:  ^Пациент:  Опис:  
  Spanish (SPAIN)  (From: Regenstrief-generated full translation based on part translation provided by the Clinical Laboratory Committee of SERVICIO EXTREMEÑO DE SALUD, with the support of BITAC MAP.)
 
  Comentario de informe de screening de recién nacidos:  Texto:  Punto temporal:  ^paciente:  Narrativo:  Comentario de informe de screening de recién nacidos:  Texto:  Punto temporal:  ^paciente:  Narrativo:  Comentario de informe de screening de recién nacidos:  Texto:  Punto temporal:  ^paciente:  Narrativo:  
  Turkish (TURKEY)  (From: Regenstrief-generated full translation based on part translation provided by LOINC Turkish Translation Group and the Turkish Ministry of Health)
 
  Yenidoğan tarama raporu genel laboratuvar önerisi:  Metin:  Zmlı:  ^Hasta:  Öykü:  Yenidoğan tarama raporu genel laboratuvar önerisi:  Metin:  Zmlı:  ^Hasta:  Öykü:  Yenidoğan tarama raporu genel laboratuvar önerisi:  Metin:  Zmlı:  ^Hasta:  Öykü:  

RELATED NAMES
  Asympt Comments Remarks
  Asymptomatic Commt Report
  Chemistry Narrative Scn
  cmmt NBS report overall lab comment Text
  cmnt New born  
  Com Point in time  
  Comm Random  

CHANGE HISTORY
  Change Type: MIN

INTERNAL FIELDS
  Attachment Units Required: N
  Long Common Name: Newborn screening report overall laboratory comment
  Shortname: NBS report overall lab comment
  Fully Specified Name: Newborn screening report overall laboratory comment: Txt: Pt: ^Patient: Nar:
     
  Component Word Count: 6
  ID: 69289
  Status (Raw): ACTIVE


57717-1   Newborn screen card data panelNewborn screen card data panelNewborn screen card data panel: -: Pt: Bld.dot: -:  

NAME
  Fully-Specified Name: 
Component   Property   Time   System   Scale   Method
Newborn screen card data panel  Pt  Bld.dot 
  Long Common Name:  Newborn screen card data panel
  Shortname:  NBS card data pnl

OBSERVATION REQUIRED IN PANEL
Conditional

BASIC ATTRIBUTES
  Class/Type: PANEL.CHEM/Lab
  Panel Type: Organizer
  First Released in Version: 2.29
  Last Updated in Version: 2.40
  Order vs. Obs.: Order
  Status: Active

MEMBER OF THESE PANELS
  54089-8   Newborn screening panel American Health Information Community (AHIC)Newborn screening panel American Health Information Community (AHIC)Newborn screening panel: -: Pt: ^Patient: -: AHIC

PARTS

Part Type    Part No.  Part Name   
Component   LP97567-9  Newborn screen card data panel 
Property   LP6769-6 
Time   LP6960-1  Pt   [Point in time (spot)] 
System   LP21304-8  Bld.dot   [Dried blood spot] 
Scale   LP7747-1 
Fragments for synonyms   LP21059-8  Panel 
Fragments for synonyms   LP91459-5  newborn 

LANGUAGE VARIANTS
  Chinese (CHINA)  (From: Regenstrief-generated full translation based on part translation provided by Bethune International Peace Hospital)
 
  新生儿筛查卡数据组套:  -:  时间点:  全血.斑点:  -:  新生儿筛查卡数据组套:  -:  时间点:  全血.斑点:  -:  新生儿筛查卡数据组套:  -:  时间点:  全血.斑点:  -:  
  Dutch (NETHERLANDS)  (From: Regenstrief-generated full translation based on part translation provided by NVKC, Dutch Society for Clinical Chemistry and Laboratory Medicine, The Netherlands)
 
  Pasgeborene Screening card data panel:  -:  Moment:  Gedroogde bloedspot:  -:  Pasgeborene Screening card data panel:  -:  Moment:  Gedroogde bloedspot:  -:  Pasgeborene Screening card data panel:  -:  Moment:  Gedroogde bloedspot:  -:  
  French (BELGIUM)  (From: Regenstrief-generated full translation based on part translation provided by Jean M. Prevost, MD, Biopathology)
 
  Newborn screen card data panel:  -:  Temps ponctuel:  Sang sur papier filtre:  -:  Newborn screen card data panel:  -:  Temps ponctuel:  Sang sur papier filtre:  -:  Newborn screen card data panel:  -:  Temps ponctuel:  Sang sur papier filtre:  -:  
  Italian (ITALY)  (From: Regenstrief-generated full translation based on part translation provided by Consiglio Nazionale delle Ricerche)
 
  Screening neonatale, panel scheda dati:  -:  Pt:  Sangue.su carta da filtro:  -:  Screening neonatale, panel scheda dati:  -:  Pt:  Sangue.su carta da filtro:  -:  Screening neonatale, panel scheda dati:  -:  Pt:  Sangue.su carta da filtro:  -:  
  Portuguese (BRAZIL)  (From: HL7 Brazil Institute)
 
  NBS card data pnlRecém-nascido quadro cartão painel de dados:  #N/​A:  Pt:  SgPapel:  -:  Recém-nascido quadro cartão painel de dados:  #N/​A:  Pt:  SgPapel:  -:  
  Russian (RUSSIAN FEDERATION)  (From: Regenstrief-generated full translation based on part translation provided by Yaroslavl State Medical Academy)
 
  Новорождённый скрин карта данные панель:  -:  ТчкВрм:  Кр.Сух.капл:  -:  Новорождённый скрин карта данные панель:  -:  ТчкВрм:  Кр.Сух.капл:  -:  Новорождённый скрин карта данные панель:  -:  ТчкВрм:  Кр.Сух.капл:  -:  
  Spanish (SPAIN)  (From: Regenstrief-generated full translation based on part translation provided by the Clinical Laboratory Committee of SERVICIO EXTREMEÑO DE SALUD, with the support of BITAC MAP.)
 
  Panel de cribado de tarjeta de datos del recién nacido:  Propiedades mixtas (sólo paneles):  Punto temporal:  Punto de sangre (papel de filtro):  -:  Panel de cribado de tarjeta de datos del recién nacido:  Propiedades mixtas (sólo paneles):  Punto temporal:  Punto de sangre (papel de filtro):  -:  Panel de cribado de tarjeta de datos del recién nacido:  Propiedades mixtas (sólo paneles):  Punto temporal:  Punto de sangre (papel de filtro):  -:  

RELATED NAMES
  Blood New born Scn
  Chemistry Pan Scr
  DBS PANEL.CHEMISTRY Scrn
  Dried blood spot Panl WB
  Filter paper Pnl Whole blood
  FP Point in time  
  NBS card data pnl Random  

CHANGE HISTORY
  Change Type: MIN

INTERNAL FIELDS
  Attachment Units Required: N
  Long Common Name: Newborn screen card data panel
  Shortname: NBS card data pnl
  Fully Specified Name: Newborn screen card data panel: -: Pt: Bld.dot: -:
     
  Component Word Count: 5
  ID: 52390
  Status (Raw): ACTIVE


57716-3   State printed on filter paper card [Identifier] in NBS cardState printed on filter paper card [Identifier] in NBS cardState printed on filter paper card: ID: Pt: NBS card: Nom:  

NAME
  Fully-Specified Name: 
Component   Property   Time   System   Scale   Method
State printed on filter paper card  ID  Pt  NBS card  Nom 
  Long Common Name:  State printed on filter paper card [Identifier] in NBS card
  Shortname:  State printed on card NBS card

TERM DEFINITION/DESCRIPTION(S)
  This is the state pre-printed on the NBS card
 
 

OBSERVATION REQUIRED IN PANEL
Required

BASIC ATTRIBUTES
  Class/Type: CHEM/Lab
  First Released in Version: 2.29
  Last Updated in Version: 2.36
  Order vs. Obs.: Observation
  Status: Active

MEMBER OF THESE PANELS
  54089-8   Newborn screening panel American Health Information Community (AHIC)Newborn screening panel American Health Information Community (AHIC)Newborn screening panel: -: Pt: ^Patient: -: AHIC

PARTS

Part Type    Part No.  Part Name   
Component   LP97566-1  State printed on filter paper card 
Property   LP6818-1  ID   [Identifier] 
Time   LP6960-1  Pt   [Point in time (spot)] 
System   LP97572-9  NBS card 
Scale   LP7750-5  Nom 

LANGUAGE VARIANTS
  Chinese (CHINA)  (From: Regenstrief-generated full translation based on part translation provided by Bethune International Peace Hospital)
 
  印刷在滤纸卡片上的州名:  标识符:  时间点:  新生儿筛查卡:  名义型:  印刷在滤纸卡片上的州名:  标识符:  时间点:  新生儿筛查卡:  名义型:  印刷在滤纸卡片上的州名:  标识符:  时间点:  新生儿筛查卡:  名义型:  
  Dutch (NETHERLANDS)  (From: Regenstrief-generated full translation based on part translation provided by NVKC, Dutch Society for Clinical Chemistry and Laboratory Medicine, The Netherlands)
 
  Gesteldheid afgedrukt op filtreerpapierkaartje:  identificator:  Moment:  NBS kaart:  Nominaal:  Gesteldheid afgedrukt op filtreerpapierkaartje:  identificator:  Moment:  NBS kaart:  Nominaal:  Gesteldheid afgedrukt op filtreerpapierkaartje:  identificator:  Moment:  NBS kaart:  Nominaal:  
  French (FRANCE)  (From: ASIP Santé (Agence des systèmes d'information partagés de santé))
 
  État imprimé carte filtre:  Identifiant:  Ponctuel:  Carte d'identité:  Résultat textuel:  État imprimé carte filtre:  Identifiant:  Ponctuel:  Carte d'identité:  Résultat textuel:  État imprimé carte filtre:  Identifiant:  Ponctuel:  Carte d'identité:  Résultat textuel:  
  Italian (ITALY)  (From: Regenstrief-generated full translation based on part translation provided by Consiglio Nazionale delle Ricerche)
 
  Stato di origine:  ID:  Pt:  NBS, gene:  Nom:  Stato di origine:  ID:  Pt:  NBS, gene:  Nom:  Stato di origine:  ID:  Pt:  NBS, gene:  Nom:  
  Portuguese (BRAZIL)  (From: HL7 Brazil Institute)
 
  State of origin NBS cardEstado de origem:  #N/​A:  Pt:  Cartão NBS:  Nom:  Estado de origem:  #N/​A:  Pt:  Cartão NBS:  Nom:  
  Russian (RUSSIAN FEDERATION)  (From: Regenstrief-generated full translation based on part translation provided by Yaroslavl State Medical Academy)
 
  Штат, напечатанный на фильтрующей бумажной карте:  ID:  ТчкВрм:  NBS карта:  Ном:  Штат, напечатанный на фильтрующей бумажной карте:  ID:  ТчкВрм:  NBS карта:  Ном:  Штат, напечатанный на фильтрующей бумажной карте:  ID:  ТчкВрм:  NBS карта:  Ном:  
  Spanish (SPAIN)  (From: Regenstrief-generated full translation based on part translation provided by the Clinical Laboratory Committee of SERVICIO EXTREMEÑO DE SALUD, with the support of BITAC MAP.)
 
  Estado de origen:  Código identificador:  Punto temporal:  Tarjeta NBS:  Nom:  Estado de origen:  Código identificador:  Punto temporal:  Tarjeta NBS:  Nom:  Estado de origen:  Código identificador:  Punto temporal:  Tarjeta NBS:  Nom:  
  Turkish (TURKEY)  (From: Regenstrief-generated full translation based on part translation provided by LOINC Turkish Translation Group and the Turkish Ministry of Health)
 
  Filtre kağıdına basılmış durum:  Tnmlyc:  Zmlı:  YenidoğanKart:  Snf:  Filtre kağıdına basılmış durum:  Tnmlyc:  Zmlı:  YenidoğanKart:  Snf:  Filtre kağıdına basılmış durum:  Tnmlyc:  Zmlı:  YenidoğanKart:  Snf:  

RELATED NAMES
  Chemistry Nominal State printed on card
  Ident Point in time  
  Identifier Random  

CHANGE HISTORY
  Change Type: MIN

INTERNAL FIELDS
  Attachment Units Required: N
  Long Common Name: State printed on filter paper card [Identifier] in NBS card
  Shortname: State printed on card NBS card
  Fully Specified Name: State printed on filter paper card: ID: Pt: NBS card: Nom:
     
  Component Word Count: 6
  ID: 52389
  Status (Raw): ACTIVE


79566-6   Collection method - Dried blood spotCollection method - Dried blood spotCollection method: Type: Pt: Bld.dot: Nom:  

NAME
  Fully-Specified Name: 
Component   Property   Time   System   Scale   Method
Collection method  Type  Pt  Bld.dot  Nom 
  Long Common Name:  Collection method - Dried blood spot
  Shortname:  Collection method DBS

TERM DEFINITION/DESCRIPTION(S)
  The method used to collect a dried blood spot specimen, typically for newborn screening.
 
 

OBSERVATION REQUIRED IN PANEL
Optional

BASIC ATTRIBUTES
  Class/Type: SPEC/Lab
  First Released in Version: 2.54
  Last Updated in Version: 2.54
  Order vs. Obs.: Observation
  Status: Active

PREFERRED ANSWER LIST    (LL3860-5)  
  SEQ#        Answer        Answer ID    
  1       Heel stick       LA25402-1  
  2       Capillary tube       LA25403-9  
  3       Line draw       LA25404-7  
  4       Other       LA46-8  
  5       Unknown       LA4489-6  

MEMBER OF THESE PANELS
  54089-8   Newborn screening panel American Health Information Community (AHIC)Newborn screening panel American Health Information Community (AHIC)Newborn screening panel: -: Pt: ^Patient: -: AHIC

PARTS

Part Type    Part No.  Part Name   
Component   LP32732-7  Collection method 
Property   LP6886-8  Type 
Time   LP6960-1  Pt   [Point in time (spot)] 
System   LP21304-8  Bld.dot   [Dried blood spot] 
Scale   LP7750-5  Nom 
Fragments for synonyms   LP20988-9  Collection 

LANGUAGE VARIANTS
  Chinese (CHINA)  (From: Regenstrief-generated full translation based on part translation provided by Bethune International Peace Hospital)
 
  采集方法:  类型:  时间点:  全血.斑点:  名义型:  采集方法:  类型:  时间点:  全血.斑点:  名义型:  采集方法:  类型:  时间点:  全血.斑点:  名义型:  
  Dutch (NETHERLANDS)  (From: Regenstrief-generated full translation based on part translation provided by NVKC, Dutch Society for Clinical Chemistry and Laboratory Medicine, The Netherlands)
 
  Verzamelmethode:  Type:  Moment:  Gedroogde bloedspot:  Nominaal:  Verzamelmethode:  Type:  Moment:  Gedroogde bloedspot:  Nominaal:  Verzamelmethode:  Type:  Moment:  Gedroogde bloedspot:  Nominaal:  
  Estonian (ESTONIA)  (From: Regenstrief-generated full translation based on part translation provided by Estonian E-Health Foundation)
 
  Kogumise meetod:  Tüüp:  Pt:  Vereplekk:  Nom:  Kogumise meetod:  Tüüp:  Pt:  Vereplekk:  Nom:  Kogumise meetod:  Tüüp:  Pt:  Vereplekk:  Nom:  
  French (BELGIUM)  (From: Regenstrief-generated full translation based on part translation provided by Jean M. Prevost, MD, Biopathology)
 
  Méthode de prélèvement:  Type:  Temps ponctuel:  Sang sur papier filtre:  Nominal:  Méthode de prélèvement:  Type:  Temps ponctuel:  Sang sur papier filtre:  Nominal:  Méthode de prélèvement:  Type:  Temps ponctuel:  Sang sur papier filtre:  Nominal:  
  French (CANADA)  (From: Regenstrief-generated full translation based on part translation provided by Canada Health Infoway Inc.)
 
  Méthode de prélèvement:  Type:  Temps ponctuel:  Sang sur papier filtre:  Nominal:  Méthode de prélèvement:  Type:  Temps ponctuel:  Sang sur papier filtre:  Nominal:  Méthode de prélèvement:  Type:  Temps ponctuel:  Sang sur papier filtre:  Nominal:  
  Italian (ITALY)  (From: Regenstrief-generated full translation based on part translation provided by Consiglio Nazionale delle Ricerche)
 
  Raccolta, metodo:  Tipo:  Pt:  Sangue.su carta da filtro:  Nom:  Raccolta, metodo:  Tipo:  Pt:  Sangue.su carta da filtro:  Nom:  Raccolta, metodo:  Tipo:  Pt:  Sangue.su carta da filtro:  Nom:  
  Russian (RUSSIAN FEDERATION)  (From: Regenstrief-generated full translation based on part translation provided by Yaroslavl State Medical Academy)
 
  Изъятия метод:  Тип:  ТчкВрм:  Кр.Сух.капл:  Ном:  Изъятия метод:  Тип:  ТчкВрм:  Кр.Сух.капл:  Ном:  Изъятия метод:  Тип:  ТчкВрм:  Кр.Сух.капл:  Ном:  
  Spanish (SPAIN)  (From: Regenstrief-generated full translation based on part translation provided by the Clinical Laboratory Committee of SERVICIO EXTREMEÑO DE SALUD, with the support of BITAC MAP.)
 
  Método de recolección:  Tipo:  Punto temporal:  Punto de sangre (papel de filtro):  Nom:  Método de recolección:  Tipo:  Punto temporal:  Punto de sangre (papel de filtro):  Nom:  Método de recolección:  Tipo:  Punto temporal:  Punto de sangre (papel de filtro):  Nom:  
  Turkish (TURKEY)  (From: Regenstrief-generated full translation based on part translation provided by LOINC Turkish Translation Group and the Turkish Ministry of Health)
 
  Toplama yöntemi:  Tip:  Zmlı:  Kan.nokta:  Snf:  Toplama yöntemi:  Tip:  Zmlı:  Kan.nokta:  Snf:  Toplama yöntemi:  Tip:  Zmlı:  Kan.nokta:  Snf:  

RELATED NAMES
  Blood Filter paper Random
  Coll FP SPEC
  Collect Meth Typ
  Collected Method of WB
  DBS Nominal Whole blood
  Dried blood spot Point in time  

CHANGE HISTORY
  Change Type: MIN

INTERNAL FIELDS
  Long Common Name: Collection method - Dried blood spot
  Shortname: Collection method DBS
  Fully Specified Name: Collection method: Type: Pt: Bld.dot: Nom:
     
  Component Word Count: 0
  ID: 83330
  Status (Raw): ACTIVE


8339-4   Birth weight MeasuredBirth weight MeasuredBody weight^at birth: Mass: Pt: ^Patient: Qn: Measured  

NAME
  Fully-Specified Name: 
Component   Property   Time   System   Scale   Method
Body weight^at birth  Mass  Pt  ^Patient  Qn  Measured
  Override Display Name for Form:  Birthweight
  Long Common Name:  Birth weight Measured
  Shortname:  Birth weight Measured

OBSERVATION REQUIRED IN PANEL
Required

BASIC ATTRIBUTES
  Class/Type: BDYWGT.MOLEC/Clinical
  First Released in Version: 1.0h(2)
  Last Updated in Version: 2.44
  Status: Active

MEMBER OF THESE PANELS
  39294-4   Children's preventive health services attachment SetChildren's preventive health services attachment SetChildren's preventive health services attachment: Cmplx: Pt: ^Patient: Set:
  54089-8   Newborn screening panel American Health Information Community (AHIC)Newborn screening panel American Health Information Community (AHIC)Newborn screening panel: -: Pt: ^Patient: -: AHIC
  68998-4   U.S. standard certificate of live birth - 2003 revisionU.S. standard certificate of live birth - 2003 revisionU.S. standard certificate of live birth - 2003 revision: -: Pt: ^Patient: -:

PARTS

Part Type    Part No.  Part Name   
Component   LP65139-5  Body weight 
     Challenge   LP71937-4  at birth 
Property   LP6826-4  Mass 
Time   LP6960-1  Pt   [Point in time (spot)] 
Super System   LP6985-8  Patient 
Scale   LP7753-9  Qn 
Method   LP6378-6  Measured 
Fragments for synonyms   LP91394-4  at birth 
Fragments for synonyms   LP28569-9  Body 

LANGUAGE VARIANTS
  Chinese (CHINA)  (From: Regenstrief-generated full translation based on part translation provided by Bethune International Peace Hospital)
 
  体重^出生时:  质量:  时间点:  ^患者:  定量型:  测量法体重^出生时:  质量:  时间点:  ^患者:  定量型:  测量法体重^出生时:  质量:  时间点:  ^患者:  定量型:  测量法
  Italian (ITALY)  (From: Regenstrief-generated full translation based on part translation provided by Consiglio Nazionale delle Ricerche)
 
  Peso corporeo^alla nascita:  Massa:  Pt:  ^Paziente:  Qn:  MisuratoPeso corporeo^alla nascita:  Massa:  Pt:  ^Paziente:  Qn:  MisuratoPeso corporeo^alla nascita:  Massa:  Pt:  ^Paziente:  Qn:  Misurato
  Portuguese (BRAZIL)  (From: HL7 Brazil Institute)
 
  Weight @ birth MeasuredPeso corpóreo^no nascimento:  Massa:  Pt:  ^Paciente:  Qn:  MensuradoPeso corpóreo^no nascimento:  Massa:  Pt:  ^Paciente:  Qn:  Mensurado
  Russian (RUSSIAN FEDERATION)  (From: Regenstrief-generated full translation based on part translation provided by Yaroslavl State Medical Academy)
 
  Масса тела^при рождении:  Масса:  ТчкВрм:  ^Пациент:  Колич:  ИзмеренныйМасса тела^при рождении:  Масса:  ТчкВрм:  ^Пациент:  Колич:  ИзмеренныйМасса тела^при рождении:  Масса:  ТчкВрм:  ^Пациент:  Колич:  Измеренный
  Spanish (ARGENTINA)  (From: Conceptum Medical Terminology Center)
 
  peso corporal^al nacimiento:masa:punto en el tiempo:^paciente:cuantitativo:medidopeso corporal^al nacimiento:  masa:  punto en el tiempo:  ^paciente:  cuantitativo:  medidopeso corporal^al nacimiento:  masa:  punto en el tiempo:  ^paciente:  cuantitativo:  medido

RELATED NAMES
  @ birth New born Quant
  Bdy weight Newborn Quantitative
  bod Point in time Random
  Bodies QNT Wt
  BODY WEIGHT.MOLEC Quan  

EXAMPLE UNITS
  Unit  Source Type
  EXAMPLE UCUM UNITS 
  lb  REGENSTRIEF 

UNITS (INTERNAL DETAILS)
  Source Type:  EXAMPLE UCUM UNITS 
  Unit: 
  Source Type:  REGENSTRIEF 
  Unit:  lb 

CHANGE HISTORY
  Change Type: MIN

INTERNAL FIELDS
  Long Common Name: Birth weight Measured
  Shortname: Birth weight Measured
  Fully Specified Name: Body weight^at birth: Mass: Pt: ^Patient: Qn: Measured
     
  Component Word Count: 4
  ID: 65852
  Status (Raw): ACTIVE


58229-6   Body weight Measured --when specimen takenBody weight Measured --when specimen takenBody weight^when specimen taken: Mass: Pt: ^Patient: Qn: Measured  

NAME
  Fully-Specified Name: 
Component   Property   Time   System   Scale   Method
Body weight^when specimen taken  Mass  Pt  ^Patient  Qn  Measured
  Long Common Name:  Body weight Measured --when specimen taken
  Shortname:  Weight when spec taken Measured

TERM DEFINITION/DESCRIPTION(S)
  requested as option in new born screening for interpretation of NBS results which may vary with infants weight at the time of the specimen which might be different enough from birth weight to be important.
 
 

OBSERVATION REQUIRED IN PANEL
Optional

BASIC ATTRIBUTES
  Class/Type: CLIN/Clinical
  First Released in Version: 2.30
  Last Updated in Version: 2.34
  Order vs. Obs.: Observation
  Status: Active

SUBMITTER'S INFORMATION
  Submitted Units: g

MEMBER OF THESE PANELS
  54089-8   Newborn screening panel American Health Information Community (AHIC)Newborn screening panel American Health Information Community (AHIC)Newborn screening panel: -: Pt: ^Patient: -: AHIC

PARTS

Part Type    Part No.  Part Name   
Component   LP65139-5  Body weight 
     Challenge   LP98851-6  when specimen taken 
Property   LP6826-4  Mass 
Time   LP6960-1  Pt   [Point in time (spot)] 
Super System   LP6985-8  Patient 
Scale   LP7753-9  Qn 
Method   LP6378-6  Measured 
Fragments for synonyms   LP28569-9  Body 

LANGUAGE VARIANTS
  Chinese (CHINA)  (From: Regenstrief-generated full translation based on part translation provided by Bethune International Peace Hospital)
 
  体重^采集标本时:  质量:  时间点:  ^患者:  定量型:  测量法体重^采集标本时:  质量:  时间点:  ^患者:  定量型:  测量法体重^采集标本时:  质量:  时间点:  ^患者:  定量型:  测量法
  Italian (ITALY)  (From: Regenstrief-generated full translation based on part translation provided by Consiglio Nazionale delle Ricerche)
 
  Peso corporeo^quando è prelevato il campione:  Massa:  Pt:  ^Paziente:  Qn:  MisuratoPeso corporeo^quando è prelevato il campione:  Massa:  Pt:  ^Paziente:  Qn:  MisuratoPeso corporeo^quando è prelevato il campione:  Massa:  Pt:  ^Paziente:  Qn:  Misurato
  Portuguese (BRAZIL)  (From: HL7 Brazil Institute)
 
  Weight when spec taken MeasuredPeso corporal^quando a amostra é utilizada:  #N/​A:  Pt:  ^Paciente:  Qn:  MensuradoPeso corporal^quando a amostra é utilizada:  #N/​A:  Pt:  ^Paciente:  Qn:  Mensurado
  Russian (RUSSIAN FEDERATION)  (From: Regenstrief-generated full translation based on part translation provided by Yaroslavl State Medical Academy)
 
  Масса тела^когда образец изъят:  Масса:  ТчкВрм:  ^Пациент:  Колич:  ИзмеренныйМасса тела^когда образец изъят:  Масса:  ТчкВрм:  ^Пациент:  Колич:  ИзмеренныйМасса тела^когда образец изъят:  Масса:  ТчкВрм:  ^Пациент:  Колич:  Измеренный

RELATED NAMES
  Bdy weight QNT Spec
  bod Quan when spec taken
  Bodies Quant Wt
  CLIN Quantitative  
  Point in time Random  

EXAMPLE UNITS
  Unit  Source Type
  EXAMPLE UCUM UNITS 
  ORIGINAL SUBMISSION 

UNITS (INTERNAL DETAILS)
  Source Type:  EXAMPLE UCUM UNITS 
  Unit: 
  Source Type:  ORIGINAL SUBMISSION 
  Unit: 

CHANGE HISTORY
  Change Type: MIN

INTERNAL FIELDS
  Attachment Units Required: N
  Long Common Name: Body weight Measured --when specimen taken
  Shortname: Weight when spec taken Measured
  Fully Specified Name: Body weight^when specimen taken: Mass: Pt: ^Patient: Qn: Measured
     
  Component Word Count: 5
  ID: 52749
  Status (Raw): ACTIVE


57715-5   Birth timeBirth timeBirth time: ClockTime: Pt: ^Patient: Qn:  

NAME
  Fully-Specified Name: 
Component   Property   Time   System   Scale   Method
Birth time  ClockTime  Pt  ^Patient  Qn 
  Override Display Name for Form:  Time of birth
  Long Common Name:  Birth time
  Shortname:  Birth time

OBSERVATION REQUIRED IN PANEL
Required

BASIC ATTRIBUTES
  Class/Type: H&P.HX/Clinical
  First Released in Version: 2.29
  Last Updated in Version: 2.48
  Order vs. Obs.: Observation
  Status: Active

MEMBER OF THESE PANELS
  54089-8   Newborn screening panel American Health Information Community (AHIC)Newborn screening panel American Health Information Community (AHIC)Newborn screening panel: -: Pt: ^Patient: -: AHIC
  75854-0   PCORnet common data model set - version 1.0 [PCORnet]PCORnet common data model set - version 1.0 [PCORnet]PCORnet common data model set - version 1.0: -: Pt: ^Patient: -: PCORnet
  85057-8   PCORnet Common Data Model set - version 3.0 [PCORnet]PCORnet Common Data Model set - version 3.0 [PCORnet]PCORnet common data model set - version 3.0: -: Pt: ^Patient: -: PCORnet

PARTS

Part Type    Part No.  Part Name   
Component   LP97565-3  Birth time 
Property   LP101588-4  ClockTime   [Clock time] 
Time   LP6960-1  Pt   [Point in time (spot)] 
Super System   LP6985-8  Patient 
Scale   LP7753-9  Qn 
Fragments for synonyms   LP75922-2  P' 

LANGUAGE VARIANTS
  Chinese (CHINA)  (From: Regenstrief-generated full translation based on part translation provided by Bethune International Peace Hospital)
 
  出生时间:  时钟时间:  时间点:  ^患者:  定量型:  出生时间:  时钟时间:  时间点:  ^患者:  定量型:  出生时间:  时钟时间:  时间点:  ^患者:  定量型:  
  Italian (ITALY)  (From: Regenstrief-generated full translation based on part translation provided by Consiglio Nazionale delle Ricerche)
 
  Nascita, ora:  ClockTime:  Pt:  ^Paziente:  Qn:  Nascita, ora:  ClockTime:  Pt:  ^Paziente:  Qn:  Nascita, ora:  ClockTime:  Pt:  ^Paziente:  Qn:  
  Portuguese (BRAZIL)  (From: HL7 Brazil Institute)
 
  Birth timeTempo de Nascimento:  Tempo:  Pt:  ^Paciente:  Qn:  Tempo de Nascimento:  Tempo:  Pt:  ^Paciente:  Qn:  
  Russian (RUSSIAN FEDERATION)  (From: Regenstrief-generated full translation based on part translation provided by Yaroslavl State Medical Academy)
 
  Рождение время:  ClockTime:  ТчкВрм:  ^Пациент:  Колич:  Рождение время:  ClockTime:  ТчкВрм:  ^Пациент:  Колич:  Рождение время:  ClockTime:  ТчкВрм:  ^Пациент:  Колич:  

RELATED NAMES
  Clock time Point in time Quantitative
  H+P QNT Random
  H+P.HX Quan  
  P prime Quant  

EXAMPLE UNITS
  Unit  Source Type
  {clock_time}  EXAMPLE UCUM UNITS 

UNITS (INTERNAL DETAILS)
  Source Type:  EXAMPLE UCUM UNITS 
  Unit:  {clock_time} 

CHANGE HISTORY
  Change Type: MIN

INTERNAL FIELDS
  Attachment Units Required: N
  Long Common Name: Birth time
  Shortname: Birth time
  Fully Specified Name: Birth time: ClockTime: Pt: ^Patient: Qn:
     
  Component Word Count: 2
  ID: 52388
  Status (Raw): ACTIVE


73806-2   Newborn age in hoursNewborn age in hoursNewborn age in hours: Time: Pt: ^Patient: Qn:  

NAME
  Fully-Specified Name: 
Component   Property   Time   System   Scale   Method
Newborn age in hours  Time  Pt  ^Patient  Qn 
  Long Common Name:  Newborn age in hours
  Shortname:  Nwbrn age hours

TERM DEFINITION/DESCRIPTION(S)
  Age of the newborn reported in hours.
 
 

OBSERVATION REQUIRED IN PANEL
Optional

BASIC ATTRIBUTES
  Class/Type: H&P.PX/Clinical
  First Released in Version: 2.44
  Last Updated in Version: 2.52
  Order vs. Obs.: Observation
  Status: Active

MEMBER OF THESE PANELS
  54089-8   Newborn screening panel American Health Information Community (AHIC)Newborn screening panel American Health Information Community (AHIC)Newborn screening panel: -: Pt: ^Patient: -: AHIC

PARTS

Part Type    Part No.  Part Name   
Component   LP172863-5  Newborn age in hours 
Property   LP6879-3  Time   [Time (e.g. seconds)] 
Time   LP6960-1  Pt   [Point in time (spot)] 
Super System   LP6985-8  Patient 
Scale   LP7753-9  Qn 
Fragments for synonyms   LP91459-5  newborn 
Fragments for synonyms   LP75922-2  P' 

LANGUAGE VARIANTS
  Chinese (CHINA)  (From: Regenstrief-generated full translation based on part translation provided by Bethune International Peace Hospital)
 
  按小时数计算的新生儿年龄:  时间:  时间点:  ^患者:  定量型:  按小时数计算的新生儿年龄:  时间:  时间点:  ^患者:  定量型:  按小时数计算的新生儿年龄:  时间:  时间点:  ^患者:  定量型:  
  Italian (ITALY)  (From: Regenstrief-generated full translation based on part translation provided by Consiglio Nazionale delle Ricerche)
 
  Neonato, età in ore:  Tempo:  Pt:  ^Paziente:  Qn:  Neonato, età in ore:  Tempo:  Pt:  ^Paziente:  Qn:  Neonato, età in ore:  Tempo:  Pt:  ^Paziente:  Qn:  
  Russian (RUSSIAN FEDERATION)  (From: Regenstrief-generated full translation based on part translation provided by Yaroslavl State Medical Academy)
 
  Новорождённый возраст в часах:  Время:  ТчкВрм:  ^Пациент:  Колич:  Новорождённый возраст в часах:  Время:  ТчкВрм:  ^Пациент:  Колич:  Новорождённый возраст в часах:  Время:  ТчкВрм:  ^Пациент:  Колич:  

RELATED NAMES
  H+P P prime Quant
  H+P.PX Point in time Quantitative
  New born QNT Random
  Nwbrn age hours Quan  

EXAMPLE UNITS
  Unit  Source Type
  EXAMPLE UCUM UNITS 

UNITS (INTERNAL DETAILS)
  Source Type:  EXAMPLE UCUM UNITS 
  Unit: 

CHANGE HISTORY
  Change Type: MIN

INTERNAL FIELDS
  Long Common Name: Newborn age in hours
  Shortname: Nwbrn age hours
  Fully Specified Name: Newborn age in hours: Time: Pt: ^Patient: Qn:
     
  Component Word Count: 0
  ID: 74096
  Status (Raw): ACTIVE


57722-1   Birth plurality of PregnancyBirth plurality of PregnancyBirth plurality: Num: Pt: Pregnancy: Ord:  

NAME
  Fully-Specified Name: 
Component   Property   Time   System   Scale   Method
Birth plurality  Num  Pt  Pregnancy  Ord 
  Long Common Name:  Birth plurality of Pregnancy
  Shortname:  Birth plurality

TERM DEFINITION/DESCRIPTION(S)
  The number of fetuses delivered live or dead at any time in the pregnancy regardless of gestational age or if the fetuses were delivered at different dates in the pregnancy.
 
 

OBSERVATION REQUIRED IN PANEL
Required

BASIC ATTRIBUTES
  Class/Type: H&P.PX/Clinical
  First Released in Version: 2.29
  Last Updated in Version: 2.32
  Status: Active

NORMATIVE ANSWER LIST    (LL829-3)  
  SEQ#        Answer        Code         Answer ID    
  1       1       1       LA6112-2  
  2       2       2       LA6113-0  
  3       3       3       LA6114-8  
  4       4       4       LA6115-5  
  5       5       5       LA10137-0  
  6       6       6       LA10138-8  
  7       7       7       LA10139-6  
  8       8       8       LA10140-4  
  9       9       9       LA10141-2  
  10       10       10       LA13942-0  
  11       11       11       LA14557-5  
  12       12       12       LA14558-3  
  13       Unknown plurality       99       LA12914-0  

MEMBER OF THESE PANELS
  54089-8   Newborn screening panel American Health Information Community (AHIC)Newborn screening panel American Health Information Community (AHIC)Newborn screening panel: -: Pt: ^Patient: -: AHIC
  68998-4   U.S. standard certificate of live birth - 2003 revisionU.S. standard certificate of live birth - 2003 revisionU.S. standard certificate of live birth - 2003 revision: -: Pt: ^Patient: -:
  69045-3   U.S. standard report of fetal death - 2003 revisionU.S. standard report of fetal death - 2003 revisionU.S. standard report of fetal death - 2003 revision: -: Pt: ^Patient: -:

PARTS

Part Type    Part No.  Part Name   
Component   LP97573-7  Birth plurality 
Property   LP6841-3  Num   [Number (count)] 
Time   LP6960-1  Pt   [Point in time (spot)] 
System   LP100811-1  Pregnancy 
Scale   LP7751-3  Ord 
Fragments for synonyms   LP75920-6  Pregnancy 
Fragments for synonyms   LP75922-2  P' 

LANGUAGE VARIANTS
  Chinese (CHINA)  (From: Regenstrief-generated full translation based on part translation provided by Bethune International Peace Hospital)
 
  出生胎儿数量:  数量(计数):  时间点:  妊娠:  序数型:  出生胎儿数量:  数量(计数):  时间点:  妊娠:  序数型:  出生胎儿数量:  数量(计数):  时间点:  妊娠:  序数型:  
  Italian (ITALY)  (From: Regenstrief-generated full translation based on part translation provided by Consiglio Nazionale delle Ricerche)
 
  Nascita, pluralità:  Num:  Pt:  Gravidanza:  Ord:  Nascita, pluralità:  Num:  Pt:  Gravidanza:  Ord:  Nascita, pluralità:  Num:  Pt:  Gravidanza:  Ord:  
  Portuguese (BRAZIL)  (From: HL7 Brazil Institute)
 
  Birth pluralityNascimentos múltiplos:  #N/​A:  Pt:  Gravidez:  Ord:  Nascimentos múltiplos:  #N/​A:  Pt:  Gravidez:  Ord:  
  Russian (RUSSIAN FEDERATION)  (From: Regenstrief-generated full translation based on part translation provided by Yaroslavl State Medical Academy)
 
  Рождение множественность:  Кол:  ТчкВрм:  Беременность:  Пор:  Рождение множественность:  Кол:  ТчкВрм:  Беременность:  Пор:  Рождение множественность:  Кол:  ТчкВрм:  Беременность:  Пор:  

RELATED NAMES
  Birth pleurality H+P.PX Qual
  Cnt Number Qualitative
  Count Ordinal Random
  Gestation P prime Screen
  Gestations Point in time  
  Gravida Pregnancies  
  H+P QL  

CHANGE HISTORY
  Change Type: MIN

INTERNAL FIELDS
  Attachment Units Required: N
  Long Common Name: Birth plurality of Pregnancy
  Shortname: Birth plurality
  Fully Specified Name: Birth plurality: Num: Pt: Pregnancy: Ord:
     
  Component Word Count: 2
  ID: 52395
  Status (Raw): ACTIVE


57714-8   Obstetric estimation of gestational ageObstetric estimation of gestational ageObstetric estimation of gestational age: Time: Pt: ^Patient: Qn:  

NAME
  Fully-Specified Name: 
Component   Property   Time   System   Scale   Method
Obstetric estimation of gestational age  Time  Pt  ^Patient  Qn 
  Long Common Name:  Obstetric estimation of gestational age
  Shortname:  OB est of GA

TERM DEFINITION/DESCRIPTION(S)
  The obstetric estimate of the infant's gestation in completed weeks based on the birth attendant's final estimate of gestation which should be determined by all perinatal factors and assessments such as ultrasound, but not the neonatal exam.
 
 

OBSERVATION REQUIRED IN PANEL
Required

BASIC ATTRIBUTES
  Class/Type: H&P.HX/Clinical
  First Released in Version: 2.29
  Last Updated in Version: 2.40
  Order vs. Obs.: Observation
  Status: Active

MEMBER OF THESE PANELS
  54089-8   Newborn screening panel American Health Information Community (AHIC)Newborn screening panel American Health Information Community (AHIC)Newborn screening panel: -: Pt: ^Patient: -: AHIC

PARTS

Part Type    Part No.  Part Name   
Component   LP99286-4  Obstetric estimation of gestational age 
Property   LP6879-3  Time   [Time (e.g. seconds)] 
Time   LP6960-1  Pt   [Point in time (spot)] 
Super System   LP6985-8  Patient 
Scale   LP7753-9  Qn 
Fragments for synonyms   LP75922-2  P' 
Fragments for synonyms   LP97554-7  Obstetric 

LANGUAGE VARIANTS
  Chinese (CHINA)  (From: Regenstrief-generated full translation based on part translation provided by Bethune International Peace Hospital)
 
  孕龄的产科学估计:  时间:  时间点:  ^患者:  定量型:  孕龄的产科学估计:  时间:  时间点:  ^患者:  定量型:  孕龄的产科学估计:  时间:  时间点:  ^患者:  定量型:  
  Italian (ITALY)  (From: Regenstrief-generated full translation based on part translation provided by Consiglio Nazionale delle Ricerche)
 
  Stima ostetrica di età gestazionale:  Tempo:  Pt:  ^Paziente:  Qn:  Stima ostetrica di età gestazionale:  Tempo:  Pt:  ^Paziente:  Qn:  Stima ostetrica di età gestazionale:  Tempo:  Pt:  ^Paziente:  Qn:  
  Portuguese (BRAZIL)  (From: HL7 Brazil Institute)
 
  OB est of GAEstimativa obstétrica da idade gestacional:  Tempo:  Pt:  ^Paciente:  Qn:  Estimativa obstétrica da idade gestacional:  Tempo:  Pt:  ^Paciente:  Qn:  
  Russian (RUSSIAN FEDERATION)  (From: Regenstrief-generated full translation based on part translation provided by Yaroslavl State Medical Academy)
 
  Акушерская оценка гестационный возраст:  Время:  ТчкВрм:  ^Пациент:  Колич:  Акушерская оценка гестационный возраст:  Время:  ТчкВрм:  ^Пациент:  Колич:  Акушерская оценка гестационный возраст:  Время:  ТчкВрм:  ^Пациент:  Колич:  

RELATED NAMES
  GA Obstetrical Quan
  Gest Obstetrics Quant
  Gestation P prime Quantitative
  H+P Point in time Random
  H+P.HX Pregnancy  
  OB Prenatal  
  OB est of GA QNT  

EXAMPLE UNITS
  Unit  Source Type
  wk  EXAMPLE UCUM UNITS 

UNITS (INTERNAL DETAILS)
  Source Type:  EXAMPLE UCUM UNITS 
  Unit:  wk 

CHANGE HISTORY
  Change Type: MIN

INTERNAL FIELDS
  Attachment Units Required: N
  Long Common Name: Obstetric estimation of gestational age
  Shortname: OB est of GA
  Fully Specified Name: Obstetric estimation of gestational age: Time: Pt: ^Patient: Qn:
     
  Component Word Count: 5
  ID: 52387
  Status (Raw): ACTIVE


57713-0   Infant factors that affect newborn screening interpretationInfant factors that affect newborn screening interpretationInfant factors that affect newborn screening interpretation: Find: Pt: ^Patient: Nom:  

NAME
  Fully-Specified Name: 
Component   Property   Time   System   Scale   Method
Infant factors that affect newborn screening interpretation  Find  Pt  ^Patient  Nom 
  Long Common Name:  Infant factors that affect newborn screening interpretation
  Shortname:  Inf factors affecting NBS imp

TERM DEFINITION/DESCRIPTION(S)
  Use this term to record various infant factors (also known as events), including treatments or conditions, that occur prior to collection of the newborn screening (NBS) specimen, and can affect the interpretation of NBS results. Select any answers that apply; you can select more than one answer. If you select "other," use the additional narrative LOINC code for "Other infant factors that affect newborn screening interpretation" to give additional details. Select the answer "Infant in ICU at time of specimen collection" if the infant was in an intensive care unit, neonatal intensive care unit (NICU) or special care baby unit (SCBU). ECMO (extra corporeal membrane oxygenation, aka heart-lung bypass) can affect NBS results for hemoglobinopathies and GALT. Dopamine can affect NBS results for TSH. Steroid treatment can affect NBS results for TSH and 17-OHP. Iodine can affect NBS results for TSH and T4. Antibiotics can affect NBS results for C5. Some anti-seizure medications can affect NBS results for fatty acids. In screening for cystic fibrosis (CF), those babies presenting with meconium ileus or other bowel obstruction often have falsely low IRT's, so some states when they have that information, skip the IRT and go directly to DNA for their screen. SOURCES: Newborn Screening Guidelines for Preterm, Low Birth Weight, and Sick Newborns; Approved Guideline. CLSI document I/LA31-A. Wayne, PA: Clinical and Laboratory Standards Institute; (2009). LABORATORY MEDICINE PRACTICE GUIDELINES: FOLLOW-UP TESTING FOR METABOLIC DISEASES IDENTIFIED BY EXPANDED NEWBORN SCREENING USING TANDEM MASS SPECTROMETRY, The National Academy of Clinical Biochemistry, 2009 http://www.aacc.org/members/nacb/lmpg/onlineguide/publishedguidelines/newborn/pages/default.aspx. Utah Department of Health's "Newborn Screening For Sick or Preterm Newborns" Available at: http://health.utah.gov/newbornscreening/PDF/SupportProcScreeningSickPreterm.pdf.
 
 

ANSWER CARDINALITY
1..*

OBSERVATION REQUIRED IN PANEL
Required

BASIC ATTRIBUTES
  Class/Type: H&P.HX/Clinical
  First Released in Version: 2.29
  Last Updated in Version: 2.58
  Order vs. Obs.: Observation
  Status: Active.
Change Reason: Changed answer list from "Normative" to "Preferred" to fit the current LOINC model.; Removed "NICU" from Component based on recommendation from APHL NBS workgroup because this term could also be used for infants that are not in the NICU.

PREFERRED ANSWER LIST    (LL830-1)  
  SEQ#        Answer        Answer ID    
  1       None       LA137-2  
  2       Infant in NICU at time of specimen collection       LA12419-0  
  3       Infant in special care setting (other than ICU) at time of specimen collection       LA25801-4  
  4       Preterm/Low birth weight (LBW)       LA25802-2  
  5       Any blood product transfusion (including ECLS/ECMO)       LA12417-4  
  6       Dopamine       LA16923-7  
  7       Topical iodine       LA16924-5  
  8       Acute illness       LA25803-0  
  9       Hypothyroxinemia of preterm birth       LA25804-8  
  10       Significant hypoxia       LA25812-1  
  11       Immature hypothalamic/pituitary axis       LA25805-5  
  12       Immature liver enzymes       LA25806-3  
  13       Immature renal system       LA25807-1  
  14       Iodine deficiency       LA25809-7  
  15       Liver disease       LA25810-5  
  16       Other conditions, such as biliary atresia, intestinal perforation, abdominal wall defects, septicemia, CMV, renal failure, T21, T18, T13       LA25811-3  
  17       Parenteral steroid treatment       LA16925-2  
  18       Systemic antibiotics before newborn screening       LA12420-8  
  19       Meconium ileus or other bowel obstruction       LA16927-8  
  20       Thoracic surgery involving thymectomy       LA25815-4  
  21       Immunosuppressive therapy of baby or mother       LA25808-9  
  22       Total parenteral nutrition (TPN) or similar feeding       LA25816-2  
  23       Special lactose-free diet       LA25813-9  
  24       Special low protein diet       LA25814-7  
  25       Other       LA46-8  

MEMBER OF THESE PANELS
  54089-8   Newborn screening panel American Health Information Community (AHIC)Newborn screening panel American Health Information Community (AHIC)Newborn screening panel: -: Pt: ^Patient: -: AHIC

PARTS

Part Type    Part No.  Part Name   
Component   LP133643-9  Infant factors that affect newborn screening interpretation 
Property   LP6813-2  Find   [Finding] 
Time   LP6960-1  Pt   [Point in time (spot)] 
Super System   LP6985-8  Patient 
Scale   LP7750-5  Nom 
Fragments for synonyms   LP91459-5  newborn 
Fragments for synonyms   LP34059-3  Screening 
Fragments for synonyms   LP75922-2  P' 

LANGUAGE VARIANTS
  Chinese (CHINA)  (From: Regenstrief-generated full translation based on part translation provided by Bethune International Peace Hospital)
 
  影响新生儿筛查解释的婴儿NICU因素:  发现:  时间点:  ^患者:  名义型:  影响新生儿筛查解释的婴儿NICU因素:  发现:  时间点:  ^患者:  名义型:  影响新生儿筛查解释的婴儿NICU因素:  发现:  时间点:  ^患者:  名义型:  
  Italian (ITALY)  (From: Regenstrief-generated full translation based on part translation provided by Consiglio Nazionale delle Ricerche)
 
  Fattori di unità di cura infantile neonatale che influenzano interpretazione di screening neonatale:  Osservazione:  Pt:  ^Paziente:  Nom:  Fattori di unità di cura infantile neonatale che influenzano interpretazione di screening neonatale:  Osservazione:  Pt:  ^Paziente:  Nom:  Fattori di unità di cura infantile neonatale che influenzano interpretazione di screening neonatale:  Osservazione:  Pt:  ^Paziente:  Nom:  
  Portuguese (BRAZIL)  (From: HL7 Brazil Institute)
 
  Clinical events that affect NBS interpOs eventos clínicos que afetam a interpretação de triagem neonatal:  Achado:  Pt:  ^Paciente:  Nom:  Os eventos clínicos que afetam a interpretação de triagem neonatal:  Achado:  Pt:  ^Paciente:  Nom:  
  Russian (RUSSIAN FEDERATION)  (From: Regenstrief-generated full translation based on part translation provided by Yaroslavl State Medical Academy)
 
  Младенец NICU факторы, которые влияют на новорождённого скрининга интерпретацию:  Находка:  ТчкВрм:  ^Пациент:  Ном:  Младенец NICU факторы, которые влияют на новорождённого скрининга интерпретацию:  Находка:  ТчкВрм:  ^Пациент:  Ном:  Младенец NICU факторы, которые влияют на новорождённого скрининга интерпретацию:  Находка:  ТчкВрм:  ^Пациент:  Ном:  

RELATED NAMES
  Asympt Inf factors affecting NBS imp P prime
  Asymptomatic Interp Point in time
  Clinical events Interpret Random
  Finding Interpt Scn
  Findings Intrp  
  H+P New born  
  H+P.HX Nominal  

CHANGE HISTORY
  Change Type: NAM

INTERNAL FIELDS
  Attachment Units Required: N
  Long Common Name: Infant factors that affect newborn screening interpretation
  Shortname: Inf factors affecting NBS imp
  Fully Specified Name: Infant factors that affect newborn screening interpretation: Find: Pt: ^Patient: Nom:
     
  Component Word Count: 8
  ID: 52386
  Status (Raw): ACTIVE


67703-9   Other infant factors that affect newborn screening interpretation NarrativeOther infant factors that affect newborn screening interpretation NarrativeOther infant factors that affect newborn screening interpretation: Find: Pt: ^Patient: Nar:  

NAME
  Fully-Specified Name: 
Component   Property   Time   System   Scale   Method
Other infant factors that affect newborn screening interpretation  Find  Pt  ^Patient  Nar 
  Long Common Name:  Other infant factors that affect newborn screening interpretation Narrative
  Shortname:  Other Inf factors affecting NBS imp

CONDITION FOR INCLUSION
Use this term to give additional detail if you select answer “Other” (LA46-8) for Infant NICU factors that affect newborn screening interpretation (57713-0).

ANSWER CARDINALITY
0..*

OBSERVATION REQUIRED IN PANEL
Conditional

BASIC ATTRIBUTES
  Class/Type: H&P.HX/Clinical
  First Released in Version: 2.38
  Last Updated in Version: 2.58
  Order vs. Obs.: Observation
  Status: Active.
Change Reason: Removed "NICU" from Component based on recommendation from APHL NBS workgroup because this term could also be used for infants that are not in the NICU.

MEMBER OF THESE PANELS
  54089-8   Newborn screening panel American Health Information Community (AHIC)Newborn screening panel American Health Information Community (AHIC)Newborn screening panel: -: Pt: ^Patient: -: AHIC

PARTS

Part Type    Part No.  Part Name   
Component   LP133644-7  Other infant factors that affect newborn screening interpretation 
Property   LP6813-2  Find   [Finding] 
Time   LP6960-1  Pt   [Point in time (spot)] 
Super System   LP6985-8  Patient 
Scale   LP7749-7  Nar 
Fragments for synonyms   LP91459-5  newborn 
Fragments for synonyms   LP75922-2  P' 
Fragments for synonyms   LP21049-9  Other 
Fragments for synonyms   LP34059-3  Screening 

LANGUAGE VARIANTS
  Chinese (CHINA)  (From: Regenstrief-generated full translation based on part translation provided by Bethune International Peace Hospital)
 
  影响新生儿筛查解释的其他婴儿NICU因素:  发现:  时间点:  ^患者:  叙述型:  影响新生儿筛查解释的其他婴儿NICU因素:  发现:  时间点:  ^患者:  叙述型:  影响新生儿筛查解释的其他婴儿NICU因素:  发现:  时间点:  ^患者:  叙述型:  
  Italian (ITALY)  (From: Regenstrief-generated full translation based on part translation provided by Consiglio Nazionale delle Ricerche)
 
  Altri fattori UTIN che influenzano interpretazione screening neonatale:  Osservazione:  Pt:  ^Paziente:  Nar:  Altri fattori UTIN che influenzano interpretazione screening neonatale:  Osservazione:  Pt:  ^Paziente:  Nar:  Altri fattori UTIN che influenzano interpretazione screening neonatale:  Osservazione:  Pt:  ^Paziente:  Nar:  
  Russian (RUSSIAN FEDERATION)  (From: Regenstrief-generated full translation based on part translation provided by Yaroslavl State Medical Academy)
 
  Другие младенец NICU факторы, которые влияют на новорождённого скрининга интерпретацию:  Находка:  ТчкВрм:  ^Пациент:  Опис:  Другие младенец NICU факторы, которые влияют на новорождённого скрининга интерпретацию:  Находка:  ТчкВрм:  ^Пациент:  Опис:  Другие младенец NICU факторы, которые влияют на новорождённого скрининга интерпретацию:  Находка:  ТчкВрм:  ^Пациент:  Опис:  

RELATED NAMES
  Asympt Interp P prime
  Asymptomatic Interpret Point in time
  Clinical events Interpt Random
  Finding Intrp Report
  Findings Narrative Scn
  H+P New born  
  H+P.HX Other Inf factors affecting NBS imp  
  Inf factors affecting NBS imp Othr  

CHANGE HISTORY
  Change Type: NAM

INTERNAL FIELDS
  Attachment Units Required: N
  Long Common Name: Other infant factors that affect newborn screening interpretation Narrative
  Shortname: Other Inf factors affecting NBS imp
  Fully Specified Name: Other infant factors that affect newborn screening interpretation: Find: Pt: ^Patient: Nar:
     
  Component Word Count: 9
  ID: 63456
  Status (Raw): ACTIVE


67706-2   Maternal factors that affect newborn screening interpretationMaternal factors that affect newborn screening interpretationMaternal factors that affect newborn screening interpretation: Find: Pt: ^Mother: Nom:  

NAME
  Fully-Specified Name: 
Component   Property   Time   System   Scale   Method
Maternal factors that affect newborn screening interpretation  Find  Pt  ^Mother  Nom 
  Long Common Name:  Maternal factors that affect newborn screening interpretation
  Shortname:  Mat factors affecting NBS imp

TERM DEFINITION/DESCRIPTION(S)
  Use this term to record various maternal factors (also known as events), including treatments applied to the newborn's mother or conditions that affect the newborn's mother, that can affect the interpretation of NBS results. Select any answers that apply; you can select more than one answer. If you select "other," use the additional narrative LOINC code for "Other maternal factors that affect newborn screening interpretation" to give additional details. Thyroid treatments (PTU - propylthiouracil, methimazole (tapazole), and radioactive iodine (I-131)) can affect NBS results for T4 and TSH. Steroid treatment (prednisone, betamethasone, dexamethasone) can affect NBS results for 17-OHP. Fatty liver of pregnancy and HELLP syndrome can affect NBS results for acylcarnitines. TPN can affect NBS results for amino acids and fatty acids. PRBC (packed red blood cell) transfusion can affect NBS results for GALT and hemoglobin. SOURCES: Newborn Screening Guidelines for Preterm, Low Birth Weight, and Sick Newborns; Approved Guideline. CLSI document I/LA31-A. Wayne, PA: Clinical and Laboratory Standards Institute; (2009). LABORATORY MEDICINE PRACTICE GUIDELINES: FOLLOW-UP TESTING FOR METABOLIC DISEASES IDENTIFIED BY EXPANDED NEWBORN SCREENING USING TANDEM MASS SPECTROMETRY, The National Academy of Clinical Biochemistry, 2009 http://www.aacc.org/members/nacb/lmpg/onlineguide/publishedguidelines/newborn/pages/default.aspx. Utah Department of Health's "Newborn Screening For Sick or Preterm Newborns" Available at: http://health.utah.gov/newbornscreening/PDF/SupportProcScreeningSickPreterm.pdf.
 
 

ANSWER CARDINALITY
0..*

OBSERVATION REQUIRED IN PANEL
Optional

BASIC ATTRIBUTES
  Class/Type: H&P.HX/Clinical
  First Released in Version: 2.38
  Last Updated in Version: 2.56
  Order vs. Obs.: Observation
  Status: Active.
Change Reason: Changed answer list from "Normative" to "Preferred" to fit the current LOINC model.

PREFERRED ANSWER LIST    (LL1736-9)  
  SEQ#        Answer        Answer ID    
  1       None       LA137-2  
  2       HELLP syndrome       LA16928-6  
  3       Fatty liver of pregnancy       LA16929-4  
  4       Packed red blood cell (PRBC) transfusion       LA16930-2  
  5       Steroid treatment       LA16931-0  
  6       Thyroid treatment (including propylthiouracil (PTU), methimazole (Tapazole), or past treatment with radioactive iodine (I-131))       LA16932-8  
  7       TPN       LA12418-2  
  8       Other       LA46-8  

MEMBER OF THESE PANELS
  54089-8   Newborn screening panel American Health Information Community (AHIC)Newborn screening panel American Health Information Community (AHIC)Newborn screening panel: -: Pt: ^Patient: -: AHIC

PARTS

Part Type    Part No.  Part Name   
Component   LP133647-0  Maternal factors that affect newborn screening interpretation 
Property   LP6813-2  Find   [Finding] 
Time   LP6960-1  Pt   [Point in time (spot)] 
Super System   LP6983-3  Mother 
Scale   LP7750-5  Nom 
Fragments for synonyms   LP91459-5  newborn 
Fragments for synonyms   LP34059-3  Screening 
Fragments for synonyms   LP75922-2  P' 

LANGUAGE VARIANTS
  Chinese (CHINA)  (From: Regenstrief-generated full translation based on part translation provided by Bethune International Peace Hospital)
 
  影响新生儿筛查解释的产妇因素:  发现:  时间点:  ^母亲:  名义型:  影响新生儿筛查解释的产妇因素:  发现:  时间点:  ^母亲:  名义型:  影响新生儿筛查解释的产妇因素:  发现:  时间点:  ^母亲:  名义型:  
  Italian (ITALY)  (From: Regenstrief-generated full translation based on part translation provided by Consiglio Nazionale delle Ricerche)
 
  Fattori materni che influenzano l'interpretazione di screening neonatale:  Osservazione:  Pt:  ^madre:  Nom:  Fattori materni che influenzano l'interpretazione di screening neonatale:  Osservazione:  Pt:  ^madre:  Nom:  Fattori materni che influenzano l'interpretazione di screening neonatale:  Osservazione:  Pt:  ^madre:  Nom:  
  Russian (RUSSIAN FEDERATION)  (From: Regenstrief-generated full translation based on part translation provided by Yaroslavl State Medical Academy)
 
  Мать факторы, которые влияют на новорождённый скрининг интерпретация:  Находка:  ТчкВрм:  ^Мать:  Ном:  Мать факторы, которые влияют на новорождённый скрининг интерпретация:  Находка:  ТчкВрм:  ^Мать:  Ном:  Мать факторы, которые влияют на новорождённый скрининг интерпретация:  Находка:  ТчкВрм:  ^Мать:  Ном:  

RELATED NAMES
  Asympt Interpret Nominal
  Asymptomatic Interpt P prime
  Clinical events, mother Intrp Point in time
  Finding Mat Random
  Findings Mat factors affecting NBS imp Scn
  H+P Maternal  
  H+P.HX Matnl  
  Interp New born  

CHANGE HISTORY
  Change Type: MIN

INTERNAL FIELDS
  Attachment Units Required: N
  Long Common Name: Maternal factors that affect newborn screening interpretation
  Shortname: Mat factors affecting NBS imp
  Fully Specified Name: Maternal factors that affect newborn screening interpretation: Find: Pt: ^Mother: Nom:
     
  Component Word Count: 7
  ID: 63459
  Status (Raw): ACTIVE


67707-0   Other maternal factors that affect newborn screening interpretation NarrativeOther maternal factors that affect newborn screening interpretation NarrativeOther maternal factors that affect newborn screening interpretation: Find: Pt: ^Mother: Nar:  

NAME
  Fully-Specified Name: 
Component   Property   Time   System   Scale   Method
Other maternal factors that affect newborn screening interpretation  Find  Pt  ^Mother  Nar 
  Long Common Name:  Other maternal factors that affect newborn screening interpretation Narrative
  Shortname:  Other mat factors affecting NBS imp

CONDITION FOR INCLUSION
Use this term to give additional detail if you select answer “Other” (LA46-8) for Maternal factors that affect newborn screening interpretation (67706-2).

ANSWER CARDINALITY
0..*

OBSERVATION REQUIRED IN PANEL
Conditional

BASIC ATTRIBUTES
  Class/Type: H&P.HX/Clinical
  First Released in Version: 2.38
  Last Updated in Version: 2.48
  Order vs. Obs.: Observation
  Status: Active

MEMBER OF THESE PANELS
  54089-8   Newborn screening panel American Health Information Community (AHIC)Newborn screening panel American Health Information Community (AHIC)Newborn screening panel: -: Pt: ^Patient: -: AHIC

PARTS

Part Type    Part No.  Part Name   
Component   LP133648-8  Other maternal factors that affect newborn screening interpretation 
Property   LP6813-2  Find   [Finding] 
Time   LP6960-1  Pt   [Point in time (spot)] 
Super System   LP6983-3  Mother 
Scale   LP7749-7  Nar 
Fragments for synonyms   LP91459-5  newborn 
Fragments for synonyms   LP75922-2  P' 
Fragments for synonyms   LP21049-9  Other 
Fragments for synonyms   LP34059-3  Screening 

LANGUAGE VARIANTS
  Chinese (CHINA)  (From: Regenstrief-generated full translation based on part translation provided by Bethune International Peace Hospital)
 
  影响新生儿筛查解释的其他产妇因素:  发现:  时间点:  ^母亲:  叙述型:  影响新生儿筛查解释的其他产妇因素:  发现:  时间点:  ^母亲:  叙述型:  影响新生儿筛查解释的其他产妇因素:  发现:  时间点:  ^母亲:  叙述型:  
  Italian (ITALY)  (From: Regenstrief-generated full translation based on part translation provided by Consiglio Nazionale delle Ricerche)
 
  Altri fattori materni che influenzano interpretazione screening neonatale:  Osservazione:  Pt:  ^madre:  Nar:  Altri fattori materni che influenzano interpretazione screening neonatale:  Osservazione:  Pt:  ^madre:  Nar:  Altri fattori materni che influenzano interpretazione screening neonatale:  Osservazione:  Pt:  ^madre:  Nar:  
  Russian (RUSSIAN FEDERATION)  (From: Regenstrief-generated full translation based on part translation provided by Yaroslavl State Medical Academy)
 
  Другие мать факторы, которые влияют на новорождённый скрининг интерпретация:  Находка:  ТчкВрм:  ^Мать:  Опис:  Другие мать факторы, которые влияют на новорождённый скрининг интерпретация:  Находка:  ТчкВрм:  ^Мать:  Опис:  Другие мать факторы, которые влияют на новорождённый скрининг интерпретация:  Находка:  ТчкВрм:  ^Мать:  Опис:  

RELATED NAMES
  Asympt Interpt Othr
  Asymptomatic Intrp P prime
  Clinical events, mother Mat Point in time
  Finding Mat factors affecting NBS imp Random
  Findings Maternal Report
  H+P Matnl Scn
  H+P.HX Narrative  
  Interp New born  
  Interpret Other Mat factors affecting NBS imp  

CHANGE HISTORY
  Change Type: MIN

INTERNAL FIELDS
  Attachment Units Required: N
  Long Common Name: Other maternal factors that affect newborn screening interpretation Narrative
  Shortname: Other mat factors affecting NBS imp
  Fully Specified Name: Other maternal factors that affect newborn screening interpretation: Find: Pt: ^Mother: Nar:
     
  Component Word Count: 8
  ID: 63508
  Status (Raw): ACTIVE


77739-1   Mother's Hepatitis B virus surface Ag statusMother's Hepatitis B virus surface Ag statusHepatitis B virus surface Ag: PrThr: Pt: ^Mother: Ord:  

NAME
  Fully-Specified Name: 
Component   Property   Time   System   Scale   Method
Hepatitis B virus surface Ag  PrThr  Pt  ^Mother  Ord 
  Long Common Name:  Mother's Hepatitis B virus surface Ag status
  Shortname:  Mother's HBV surface Ag Ql

TERM DEFINITION/DESCRIPTION(S)
  This term should be used to report the birth mother's Hepatitis B surface antigen status.
 
 

PART DEFINITION/DESCRIPTION(S)
  Part: Hepatitis B virus surface
  The hepatitis B surface antigen (HBsAg) is most frequently used to screen for the presence of this infection. It is the first detectable viral antigen to appear during infection. However, early in an infection, this antigen may not be present and it may be undetectable later in the infection as it is being cleared by the host. The infectious virion contains an inner "core particle" enclosing viral genome. The icosahedral core particle is made of 180 or 240 copies of core protein, alternatively known as hepatitis B core antigen, or HBcAg. During this 'window' in which the host remains infected but is successfully clearing the virus, IgM antibodies to the hepatitis B core antigen (anti-HBc IgM) may be the only serological evidence of disease. Therefore most hepatitis B diagnostic panels contain HBsAg and total anti-HBc(both IgM and IgG).
  Copyright: Text is available under the Creative Commons Attribution/Share-Alike License. See http://creativecommons.org/licenses/by-sa/3.0/ for details.
 
 

CONDITION FOR INCLUSION
This term should be used in the context of the card data panel if maternal Hep B surface Ag result is included on the DBS card

OBSERVATION REQUIRED IN PANEL
Conditional

BASIC ATTRIBUTES
  Class/Type: MICRO/Lab
  First Released in Version: 2.52
  Last Updated in Version: 2.56
  Order vs. Obs.: Both
  Status: Active.
Change Reason: The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016.

PREFERRED ANSWER LIST    (LL3639-3)  
  SEQ#        Answer        Code 
System
   
    Answer ID    
  1       Positive           LA6576-8  
  2       Negative           LA6577-6  
  3       Not tested           LA13538-6  
  4       Unknown       HL7       LA4489-6  

MEMBER OF THESE PANELS
  54089-8   Newborn screening panel American Health Information Community (AHIC)Newborn screening panel American Health Information Community (AHIC)Newborn screening panel: -: Pt: ^Patient: -: AHIC

PARTS

Part Type    Part No.  Part Name   
Component   LP38331-2  Hepatitis B virus surface Ag 
Component   LP14820-2  Hepatitis B virus surface 
     Suffix   LP20666-1  Ag 
Property   LP217195-9  PrThr   [Presence or Threshold] 
Time   LP6960-1  Pt   [Point in time (spot)] 
Super System   LP6983-3  Mother 
Scale   LP7751-3  Ord 
Fragments for synonyms   LP21372-5  Surface 
Fragments for synonyms   LP20771-9  Hepatitis 

LANGUAGE VARIANTS
  Chinese (CHINA)  (From: Regenstrief-generated full translation based on part translation provided by Bethune International Peace Hospital)
 
  乙型肝炎病毒表面 抗原:  存在情况或阈值:  时间点:  ^母亲:  序数型:  乙型肝炎病毒表面 抗原:  存在情况或阈值:  时间点:  ^母亲:  序数型:  乙型肝炎病毒表面 抗原:  存在情况或阈值:  时间点:  ^母亲:  序数型:  
  Dutch (NETHERLANDS)  (From: Regenstrief-generated full translation based on part translation provided by NVKC, Dutch Society for Clinical Chemistry and Laboratory Medicine, The Netherlands)
 
  Hepatitis B-virusoppervlakte Ag:  PrThr:  Moment:  ^moeder:  Ordinaal:  Hepatitis B-virusoppervlakte Ag:  PrThr:  Moment:  ^moeder:  Ordinaal:  Hepatitis B-virusoppervlakte Ag:  PrThr:  Moment:  ^moeder:  Ordinaal:  
  French (FRANCE)  (From: ASIP Santé (Agence des systèmes d'information partagés de santé))
 
  Hépatite B virus surface Ag:  Présence:  Ponctuel:  Mère:  Qualitatif:  Hépatite B virus surface Ag:  Présence:  Ponctuel:  Mère:  Qualitatif:  Hépatite B virus surface Ag:  Présence:  Ponctuel:  Mère:  Qualitatif:  
  Italian (ITALY)  (From: Regenstrief-generated full translation based on part translation provided by Consiglio Nazionale delle Ricerche)
 
  Epatite B virus, superficie , Ag:  PrThr:  Pt:  ^madre:  Ord:  Epatite B virus, superficie , Ag:  PrThr:  Pt:  ^madre:  Ord:  Epatite B virus, superficie , Ag:  PrThr:  Pt:  ^madre:  Ord:  
  Russian (RUSSIAN FEDERATION)  (From: Regenstrief-generated full translation based on part translation provided by Yaroslavl State Medical Academy)
 
  Гепатита В вируса поверхностный Аг:  PrThr:  ТчкВрм:  ^Мать:  Пор:  Гепатита В вируса поверхностный Аг:  PrThr:  ТчкВрм:  ^Мать:  Пор:  Гепатита В вируса поверхностный Аг:  PrThr:  ТчкВрм:  ^Мать:  Пор:  
  Spanish (SPAIN)  (From: Regenstrief-generated full translation based on part translation provided by the Clinical Laboratory Committee of SERVICIO EXTREMEÑO DE SALUD, with the support of BITAC MAP.)
 
  Antígeno de superficie virus Hepatitis B Ag:  Propiedad utilizada para términos LOINC cuyos resultados estan en escala categórica ordenada.:  Punto temporal:  ^Madre:  Ord:  Antígeno de superficie virus Hepatitis B Ag:  Propiedad utilizada para términos LOINC cuyos resultados estan en escala categórica ordenada.:  Punto temporal:  ^Madre:  Ord:  Antígeno de superficie virus Hepatitis B Ag:  Propiedad utilizada para términos LOINC cuyos resultados estan en escala categórica ordenada.:  Punto temporal:  ^Madre:  Ord:  
  Turkish (TURKEY)  (From: Regenstrief-generated full translation based on part translation provided by LOINC Turkish Translation Group and the Turkish Ministry of Health)
 
  Hepatit B virüsü yüzey Ag:  MevcEşik:  Zmlı:  ^Anne:  Srl:  Hepatit B virüsü yüzey Ag:  MevcEşik:  Zmlı:  ^Anne:  Srl:  Hepatit B virüsü yüzey Ag:  MevcEşik:  Zmlı:  ^Anne:  Srl:  

RELATED NAMES
  Antigen Hep Bs Point in time
  Antigens Hepatis PR
  Australia antigen Hepatit QL
  HBs HepB Qual
  HBsAG Mat Qualitative
  HBV Maternal Random
  HBV surface Matnl Screen
  Hep Microbiology Surf
  Hep B Ordinal  

CHANGE HISTORY
  Change Type: MIN

INTERNAL FIELDS
  Long Common Name: Mother's Hepatitis B virus surface Ag status
  Shortname: Mother's HBV surface Ag Ql
  Fully Specified Name: Hepatitis B virus surface Ag: PrThr: Pt: ^Mother: Ord:
     
  Component Word Count: 0
  ID: 80220
  Status (Raw): ACTIVE


57712-2   Mother's educationMother's education